



Icahn School of Medicine at  
**Mount Sinai**

Grants and Contracts Office

**Funding Opportunities Monthly Edition  
Feb 2024 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Feb 2024. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

113157	<a href="#">RFA-CA-22-050 -- NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-22-050	06-Feb-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Brandy Heckman-Stoddard, PhD, MPH
Contact Telephone	240-276-7048
Contact Email	<a href="mailto:brandy.heckman-stoddard@nih.gov">brandy.heckman-stoddard@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Feb-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups (NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply.</p>

110473	<a href="#">Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-162	28-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Joanne Elena, PhD, MPH
Contact Telephone	240-276-6818
Contact Email	<a href="mailto:joanne.elena@nih.gov">joanne.elena@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	28-Feb-2024 , 29-Jul-2024 , 28-Feb-2025
Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121014	<a href="#">Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-280	16-Feb-2024	275,000 USD
	Contact Name	Edward R. Sauter, MD, PhD			
	Contact Telephone	240-276-7657			
	Contact Email	<a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.			
103024	<a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-206	05-Feb-2024	2,495,000 USD
	Contact Name	Miguel Ossandon MS			
	Contact Telephone	240-276-5714			
	Contact Email	<a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production or basic research projects.</p>				
109909	<a href="#">Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)</a> <a href="#">(R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-139	05-Feb-2024	2,500,000 USD
	Contact Name	Michael Graham Espey, Ph.D.			
	Contact Telephone	240-276-7619			
	Contact Email	<a href="mailto:SP@nih.gov">SP@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.			
112619	<a href="#">Biology of Bladder Cancer (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-218	05-Feb-2024	Not Specified
	Contact Name	Ron Johnson, Ph. D.			
	Contact Telephone	240-276-6250			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>				
120897	<p><a href="#">Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)</a></p>	National Cancer Institute/NIH/DHHS	PAR-23-281	05-Feb-2024	2,495,000 USD
	<p>Contact Name Joanna Watson, Ph.D.</p> <p>Contact Telephone 240-276-6206</p> <p>Contact Email <a href="mailto:Joanna.Watson@nih.gov">Joanna.Watson@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120756	<a href="#">Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-23-273	05-Feb-2024	Not Specified
	<p>Contact Name   Rebecca Ferrer</p> <p>Contact Telephone   240-276-6914</p> <p>Contact Email   <a href="mailto:ferrerra@mail.nih.gov">ferrerra@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one’s response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.</p>				
106546	<a href="#">Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-329	05-Feb-2024	Not Specified
	<p>Contact Name   Kelly Filipski PhD, MPH</p> <p>Contact Telephone   240-276-6841</p> <p>Contact Email   <a href="mailto:Filipskikk@mail.nih.gov">Filipskikk@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.			
108548	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-083	05-Feb-2024	Not Specified
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.			
108551	<a href="#">Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-099	05-Feb-2024	2,000,000 USD
	Contact Name	Steven Becker, Ph.D.			
	Contact Telephone	240-276-6210			
	Contact Email	<a href="mailto:steven.becker@nih.gov">steven.becker@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

117334	<a href="#">Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-153	05-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Curt DellaValle, Ph.D., MPH
Contact Telephone	240-276-7225
Contact Email	<a href="mailto:curt.dellavalle@nih.gov">curt.dellavalle@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026
Synopsis	This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.

106319	<a href="#">Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-330	13-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Claire Zhu, Ph.D.
Contact Telephone	240-276-7013
Contact Email	<a href="mailto:zhucla@mail.nih.gov">zhucla@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Feb-2024 , 11-Jun-2024 , 11-Oct-2024
Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer’s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

111847	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-164	05-Feb-2024	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Kelly D. Blake, ScD
Contact Telephone	240-281-5934
Contact Email	<a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025

Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

111859	<a href="#">Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-198	05-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Michael Graham Espey, Ph.D.
Contact Telephone	240-276-5609

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:SP@nih.gov">SP@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
121826	<p><a href="#">Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)</a></p>	National Cancer Institute/NIH/DHHS	PAR-24-047	20-Feb-2024	450,000 USD
	<p>Contact Name Sumana Dey, Ph.D.</p> <p>Contact Telephone 240-276-5748</p> <p>Contact Email <a href="mailto:sumana.dey@nih.gov">sumana.dey@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 09-Jul-2024 , 08-Oct-2024 , 14-Feb-2025 , 11-Jul-2025 , 14-Oct-2025 , 13-Feb-2026 , 10-Jul-2026 , 13-Oct-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this NOFO encourage multidisciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102792	<a href="#">The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-318	12-Feb-2024	450,000 USD
	<p>Contact Name   Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone   240-276-5630</p> <p>Contact Email   <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants planning studies with specific application toward processes or products in mind should submit under the "Independent Clinical Trial Required" companion FOA (PAR-21-111). Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial or independent basic experimental study with humans, must apply to the "Independent Clinical Trial Not Allowed" companion FOA (PAR-21-128).</p>				
115286	<a href="#">Notice of Special Interest (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-035	07-Jan-2024	Not Specified
	<p>Contact Name   Jessica Faupel-Badger</p> <p>Contact Telephone   240-276-7296</p> <p>Contact Email   <a href="mailto:Jessica.Faupel-Badger@nih.gov">Jessica.Faupel-Badger@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Deadline Dates (ALL)   07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024</p> <p>Synopsis   This NOSI from the NCI expresses continued interest in receiving Career Development Award applications from early career scientists conducting research within the mission of the Division of Cancer Prevention.</p>					
110471	<a href="#">Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-131	05-Feb-2024	Not Specified
<p>Contact Name   Sudhir Srivastava, Ph.D., MPH</p> <p>Contact Telephone   240-276-7028</p> <p>Contact Email   <a href="mailto:svrivasts@mail.nih.gov">svrivasts@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>					
106733	<a href="#">Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-121	28-Dec-2023	Not Specified
<p>Contact Name   Phillip J. Daschner, MSc</p> <p>Contact Telephone   240-276-6227</p> <p>Contact Email   <a href="mailto:pd93u@nih.gov">pd93u@nih.gov</a></p> <p>Sponsor Website  </p>					

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.</p>				
106036	<a href="#">Notice of Special Interest (NOSI): Advancing the Development of Tumor Site-Activated Small Molecules</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-101	07-Jan-2024	Not Specified
	<p>Contact Name Sharad K. Verma, PhD</p> <p>Contact Telephone 202-657-3694</p> <p>Contact Email <a href="mailto:sharad.verma@nih.gov">sharad.verma@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Treatment and Diagnosis (DCTD) to support investigation of the development of novel therapies for cancer-applied research encompassing chemistry and biology disciplines to support the discovery and testing of novel therapeutics offering improved safety and efficacy profiles for eventual translation to the clinic.</p>				
114326	<a href="#">Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (UH2 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-052	14-Feb-2024	275,000 USD
	<p>Contact Name Kristine Willis, Ph.D.</p> <p>Contact Telephone 301-792-1338</p> <p>Contact Email <a href="mailto:Kristine.Willis@nih.gov">Kristine.Willis@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   14-Feb-2024 , 23-Oct-2024 , 14-Feb-2025 , 23-Oct-2025</p> <p>Synopsis   The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. For this announcement, unpublished preliminary data are limited to one figure, comprising no more than one-half page, to facilitate the entry of qualified new investigators to the field.</p>				
114325	<a href="#">Mechanistic Links Between Diet, Lipid Metabolism, and Tumor Growth and Progression (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-051	14-Feb-2024	2,500,000 USD
	<p>Contact Name   Kristine Willis, Ph.D.</p> <p>Contact Telephone   301-792-1338</p> <p>Contact Email   <a href="mailto:Kristine.Willis@nih.gov">Kristine.Willis@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Feb-2024 , 23-Oct-2024 , 14-Feb-2025 , 23-Oct-2025</p> <p>Synopsis   The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.</p>				
112021	<a href="#">Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-174	07-Jan-2024	Not Specified
	<p>Contact Name   Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone   240-276-7048</p> <p>Contact Email   <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 27-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.</p>				
112019	<a href="#">Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-173	07-Jan-2024	Not Specified
	<p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7048</p> <p>Contact Email <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 27-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025 , 25-Feb-2025 , 07-May-2025 , 25-Jun-2025</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

120973	<a href="#">Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-279	05-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Edward R. Sauter, MD, PhD
Contact Telephone	240-276-7657
Contact Email	<a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026
Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.

113746	<a href="#">Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	05-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Matthew Young, Ph.D.
Contact Telephone	240-276-5846
Contact Email	<a href="mailto:matthew.young@nih.gov">matthew.young@nih.gov</a>
Sponsor Website	

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 13-Feb-2024 , 01-Mar-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 11-Jun-2024 , 12-Jun-2024 , 01-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 01-Oct-2024 , 05-Oct-2024 , 10-Oct-2024 , 11-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 13-Feb-2025 , 01-Mar-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Jul-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI.</p>				
114679	<a href="#">Co-infection and Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-056	16-Feb-2024	275,000 USD
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email <a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
115117	<a href="#">Notice of Special Interest (NOSI): Adaptive Biomaterials for Cancer Biology</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-030	07-Jan-2024	Not Specified
	<p>Contact Name Eric M. Johnson Chavarria, Ph.D.</p> <p>Contact Telephone 240-276-7416</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:eric.johnsonchavarria@nih.gov">eric.johnsonchavarria@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.</p>				
117338	<a href="#">Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-152	16-Feb-2024	275,000 USD
	<p>Contact Name Curt DellaValle, Ph.D., MPH</p> <p>Contact Telephone 240-276-7225</p> <p>Contact Email <a href="mailto:curt.dellavalle@nih.gov">curt.dellavalle@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.</p>				
117714	<a href="#">Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-060	28-Dec-2023	Not Specified
	<p>Contact Name Stefan Maas, Ph.D.</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email <a href="mailto:stefan.maas@nih.gov">stefan.maas@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.</p>			
102778	<p><a href="#">The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)</a></p>	National Cancer Institute/NIH/DHHS	PAR-21-111	12-Feb-2024	450,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sonia B. Jakowlew, Ph.D.</p> <p>240-276-5630</p> <p><a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>12-Feb-2024</p> <p>This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial must apply to the "Independent Clinical Trial Not Allowed companion FOA (PAR-21-128).</p>			
102781	<p><a href="#">The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)</a></p>	National Cancer Institute/NIH/DHHS	PAR-21-128	12-Feb-2024	450,000 USD
	<p>Contact Name</p>	<p>Sonia B. Jakowlew, Ph.D.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-5630</p> <p>Contact Email   <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing a clinical trial, a clinical trial feasibility study, or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOAs (PAR-21-111 or PAR-21-318).</p>				
106354	<p><a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)</a></p>	National Cancer Institute/NIH/DHHS	PAR-21-299	12-Feb-2024	Not Specified
	<p>Contact Name   Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone   240-276-7360</p> <p>Contact Email   <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis   The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-300).

106355	<a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-300	12-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D
Contact Telephone	240-276-7360
Contact Email	<a href="mailto:muluaem.tilahun@nih.gov">muluaem.tilahun@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Feb-2024 , 12-Jun-2024

**Synopsis** The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-299).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106228	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-295	12-Feb-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Mulualem E. Tilahun, D.V.M., Ph.D 240-276-7360 <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a>  <a href="#">Link to program URL</a> 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA.			
106230	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-296	12-Feb-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Mulualem E. Tilahun, D.V.M., Ph.D 240-276-7360 <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a>  <a href="#">Link to program URL</a> 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

108550	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-084	16-Feb-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Tram Kim Lam, Ph.D., MPH
Contact Telephone	240-276-6967
Contact Email	<a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

108359	<a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-091	16-Feb-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Miguel R. Ossandon, Ph.D.
Contact Telephone	240-276-5714
Contact Email	<a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024
Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA

112622	<a href="#">Biology of Bladder Cancer (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-219	16-Feb-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Ron Johnson, Ph. D.
Contact Telephone	240-276-6250
Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.</p>

109910	<a href="#">Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-140	16-Feb-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Michael Graham Espey, Ph.D.
Contact Telephone	240-276-7619
Contact Email	<a href="mailto:SP@nih.gov">SP@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.</p>				
110931	<a href="#">Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-085	28-Dec-2023	Not Specified
	<p>Contact Name   Ron Johnson, Ph.D.            Contact Telephone   240-276-6250            Contact Email   <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 12-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-2027 , 16-Feb-2027 , 07-May-2027            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.</p>				
111322	<a href="#">Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-038	07-Jan-2024	Not Specified
	<p>Contact Name   Mark Parascandola, Ph.D., M.P.H.            Contact Telephone   240-276-6871            Contact Email   <a href="mailto:paramark@mail.nih.gov">paramark@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice is to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs). This Notice also aligns with the Global Alliance for Chronic Diseases (GACD) 2020 Cancer Call.			
114360	<a href="#">Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-22-256	14-Feb-2024	Not Specified
	Contact Name	Wynne E. Norton, PhD			
	Contact Telephone	240-276-6875			
	Contact Email	<a href="mailto:wynne.norton@nih.gov">wynne.norton@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Feb-2024 , 14-Jun-2024 , 17-Oct-2024 , 14-Feb-2025 , 14-Jun-2025 , 17-Oct-2025			
	Synopsis	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.			
114550	<a href="#">NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-058	07-Jan-2024	100,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 22-Feb-2024 , 07-May-2024 , 20-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 24-Feb-2025 , 07-May-2025 , 20-Jun-2025 , 07-Sep-2025 , 17-Oct-2025 , 07-Jan-2026			
	Synopsis	This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.			
107760	<a href="#">Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	28-Dec-2023	Not Specified
	<p>Contact Name   Sallie J. Weaver, PhD, MHS</p> <p>Contact Telephone   240-276-6254</p> <p>Contact Email   <a href="mailto:sallie.weaver@nih.gov">sallie.weaver@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 08-Oct-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) highlights the NCI Healthcare Delivery Research Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment.</p>				
105645	<a href="#">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-290	07-Jan-2024	499,999 USD
	<p>Contact Name   Shane Woodward</p> <p>Contact Telephone   240-276-6624</p> <p>Contact Email   <a href="mailto:woodwars@mail.nih.gov">woodwars@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
108323	<a href="#">Notice of Special Interest (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors</a>	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	28-Dec-2023	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Veronica Chollette, RN, MS</p> <p>Contact Telephone   240-276-6969</p> <p>Contact Email   <a href="mailto:cholletv@mail.nih.gov">cholletv@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 08-Oct-2024</p> <p>Synopsis   The purpose of this Notice is to highlight the interest of the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) in receiving applications to understand and address the full spectrum of factors that contribute to disparities in survivorship care, healthcare utilization, and health outcomes among childhood cancer survivors. Studies that focus on factors that extend beyond the individual (e.g., survivor, caregiver, clinician) to include an examination or intervention that involves healthcare teams, healthcare system, community, payer, and/or policy-level factors that contribute to disparities in health outcomes and result in inequitable survivorship care are strongly encouraged.</p>				
113232	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-242	07-Jan-2024	Not Specified
	<p>Contact Name   Rao Divi, Ph.D.</p> <p>Contact Telephone   240-276-6913</p> <p>Contact Email   <a href="mailto:divir@mail.nih.gov">divir@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis   The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.				
113233	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-243	07-Jan-2024	Not Specified
	Contact Name	Rao Divi, Ph.D.			
	Contact Telephone	240-276-6913			
	Contact Email	<a href="mailto:divir@mail.nih.gov">divir@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025			
	Synopsis	<p>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production.</p>			
106261	<a href="#">Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-322	05-Feb-2024	Not Specified
	Contact Name	Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	<a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Mar-2024 , 05-Jun-2024 , 05-Jul-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
106282	<a href="#">Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-331	05-Feb-2024	2,500,000 USD
	<p>Contact Name Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone 240-276-7657</p> <p>Contact Email <a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Mar-2024 , 05-Jun-2024 , 05-Jul-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</p>				
115306	<a href="#">Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer</a>	National Cancer Institute/NIH/DHHS	NOT-CA-23-018	28-Dec-2023	Not Specified
	<p>Contact Name Gary Della'Zanna</p> <p>Contact Telephone 240-276-7042</p> <p>Contact Email <a href="mailto:Gary.DellaZanna@nih.gov">Gary.DellaZanna@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	28-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 12-Feb-2024 , 13-Feb-2024 , 16-Feb-2024 , 27-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to solicit applications directed toward identifying, characterizing, and mitigating risk factors, identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.			
107221	<a href="#">Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-061	05-Feb-2024	Not Specified
	Contact Name	Phillip J. Daschner, M.Sc.			
	Contact Telephone	240-276-6227			
	Contact Email	<a href="mailto:PD93u@nih.gov">PD93u@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.			
114678	<a href="#">Co-infection and Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-055	05-Feb-2024	Not Specified
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
120755	<a href="#">Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-264	05-Feb-2024	Not Specified
	<p>Contact Name Suzanne Forry, Ph.D.</p> <p>Contact Telephone 240-276-5922</p> <p>Contact Email <a href="mailto:forryscs@mail.nih.gov">forryscs@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
120726	<a href="#">Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-23-259	05-Feb-2024	2,499,995 USD
	<p>Contact Name Darrell Tata, Ph.D.</p> <p>Contact Telephone 240-276-5894</p> <p>Contact Email <a href="mailto:Darrell.Tata@nih.gov">Darrell.Tata@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   05-Feb-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Oct-2026</p> <p>Synopsis   Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.</p>				
103489	<a href="#">Notice of Special Interest (NOSI): Telehealth in Cancer Care</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-043	07-Jan-2024	Not Specified
	<p>Contact Name   Gurvaneet Randhawa, M.D., M.P.H.</p> <p>Contact Telephone   240-276-6940</p> <p>Contact Email   <a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of the NCI's Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. This NOSI for R01 and R21 applications is a companion announcement to the RFA titled "Centers on Telehealth Research and Cancer-Related Care" (RFA-CA-21-029).</p>				
107222	<a href="#">Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-22-062	16-Feb-2024	275,000 USD
	Contact Name   Phillip J. Daschner, M.Sc.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-6227</p> <p>Contact Email   <a href="mailto:PD93u@nih.gov">PD93u@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.</p>				
111848	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-165	16-Feb-2024	275,000 USD
	<p>Contact Name   Kelly D. Blake, ScD</p> <p>Contact Telephone   240-281-5934</p> <p>Contact Email   <a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p>				
111860	<a href="#">Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-199	16-Feb-2024	275,000 USD
	Contact Name   Michael Graham Espey, Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-5609</p> <p>Contact Email   <a href="mailto:SP@nih.gov">SP@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.</p>				
106356	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-301	12-Feb-2024	Not Specified

Contact Name	Muluaem E. Tilahun, D.V.M., Ph.D
Contact Telephone	240-276-7360
Contact Email	<a href="mailto:muluaem.tilahun@nih.gov">muluaem.tilahun@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Feb-2024 , 12-Jun-2024
Synopsis	The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-21-302).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106358	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-302	12-Feb-2024	Not Specified
	<p>Contact Name   Mulualem E. Tilahun, D.V.M., Ph.D</p> <p>Contact Telephone   240-276-7360</p> <p>Contact Email   <a href="mailto:mulualem.tilahun@nih.gov">mulualem.tilahun@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis   The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-301).</p>				
122281	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-313	20-Feb-2024	Not Specified
	<p>Contact Name   Tracy G. Lively, Ph.D.</p> <p>Contact Telephone   240-276-5944</p> <p>Contact Email   <a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 10-Jun-2024 , 08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this NOFO must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.

122288	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-314	20-Feb-2024	750,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944
Contact Email	<a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Feb-2024 , 10-Jun-2024 , 08-Oct-2024 , 14-Feb-2025 , 11-Jun-2025 , 15-Oct-2025 , 13-Feb-2026 , 10-Jun-2026 , 14-Oct-2026

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multidisciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

112442	<a href="#">NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-22-216	13-Feb-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	William C. Timmer, Ph.D
Contact Telephone	240-276-6130
Contact Email	<a href="mailto:william.timmer@nih.gov">william.timmer@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Feb-2024 , 01-Mar-2024 , 12-Jun-2024 , 01-Jul-2024 , 10-Oct-2024 , 01-Nov-2024 , 13-Feb-2025 , 01-Mar-2025 , 12-Jun-2025 , 01-Jul-2025
Synopsis	This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among underserved populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative correlative studies in cancer patients with age, gender, racial/ethnic, or health disparities are encouraged to explore mechanisms underlying their differential responses (efficacy and toxicity) and resistance to therapeutic interventions. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

106264	<a href="#">Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-323	16-Feb-2024	400,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Anu Sharman, Ph.D.
Contact Telephone	240-276-6250
Contact Email	<a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024
Synopsis	National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
104859	<a href="#">Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-085	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Gurvaneet S. Randhawa, M.D., M.P.H.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6940</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer.</td> </tr> </table>					Contact Name	Gurvaneet S. Randhawa, M.D., M.P.H.	Contact Telephone	240-276-6940	Contact Email	<a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024	Synopsis	This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer.
Contact Name	Gurvaneet S. Randhawa, M.D., M.P.H.																		
Contact Telephone	240-276-6940																		
Contact Email	<a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024																		
Synopsis	This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer.																		
106265	<a href="#">Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-324	16-Feb-2024	100,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Anu Sharman, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6250</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.</td> </tr> </table>					Contact Name	Anu Sharman, Ph.D.	Contact Telephone	240-276-6250	Contact Email	<a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024	Synopsis	This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.
Contact Name	Anu Sharman, Ph.D.																		
Contact Telephone	240-276-6250																		
Contact Email	<a href="mailto:sharmananu@nih.gov">sharmananu@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.																		
106283	<a href="#">Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-332	16-Feb-2024	550,000 USD														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Edward R. Sauter, M.D., Ph.D.</p> <p>Contact Telephone   240-276-7657</p> <p>Contact Email   <a href="mailto:edward.sauter@nih.gov">edward.sauter@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes.</p>				
122437	<p><a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)</a></p>	National Cancer Institute/NIH/DHHS	PAR-23-288	14-Feb-2024	Not Specified
	<p>Contact Name   Sergey Radaev, PhD</p> <p>Contact Telephone   240-276-5630</p> <p>Contact Email   <a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Feb-2024 , 14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026</p> <p>Synopsis   The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286). This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

122436	<a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-23-287	14-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Sergey Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	<a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	14-Feb-2024 , 14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026
Synopsis	The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).			
122435	<a href="#">NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-23-286	14-Feb-2024	Not Specified
	Contact Name	Sergey Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	<a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Feb-2024 , 14-Jun-2024 , 15-Oct-2024 , 14-Feb-2025 , 16-Jun-2025 , 14-Oct-2025 , 17-Feb-2026 , 15-Jun-2026 , 14-Oct-2026			
	Synopsis	<p>The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).</p>			
102903	<a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on Complementary and Integrative Health Approaches</a>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-21-006	07-Jan-2024	Not Specified
	Contact Name	Wen Chen, M.M.Sc., Ph.D.			
	Contact Telephone	301-451-3989			
	Contact Email	<a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to describe NCCIH priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches.			
104713	<a href="#">Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-243	20-Feb-2024	Not Specified
	Contact Name	Lanay Mudd, Ph.D.			
	Contact Telephone	301-594-9346			
	Contact Email	<a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed fully powered multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application (U24), submitted under PAR-21-242 proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<a href="https://nccih.nih.gov/about/plans">https://nccih.nih.gov/about/plans</a>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
104709	<a href="#">NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-241	20-Feb-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Della White, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-6538</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:della.white@nih.gov">della.white@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>20-Feb-2024 , 11-Mar-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Prior to submitting to this FOA, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.</td> </tr> </table>					Contact Name	Della White, Ph.D.	Contact Telephone	301-827-6538	Contact Email	<a href="mailto:della.white@nih.gov">della.white@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Prior to submitting to this FOA, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.
Contact Name	Della White, Ph.D.																		
Contact Telephone	301-827-6538																		
Contact Email	<a href="mailto:della.white@nih.gov">della.white@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Prior to submitting to this FOA, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.																		
104706	<a href="#">Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-240	20-Feb-2024	450,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Peter Murray, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-4054</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:peter.murray@nih.gov">peter.murray@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> </table>					Contact Name	Peter Murray, Ph.D.	Contact Telephone	301-496-4054	Contact Email	<a href="mailto:peter.murray@nih.gov">peter.murray@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>				
Contact Name	Peter Murray, Ph.D.																		
Contact Telephone	301-496-4054																		
Contact Email	<a href="mailto:peter.murray@nih.gov">peter.murray@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 20-Feb-2024 , 11-Mar-2024</p> <p>Synopsis The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to make a significant impact on public health.</p>				
104712	<a href="#">Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-242	20-Feb-2024	Not Specified
	<p>Contact Name Lanay Mudd, Ph.D.</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email <a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 11-Mar-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-21-243. The DCC application must be specific to the companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult NCCIH website: (<http://www.nccih.nih.gov>). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA

119560	<a href="#">NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-23-200	16-Feb-2024	Not Specified
--------	--	---------------------------------	------------	-------------	---------------

Contact Name	Tony Gover, Ph.D.
Contact Telephone	301-529-7320
Contact Email	<a href="mailto:tony.gover@nih.gov">tony.gover@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Feb-2025
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.

119565	<a href="#">NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-23-205	16-Feb-2024	3,000,000 USD
--------	--	---------------------------------	------------	-------------	---------------

Contact Name	Tony Gover, Ph.D.
Contact Telephone	301-529-7320



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:tony.gover@nih.gov">tony.gover@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Feb-2025</p> <p>Synopsis The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PAR-23-200.</p>				
108854	<a href="#">Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment</a>	National Eye Institute/NIH/DHHS	NOT-EY-22-010	05-Jan-2024	Not Specified
	<p>Contact Name Sangeeta Bhargava, Ph.D</p> <p>Contact Telephone 301-435-8175</p> <p>Contact Email <a href="mailto:sangeeta.bhargava@nih.gov">sangeeta.bhargava@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to support research addressing the urgent need to provide accessible home-based COVID testing to people who are visually impaired.</p>				
109678	<a href="#">NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-135	07-Jan-2024	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-435-8181</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109530	<a href="#">NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-128	07-Jan-2024	300,000 USD

Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial’s rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.

Contact Name	Donald Everett, MA
Contact Telephone	301-435-8181
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

109824	<a href="#">NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-22-141	07-Jan-2024	275,000 USD
--------	--	---------------------------------	------------	-------------	-------------

Contact Name	Donald Everett, M.A.
Contact Telephone	301-435-8181
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

117409	<a href="#">Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research</a>	National Eye Institute/NIH/DHHS	NOT-EY-23-005	05-Jan-2024	Not Specified
--------	--	---------------------------------	---------------	-------------	---------------

Contact Name	James Gao, Ph.D.
Contact Telephone	301-594-6074
Contact Email	<a href="mailto:james.gao@nih.gov">james.gao@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jan-2024 , 07-Jan-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 16-Feb-2026			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.			
108264	<a href="#">RFA-HL-23-003 -- Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-003	27-Feb-2024 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Lisbeth Welniak, PhD			
	Contact Telephone	301-435-0050			
	Contact Email	<a href="mailto:welniakla@mail.nih.gov">welniakla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Feb-2024 [Optional][LOI/Pre-App], 28-Mar-2024			
	Synopsis	The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (R00) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This FOA offers the opportunity for current RFA-HL-20-001 or RFA-HL-20-002 K99 awardees to apply for the independent phase (R00) of the program. In the R00 phase, successful blood science physician scientist scholars will receive up to three years of funding to continue their research activity with support from this FOA, which will require updated research plans and a limited competition review.			
103977	<a href="#">RFA-HL-23-004 -- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-004	16-Jan-2024 [Optional][LOI/Pre-App]	4,900,000 USD
	Contact Name	Narasimhan Danthi, Ph.D.			
	Contact Telephone	301-451-5170			
	Contact Email	<a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App], 25-Apr-2024</p> <p>Synopsis The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.</p>				
103978	<a href="#">RFA-HL-23-005 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-005	16-Jan-2024 [Optional][LOI/Pre-App]	4,900,000 USD
	<p>Contact Name Narasimhan Danthi, Ph.D.</p> <p>Contact Telephone 301-451-5170</p> <p>Contact Email <a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App]</p> <p>Synopsis The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104079	<a href="#">RFA-HL-22-001 -- T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-001	29-Jan-2024 [Optional][LOI/Pre-App]	1,610,000 USD

research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission. It is anticipated that the EIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service

Contact Name | Traci Mondoro, PhD  
 Contact Telephone | 301-435-0050  
 Contact Email | [NHLBI\\_Blood\\_Training@nhlbi.nih.gov](mailto:NHLBI_Blood_Training@nhlbi.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024

Synopsis | The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse backgrounds, including those from groups that are nationally underrepresented in cardiovascular, pulmonary, hematologic and sleep disorders research across the career development continuum by providing support to institutions that promote diversity. The NHLBI's T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research Service Award Program intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for these populations. This Funding Opportunity Announcement (FOA) does not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

112358	<a href="#">Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-193	11-Jan-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Nancy DiFronzo, PhD</p> <p>301-435-0065</p> <p><a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>11-Jan-2024 , 13-Feb-2024 , 10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>
---	--

112357	<a href="#">Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-192	11-Jan-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Nancy DiFronzo, PhD</p> <p>301-435-0065</p>
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jan-2024 , 13-Feb-2024 , 10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 10-Jan-2025 , 11-Feb-2025 , 12-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.</p>				
111425	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	11-Jan-2024	Not Specified
	<p>Contact Name Nahed El Kassar, MD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email <a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jan-2024 , 13-Feb-2024 , 10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112356	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-189	11-Jan-2024	Not Specified

Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP),.

Contact Name	Nahed El Kassar, MD
Contact Telephone	301-435-0065
Contact Email	<a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	11-Jan-2024 , 13-Feb-2024 , 10-May-2024 , 11-Jun-2024 , 11-Sep-2024 , 11-Oct-2024 , 11-Jan-2025 , 11-Feb-2025 , 11-May-2025 , 11-Jun-2025 , 11-Sep-2025
Synopsis	This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).			
114141	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Lipoprotein(a) and Cardiovascular Disease (R01 Clinical Trials Allowed) and (R01 No Clinical Trials Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-052	07-Jan-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Lijuan Liu, PhD 301-435-0582 <a href="mailto:lliu@nhlbi.nih.gov">lliu@nhlbi.nih.gov</a>  <a href="#">Link to program URL</a> 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 The purpose of this NOSI is to stimulate research on lipoprotein(a) [Lp(a)] and its role in cardiovascular disease (CVD). We encourage multidisciplinary collaborations to conduct basic, preclinical, and mechanistic clinical studies on Lp(a) and CVD.			
116586	<a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-067	07-Jan-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	James Luo, Ph.D. 301-435-0533 <a href="mailto:luoja@nih.gov">luoja@nih.gov</a>  <a href="#">Link to program URL</a> 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>(WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.</p>			
108068	<a href="#">Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-024	07-Jan-2024	Not Specified
	<p>Contact Name   Bishow Adhikari, Ph.D.</p> <p>Contact Telephone   301-594-2791</p> <p>Contact Email   <a href="mailto:adhikarb@nhlbi.nih.gov">adhikarb@nhlbi.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis   The purpose of this NOSI is to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. Underserved populations, for the purpose of this NOSI, can include racial and ethnic minorities, immigrants, the homeless, low-income individuals, the uninsured and people who live in communities that are socioeconomically disadvantaged, rural or have few health care resources. Please see NOT-OD-20-031 for NIH definitions. Special consideration will be given to technology solutions that are accessible and feasible in these communities. Working with community partners is required throughout the project to ensure successful development and implementation.</p>				
108064	<a href="#">Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-003	07-Jan-2024	Not Specified
	<p>Contact Name   Jining Lu</p> <p>Contact Telephone   301-827-2807</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:jining.lu@nih.gov">jining.lu@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis The purpose of this NOSI is to stimulate research focused on cell-type-specific signatures of mitochondrial behavior in healthy and diseased lungs. Multidisciplinary collaboration among experts in recently developed technologies, such as iPSC cell and lung progenitor/organoid culture systems, advanced single cell-and “-omic” technologies, and lung cell biology is encouraged. We encourage investigators to Utilization of lung cells from human donors and animal models with respiratory diseases and/or well-defined congenital mitochondrial diseases is also encouraged.</p>				
112260	<p><a href="#">Notice of Special Interest (NOSI): Studies of Cellular/Molecular Pathobiological Mechanisms of Lung Diseases Using Human 3-Dimensional Cellular Systems (R01)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-030	07-Jan-2024	Not Specified
	<p>Contact Name Qing Lu, Ph.D.</p> <p>Contact Telephone 301-480-9158</p> <p>Contact Email <a href="mailto:qing.lu@nih.gov">qing.lu@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this NOSI is to promote research characterizing the pathobiological processes and mechanisms that drive the onset and progression of lung diseases at a molecular/cellular level, providing a systems-level understanding by studying experimental systems with cellular heterogeneity and 3-D architecture. It is expected that projects supported by this NOSI will utilize ex vivo preparations (e.g., thin human lung slices) or 3-D multi-cellular in vitro systems (e.g., organoids) of human lung cells and will employ state-of-art multi-omics measures (e.g., spatial or single cell/nucleus omics) to better understand specific pathobiological processes in systems of interacting cell types.</p>				
106202	<p><a href="#">Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-Jan-2024	Not Specified
	<p>Contact Name Alison G.M. Brown, PhD, MS, RDN</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-0583</p> <p>Contact Email   <a href="mailto:Alison.brown@nih.gov">Alison.brown@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026</p> <p>Synopsis   This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.</p>				
113286	<p><a href="#">Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-043	07-Jan-2024	Not Specified
	<p>Contact Name   Ravi Balijepalli, Ph.D.</p> <p>Contact Telephone   301-435-0504</p> <p>Contact Email   <a href="mailto:ravi.balijepalli@nih.gov">ravi.balijepalli@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis   This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

115585	<a href="#">Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-23-066	05-Jan-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Charlene Schramm, Ph.D.
Contact Telephone	301-402-3793
Contact Email	<a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026 , 05-Sep-2026 , 07-Sep-2026
Synopsis	The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s): Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders Defining causal relationships between genotypes and phenotypes Development and validation of functionally informed risk predictions

107287	<a href="#">Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-030	07-Jan-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name | Jue Chen, Ph.D.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-0550</p> <p>Contact Email   <a href="mailto:jue.chen@nih.gov">jue.chen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021).</p>				
106072	<p><a href="#">Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-024	07-Jan-2024	Not Specified
	<p>Contact Name   Narasimhan Danthi, Ph.D.</p> <p>Contact Telephone   301-435-5170</p> <p>Contact Email   <a href="mailto:ndanthi@mail.nih.gov">ndanthi@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   This Notice of Special Interest is a reissue of NOT-HL-20-796. The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
114386	<a href="#">Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-23-036	08-Jan-2024	150,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Ruth Kirby, RN, BS</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-0401</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:kirbyr@nhlbi.nih.gov">kirbyr@nhlbi.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>08-Jan-2024 , 28-Feb-2024 , 07-May-2024 , 28-Oct-2024 , 07-Jan-2025 , 28-Feb-2025 , 07-May-2025 , 28-Oct-2025 , 07-Jan-2026</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.</td> </tr> </table>					Contact Name	Ruth Kirby, RN, BS	Contact Telephone	301-435-0401	Contact Email	<a href="mailto:kirbyr@nhlbi.nih.gov">kirbyr@nhlbi.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	08-Jan-2024 , 28-Feb-2024 , 07-May-2024 , 28-Oct-2024 , 07-Jan-2025 , 28-Feb-2025 , 07-May-2025 , 28-Oct-2025 , 07-Jan-2026	Synopsis	This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.
Contact Name	Ruth Kirby, RN, BS																		
Contact Telephone	301-435-0401																		
Contact Email	<a href="mailto:kirbyr@nhlbi.nih.gov">kirbyr@nhlbi.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	08-Jan-2024 , 28-Feb-2024 , 07-May-2024 , 28-Oct-2024 , 07-Jan-2025 , 28-Feb-2025 , 07-May-2025 , 28-Oct-2025 , 07-Jan-2026																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.																		
107093	<a href="#">Notice of Special Interest (NOSI): DEA2Health: Innovative Data Evaluation and Analysis to Health</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-001	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Lucy L. Hsu, M.P.H.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-3276</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:lucy.hsu@nih.gov">lucy.hsu@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.</td> </tr> </table>					Contact Name	Lucy L. Hsu, M.P.H.	Contact Telephone	301-402-3276	Contact Email	<a href="mailto:lucy.hsu@nih.gov">lucy.hsu@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.
Contact Name	Lucy L. Hsu, M.P.H.																		
Contact Telephone	301-402-3276																		
Contact Email	<a href="mailto:lucy.hsu@nih.gov">lucy.hsu@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate research and advancement of methodologies in data science in heart, lung, blood, or sleep (HLBS) biomedical research, and ultimately translate new insights into decision-making to improve health.																		
104361	<a href="#">RFA-HL-22-010 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-010	07-Jan-2024	750,000 USD														



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	<a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 13-Feb-2024 , 07-May-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-HL-22-011).</p>

104360	<a href="#">RFA-HL-22-011 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-011	07-Jan-2024	750,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	<a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 13-Feb-2024 , 07-May-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106893	<a href="#">NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-034	12-Feb-2024	Not Specified

career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator should apply to the companion FOA (RFA-HL-22-010).

Contact Name | Shawn Bediako, Ph.D.  
 Contact Telephone | 301-827-5163  
 Contact Email | [direducation@nhlbi.nih.gov](mailto:direducation@nhlbi.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Feb-2024 , 12-Jun-2024

Synopsis | The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required)".

106898	<a href="#">NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-22-040	12-Feb-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | Shawn Bediako, Ph.D.  
 Contact Telephone | 301-827-5163  
 Contact Email | [direducation@nhlbi.nih.gov](mailto:direducation@nhlbi.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Feb-2024 , 12-Jun-2024

Synopsis | The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers currently in training in the NHLBI Division of Intramural Research with the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not proposing to serve as lead investigator of an independent clinical trial must apply to the companion FOA (PAR-22-034).

113729	<a href="#">RFA-HL-24-005 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-24-005	07-Jan-2024	150,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name | Qing Lu, Ph.D.  
 Contact Telephone | 301-480-9158  
 Contact Email | [Qing.Lu@nih.gov](mailto:Qing.Lu@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>07-Jan-2024 , 13-Feb-2024 , 07-May-2024 , 13-Jun-2024 , 07-Sep-2024 , 17-Oct-2024 , 07-Jan-2025 , 13-Feb-2025 , 07-May-2025 , 13-Jun-2025 , 07-Sep-2025 , 13-Oct-2025 , 07-Jan-2026</p> <p>The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.</p>			
122332	<a href="#">NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-24-049	16-Feb-2024	450,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Patrice Desvigne-Nickens, MD</p> <p>301-435-0504</p> <p><a href="mailto:desvignp@mail.nih.gov">desvignp@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026 , 16-Oct-2026 , 07-Jan-2027</p> <p>This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum | NHLBI, NIH), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. - Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

108576	<a href="#">RFA-HL-23-012 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-012	21-Dec-2023	700,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Mike Pieck, Ph.D.
Contact Telephone	301-827-7986
Contact Email	<a href="mailto:nhlbi_catalyze@nih.gov">nhlbi_catalyze@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis   This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
108577	<p><a href="#">RFA-HL-23-013 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-013	21-Dec-2023	750,000 USD
	<p>Contact Name   Mike Pieck, Ph.D.</p> <p>Contact Telephone   301-827-7986</p> <p>Contact Email   <a href="mailto:nhlbi_catalyze@nih.gov">nhlbi_catalyze@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis   This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
108578	<p><a href="#">RFA-HL-23-014 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-014	21-Dec-2023	500,000 USD
	<p>Contact Name   Mike Pieck, Ph.D.</p> <p>Contact Telephone   301-827-7986</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:nhlbi_catalyze@nih.gov">nhlbi_catalyze@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
108575	<p><a href="#">RFA-HL-23-011 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-011	21-Dec-2023	1,050,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p> <p>Contact Telephone 301-827-7986</p> <p>Contact Email <a href="mailto:nhlbi_catalyze@nih.gov">nhlbi_catalyze@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
108574	<p><a href="#">RFA-HL-23-010 -- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-010	21-Dec-2023	600,000 USD
	<p>Contact Name Mike Pieck, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-7986</p> <p>Contact Email   <a href="mailto:nhlbi_catalyze@nih.gov">nhlbi_catalyze@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Dec-2023 , 21-Feb-2024 , 18-Apr-2024 , 22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024 , 20-Dec-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.</p>				
107717	<a href="#">RFA-HG-22-001 -- Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-22-001	27-Jan-2024 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name   Lisa H. Chadwick, Ph.D.</p> <p>Contact Telephone   301-435-7275</p> <p>Contact Email   <a href="mailto:lisa.chadwick@nih.gov">lisa.chadwick@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Jan-2024 [Optional][LOI/Pre-App], 27-Feb-2024</p> <p>Synopsis   This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications of genomics.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107786	<a href="#">Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-007	05-Jan-2024	Not Specified
	<p>Contact Name   Lisa D. Brooks, Ph.D.</p> <p>Contact Telephone   301-547-1387</p> <p>Contact Email   <a href="mailto:lisa.brooks@nih.gov">lisa.brooks@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024</p> <p>Synopsis   The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease.</p>				
108325	<a href="#">Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients' Use of Genomic Information</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-22-011	07-Jan-2024	Not Specified
	<p>Contact Name   Ken Wiley, Jr., Ph.D.</p> <p>Contact Telephone   301-435-5540</p> <p>Contact Email   <a href="mailto:ken.wiley@nih.gov">ken.wiley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Human Genome Research Institute (NHGRI) is issuing a Notice of Special Interest (NOSI) to encourage applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.</p>				
121827	<a href="#">RFA-AI-23-057 -- Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (U19 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-057	12-Feb-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Josh Radke, PhD</p> <p>Contact Telephone   301-761-6525</p> <p>Contact Email   <a href="mailto:josh.radke@nih.gov">josh.radke@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to support research to better understand the impact of host and viral heterogeneity on pathogenesis of disease, viral persistence, and immunopathology of Hepatitis B (HBV) and inform cure strategies for HBV in people living with HIV (PLWH). Applicants will establish multidisciplinary teams that span the clinical and basic/translational research arenas and establish an observational cohort to accelerate discovery and increase clinical impact.</p>				
107638	<a href="#">Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-014	07-Jan-2024	Not Specified
	<p>Contact Name   Annie Mo, Ph.D.</p> <p>Contact Telephone   240-627-3320</p> <p>Contact Email   <a href="mailto:moa@niaid.nih.gov">moa@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.</p>				
115066	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-071	07-Jan-2024	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   301-594-5945</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).</p>				
115065	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-070	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-594-5945</p> <p>Contact Email <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-23-071)</p>				
102961	<a href="#">Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-032	07-Jan-2024	Not Specified
	<p>Contact Name   Frosso Voulgaropoulou, PhD            Contact Telephone   240-627-3205            Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024            Synopsis   This Notice of Special Interest (NOSI) is to support the discovery and characterization of Inborn Errors of Immunity, also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.</p>				
107851	<a href="#">Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-013	07-Jan-2024	Not Specified
	<p>Contact Name   Jennifer L. Gordon, Ph.D.            Contact Telephone   301-761-6805            Contact Email   <a href="mailto:Jennifer.gordon2@nih.gov">Jennifer.gordon2@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to support research that contributes to the areas of interest outlined in "A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases."</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122105	<a href="#">RFA-AI-23-060 -- Engineering and Preclinical Development of Biological Products that Eliminate HIV-infected Cells (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-060	12-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Stephen Smiley, Ph.D.</p> <p>Contact Telephone   240-627-3071</p> <p>Contact Email   <a href="mailto:stephen.smiley@nih.gov">stephen.smiley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to support the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules.</p>				
121991	<a href="#">Notice of Special Interest (NOSI): Administrative Supplement to Support Research Opportunities at NIAID Intramural Facilities</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-074	02-Feb-2024	50,000 USD
	<p>Contact Name   Meredith Shaffer, Ph.D.</p> <p>Contact Telephone   301-594-0517</p> <p>Contact Email   <a href="mailto:shaffermh@nih.gov">shaffermh@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Feb-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) is specifically designed to promote partnerships between eligible NIAID-funded extramural research investigators and NIAID intramural research investigators (i.e., those conducting research within the laboratories and clinics of NIAID). The intent is to foster and stimulate basic, translational, and applied research that will advance scientific discovery and engage extramural researchers working collaboratively in the areas of immunology, infectious diseases, and allergy. This NOSI will provide funding to NIAID-supported extramural research investigator to travel to NIAID laboratories for a short duration to perform research in partnership with a host intramural research investigator.</p>				
105735	<a href="#">Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-071	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone   301-761-6621</p> <p>Contact Email   <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute of Allergy and Immunology (NIAID) is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focusing on the following area(s): Use mouse lines from the Collaborative Cross (CC) and recombinant inbred intercrosses of CC lines (CC-RIX) to more faithfully reproduce human immune responses and to advance understanding of the host genetics involved in immune regulation and function Screen CC mouse lines to identify and characterize lines suitable for specific studies and disease models within the mission of NIAID (e.g., fundamental immunology, immune-mediated diseases, infectious diseases).</p>				
105630	<a href="#">Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-066	07-Jan-2024	Not Specified
	<p>Contact Name   Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone   301-761-6621</p> <p>Contact Email   <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.</p>				
109336	<a href="#">Notice of Special Interest (NOSI): ptimizing Vascularized Composite Allograft Survival</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-023	07-Jan-2024	Not Specified
	<p>Contact Name   Patricia Kehn, Ph.D.</p> <p>Contact Telephone   240-627-3547</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:pkehn@NIAID.nih.gov">pkehn@NIAID.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.</p>				
114374	<a href="#">Notice of Special Interest (NOSI): Complement in Fundamental Immunology</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-012	07-Jan-2024	Not Specified
	<p>Contact Name Ari Joffe, PhD</p> <p>Contact Telephone 240-669-5084</p> <p>Contact Email <a href="mailto:ari.joffe@nih.gov">ari.joffe@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.</p>				
116360	<a href="#">Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-23-031	05-Jan-2024	Not Specified
	<p>Contact Name Dona C. Love, Ph.D.</p> <p>Contact Telephone 301-761-7788</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Dona.Love@nih.gov">Dona.Love@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in supporting research in the areas outlined in the NIAID Strategic Plan For Research To Develop A Valley Fever Vaccine. The proposed research should have clear relevance to the strategic priorities defined in the strategic plan, which encompasses three major research areas: 1) address gaps in Coccidioides basic research to support the development of a vaccine; 2) develop tools and resources to support vaccine development; 3) develop and advance vaccines to prevent coccidioidomycosis.</p>				
113372	<a href="#">Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-064	07-Jan-2024	Not Specified
	<p>Contact Name Karen Lacourciere, Ph.D.</p> <p>Contact Telephone 240-627-3297</p> <p>Contact Email <a href="mailto:lacourcierek@niaid.nih.gov">lacourcierek@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.</p>				
113565	<a href="#">Notice of Special Interest (NOSI): argeting the Pathogen within the Arthropod Vector</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-074	07-Jan-2024	Not Specified
	Contact Name	Adriana Costero-Saint Denis, Ph.D.			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-292-4184</p> <p>Contact Email   <a href="mailto:acostero@niaid.nih.gov">acostero@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Notice of Special Interest (NOSI) invites applications to stimulate multidisciplinary research to better understand pathogen/vector interactions to identify approaches to prevent pathogen transmission to the vertebrate host.</p>				
121130	<a href="#">RFA-AI-23-055--Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-055	03-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Dona Love, Ph.D.</p> <p>Contact Telephone   301-761-7788</p> <p>Contact Email   <a href="mailto:Dona.Love@nih.gov">Dona.Love@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jan-2024 [Optional][LOI/Pre-App], 02-Feb-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to support high risk, milestone-driven approaches for the development of robust culture techniques, and/or genetic and molecular tools to better understand the biology of select human eukaryotic pathogens including the microsporidian Enterocytozoon bienewisi; Pneumocystis jirovecii; Plasmodium vivax; and Babesia microti. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.</p>				
108513	<a href="#">NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-075	07-Jan-2024	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by another investigator.</p>				
107589	<a href="#">Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-082	07-Jan-2024	Not Specified
	<p>Contact Name Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone 240-627-3205</p> <p>Contact Email <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</p>				
113395	<a href="#">NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-Jan-2024	Not Specified
	<p>Contact Name Diane Adger-Johnson, MPH</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025 , 05-Jun-2025 , 05-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage applications for research projects within the NIAID mission. This FOA seeks to support either (a) a New Investigator (NI), an individual who has not previously competed successfully for substantial, independent funding from NIH, or (b) are an 'At-Risk' investigator, an individual who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year, from diverse backgrounds, including those from groups underrepresented in the health-related sciences.</p>				
106991	<a href="#">Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-072	07-Jan-2024	Not Specified
	<p>Contact Name Qian "Joy" Liu, M.D., M.Sc.</p> <p>Contact Telephone 301-761-6621</p> <p>Contact Email <a href="mailto:niaidmousemodelnosi@nih.gov">niaidmousemodelnosi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) solicits research on immunologic characterization of mice with diverse microbial exposures (commonly referred to as "dirty mice") to determine their usefulness as research tools to advance understanding of human immune function in homeostasis and in response to infectious or immune-mediated diseases.</p>				
114026	<a href="#">Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-033	14-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sujata Vijh, Ph.D.</p> <p>Contact Telephone 301-761-7713</p> <p>Contact Email <a href="mailto:sujata.vijh@nih.gov">sujata.vijh@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Feb-2024 [Optional][LOI/Pre-App], 15-Mar-2024 , 13-Feb-2025 [Optional][LOI/Pre-App], 14-Mar-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.</p>				
122572	<a href="#">FCO -- Humoral Immunology Core Laboratory for AIDS Vaccine Research</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	75N93023R00012	16-Feb-2024	Not Specified
	<p>Contact Name Christopher Ray</p> <p>Contact Telephone 240-627-3365</p> <p>Contact Email <a href="mailto:chris.ray@nih.gov">chris.ray@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024</p> <p>Synopsis Please see the attached PDF for the solicitation notice (75N93023R00012).</p>				
109528	<a href="#">Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed)</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-22-119	20-Feb-2024	100,000 USD
	<p>Contact Name Su-Yau Mao, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email <a href="mailto:maos2@mail.nih.gov">maos2@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 19-Jun-2024 , 21-Oct-2024 , 19-Feb-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$100,000 direct costs for the entire project period of up to two years, the NIAMS is seeking to enhance the capability of its scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide support, in addition to the career development award, for a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>			
114290	<a href="#">Notice of Special Interest (NOSI): Promoting Research Opportunities on HIV/AIDS in NIAMS</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-004	06-Dec-2023	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p>Heiyoung Park, Ph.D.            301-594-5032  <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a>    <a href="#">Link to program URL</a>            06-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 04-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027 , 07-Jan-2028</p> <p>The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.</p>			
117716	<a href="#">Notice of Special Interest (NOSI): Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-23-006	06-Dec-2023	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Jana Eisenstein
Contact Telephone	301-594-5032
Contact Email	<a href="mailto:jana.eisenstein@nih.gov">jana.eisenstein@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 04-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 06-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 09-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Dec-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027
Synopsis	The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.

117677	<a href="#">Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-23-002	09-Jan-2024	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Hye-Sook Kim, Ph.D.
Contact Telephone	301-827-6910
Contact Email	<a href="mailto:hye-sook.kim@nih.gov">hye-sook.kim@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	09-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 06-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 06-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 08-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 16-Oct-2025
Synopsis	The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA),

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.

109946	<a href="#">Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT-EB-22-006	08-Dec-2023	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	I. George Zubal, Ph.D.
Contact Telephone	301-827-5168
Contact Email	<a href="mailto:igeorge.zubal@nih.gov">igeorge.zubal@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024
Synopsis	The purpose of this Notice is to inform potential applicants to the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in developing nuclear medicine imaging technologies to achieve more cost-efficient clinical Single-Photon Emission Computerized Tomography (SPECT) applications.

112833	<a href="#">Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-215	05-Feb-2024	2,499,995 USD
--------	--	---	------------	-------------	---------------

Contact Name	Reiko Toyama, Ph.D.
Contact Telephone	301-435-2723
Contact Email	<a href="mailto:toyamar@nih.gov">toyamar@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, 'omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations.			
105349	<a href="#">Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-248	07-Jan-2024	Not Specified
	Contact Name	Sai Majji, PhD			
	Contact Telephone	301-661-9816			
	Contact Email	<a href="mailto:sai.majji@nih.gov">sai.majji@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period.			
107317	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-353	05-Feb-2024	Not Specified
	Contact Name	Mollie Minear, Ph.D.			
	Contact Telephone	301-827-9442			
	Contact Email	<a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.			
115063	<a href="#">Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-22-261	16-Feb-2024	100,000 USD
	Contact Name	Rebecca L. Clark, PhD			
	Contact Telephone	301-496-1175			
	Contact Email	<a href="mailto:rclark@mail.nih.gov">rclark@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.			
115912	<a href="#">Notice of Special Interest (NOSI): Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-23-003	07-Jan-2024	Not Specified
	Contact Name	Ronna Popkin, PhD			
	Contact Telephone	301-827-5121			
	Contact Email	<a href="mailto:ronna.popkin@nih.gov">ronna.popkin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Notice of Special Interest (NOSI) is to encourage research on the processes that facilitate or hinder the achievement of healthy interbirth intervals and promote healthy birth outcomes. Because short interbirth intervals are associated with a range of risk factors and poor maternal and child health outcomes, reducing the proportion of pregnancies conceived within 18 months of a previous pregnancy is a Healthy People 2030 objective. These negative outcomes include a lack of preconception health care, delayed prenatal care, preeclampsia, prematurity, low birth weight, infant mortality, and maternal morbidity and mortality. Short interbirth intervals may also reduce the duration of breastfeeding; conversely, the continuation of breastfeeding can contribute to the lengthening of interbirth intervals. This NOSI is intended to encourage collaboration among researchers across the social, behavioral, biomedical, and public health sciences to elucidate understanding of the modifiable factors behind barriers to enhancing birth intervals.

105045	<a href="#">Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-038	07-Jan-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Regina M. Bures, Ph.D.
Contact Telephone	301-496-9485
Contact Email	<a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.

113756	<a href="#">NCMRR Early Career Research Award (R03 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-23-029	16-Feb-2024	200,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Maria Nurminskaya, PhD
Contact Telephone	240-591-9986
Contact Email	<a href="mailto:Maria.nurminskaya@nih.gov">Maria.nurminskaya@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis   The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (<a href="https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan">https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan</a>). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
113468	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Placental Research for Healthy Pregnancies (Reissue)</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-22-049	07-Jan-2024	Not Specified
	<p>Contact Name   John V. Ilekis, PhD</p> <p>Contact Telephone   301-435-6895</p> <p>Contact Email   <a href="mailto:ilekisj@nih.gov">ilekisj@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025</p> <p>Synopsis   Although the placenta is a short-lived organ limited to pregnancy, its importance is often underappreciated in being a crucial organ for the propagation of our species and future health of our progeny. Perturbations in any one of its many functions may result in many common adverse pregnancy outcomes. These include early pregnancy loss, preeclampsia, fetal growth restriction, stillbirth, and preterm birth. In addition, a poorly functioning placenta can lead to aberrant programming of the fetus that can impact the health of the individual later in adult life. This includes an increased incidence of adult diseases such as obesity, cardiovascular disease, and diabetes. Thus, a more comprehensive understanding of the placenta is necessary to help address a number of major gaps in knowledge.</p>				
107320	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-354	16-Feb-2024	100,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Mollie Minear, Ph.D.</p> <p>Contact Telephone   301-827-9442</p> <p>Contact Email   <a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis   This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.</p>				
103657	<a href="#">NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-231	07-Jan-2024	50,000 USD
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103808	<a href="#">Notice of Special Interest (NOSI): Reproductive Health, Pregnancy, and Parenting among Women with Disabilities</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-025	07-Jan-2024	Not Specified
	<p>Contact Name   Rosalind King, Ph.D.</p> <p>Contact Telephone   301-435-6986</p> <p>Contact Email   <a href="mailto:kingros@mail.nih.gov">kingros@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to encourage and support research studies in women with disabilities (WWD) in any of three interconnected areas of high priority to NICHD: Gynecologic care and preconception health for women and adolescent girls with disabilities Pregnancy in WWD Postpartum and parenting needs of WWD It is not expected or required that all areas will be addressed in one application.</p>				
103810	<a href="#">Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth</a>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-026	07-Jan-2024	Not Specified
	<p>Contact Name   Valerie Maholmes, Ph.D., CAS</p> <p>Contact Telephone   301-496-1514</p> <p>Contact Email   <a href="mailto:maholmev@mail.nih.gov">maholmev@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   Pre-existing disparities and apparent challenges in resources for treatment and care of children experiencing abuse call for more data and research resources to identify, substantiate and improve care and ultimately outcomes for vulnerable children and youth during and following the current crisis. It is anticipated that research stemming from this NOSI will help to provide greater recognition of the need for better resources and support for vulnerable children. More touchpoints for communication, identification and screening for risks of child trauma, and injury will help inform processes for screening, identification, treatment and care in new and emerging disaster related contexts in the future.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103656	<a href="#">NICHD Small Research Grant Program (R03 Clinical Trial Required)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-21-221	07-Jan-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
107319	<a href="#">Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-355	16-Feb-2024	275,000 USD
	<p>Contact Name Mollie Minear, Ph.D.</p> <p>Contact Telephone 301-827-9442</p> <p>Contact Email <a href="mailto:mollie.minear@nih.gov">mollie.minear@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</p> <p>Synopsis This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
122319	<a href="#">RFA-HD-25-008 -- Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-25-008	29-Feb-2024 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Leigh Allen, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-594-9151</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:leigh.allen@nih.gov">leigh.allen@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>29-Feb-2024 [Optional][LOI/Pre-App], 29-Mar-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this notice of funding opportunity (NOFO) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization using high molecular weight polymers, biologics, and devices. This NOFO aims to position innovative and validated methods for future clinical development.</td> </tr> </table>					Contact Name	Leigh Allen, PhD	Contact Telephone	301-594-9151	Contact Email	<a href="mailto:leigh.allen@nih.gov">leigh.allen@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	29-Feb-2024 [Optional][LOI/Pre-App], 29-Mar-2024	Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization using high molecular weight polymers, biologics, and devices. This NOFO aims to position innovative and validated methods for future clinical development.
Contact Name	Leigh Allen, PhD																		
Contact Telephone	301-594-9151																		
Contact Email	<a href="mailto:leigh.allen@nih.gov">leigh.allen@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	29-Feb-2024 [Optional][LOI/Pre-App], 29-Mar-2024																		
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization using high molecular weight polymers, biologics, and devices. This NOFO aims to position innovative and validated methods for future clinical development.																		
121650	<a href="#">RFA-DE-24-006 -- NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-24-006	26-Dec-2023 [Optional][LOI/Pre-App]	5,200,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Lillian Shum, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-594-0618</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:ShumL@mail.nih.gov">ShumL@mail.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>26-Dec-2023 [Optional][LOI/Pre-App], 26-Jan-2024 , 13-Feb-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship, and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow them to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.</td> </tr> </table>					Contact Name	Lillian Shum, PhD	Contact Telephone	301-594-0618	Contact Email	<a href="mailto:ShumL@mail.nih.gov">ShumL@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	26-Dec-2023 [Optional][LOI/Pre-App], 26-Jan-2024 , 13-Feb-2024	Synopsis	The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship, and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow them to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
Contact Name	Lillian Shum, PhD																		
Contact Telephone	301-594-0618																		
Contact Email	<a href="mailto:ShumL@mail.nih.gov">ShumL@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	26-Dec-2023 [Optional][LOI/Pre-App], 26-Jan-2024 , 13-Feb-2024																		
Synopsis	The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship, and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow them to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.																		
102596	<a href="#">NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-160	07-Jan-2024	Not Specified														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Dena Fischer, DDS, MSD, MS</p> <p>301-594-4876</p> <p><a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 06-Feb-2024 , 07-May-2024</p> <p>This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing diagnostic, prevention or treatment approaches to test a drug, biologic, device, or procedure for dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven UG3 planning phase, with possible transition to a UH3 clinical trial implementation phase of up to five years. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. The UG3 planning phase permits both operational and scientific planning activities. Operational planning activities include, at minimum, finalizing the protocol and preparing other documents to implement the clinical trial (e.g., data collection instruments, Manual of Procedures, data management plan). Allowable scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned intervention and associated study procedures (e.g., acceptability of mode of intervention delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures) and assessment of the subject population to determine recruitment potential for the future trial. The UG3 phase cannot be used to test for intervention safety or efficacy. If the application proposes a clinical trial with an investigational drug, biologic or device, the investigators must have submitted the appropriate investigational application to the FDA prior to the UH3 phase.</p>
---	---

117461	<a href="#">NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-162	07-Jan-2024	Not Specified
--------	--	---	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Lorena Baccaglini, DDS, MS, PhD</p> <p>301-435-7908</p> <p><a href="mailto:lorena.baccaglini@nih.gov">lorena.baccaglini@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p>
---	---



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026			
	Synopsis	This NOFO will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens.			
117230	<a href="#">NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-133	07-Jan-2024	Not Specified
	Contact Name	Noffisat Oki			
	Contact Telephone	301-402-6778			
	Contact Email	<a href="mailto:noffisat.oki@nih.gov">noffisat.oki@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026			
	Synopsis	The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.			
108355	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Basic Experimental Studies Involving Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-043	07-Jan-2024	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	<p>The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>

108353	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-041	07-Jan-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-042). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-22-043).

108354	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-042	07-Jan-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independently funded dentist scientists dedicated to improving dental, oral and craniofacial health. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. An option for five years of independent (R00) support is available to accommodate clinical training in a dental specialty program at no more than 3 person-months effort (25% full-time professional effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-041).			
108402	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-044	07-Jan-2024	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025			
	Synopsis	The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-22-045).			
108403	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-045	07-Jan-2024	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	<p>The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-044).</p>				
117231	<a href="#">NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-23-132	07-Jan-2024	200,000 USD	
	Contact Name	Noffisat Oki				
	Contact Telephone	301-402-6778				
	Contact Email	<a href="mailto:noffisat.oki@nih.gov">noffisat.oki@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026				
	Synopsis	<p>The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.</p>				
116699	<a href="#">Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-23-004	07-Jan-2024	Not Specified	
	Contact Name	Amanda Melillo, Ph.D.				
	Contact Telephone	301-529-7217				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:amanda.melillo@nih.gov">amanda.melillo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is reissuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19).</p>				
108981	<p><a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-052	07-Jan-2024	Not Specified
	<p>Contact Name Leslie A. Frieden, Ph.D.</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

108979	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-051	07-Jan-2024	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-22-050).

108980	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-050	07-Jan-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, Ph.D.
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and social sciences, to ensure a well-trained dental, oral, and craniofacial research workforce. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-22-051).

108427	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Basic Experimental Studies Involving Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-046	07-Jan-2024	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name Leslie A. Frieden, PhD  
 Contact Telephone 301-496-4263  
 Contact Email [leslie.frieden@nih.gov](mailto:leslie.frieden@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Oct-2024 , 07-Jan-2025

Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.					
110754	<a href="#">Notice of Special Interest (NOSI): Achieving Tissue Robustness Through Harnessing Immune System Plasticity</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE-22-005	07-Jan-2024	Not Specified
	<p>Contact Name   Preethi Chander, PhD</p> <p>Contact Telephone   301-827-4620</p> <p>Contact Email   <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.</p>				
100931	<a href="#">NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-084	07-Jan-2024	200,000 USD
	<p>Contact Name   Preethi Chander, PhD</p> <p>Contact Telephone   301-827-4620</p> <p>Contact Email   <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.			
106245	<a href="#">NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317	07-Jan-2024	Not Specified
	Contact Name	Melissa W. Riddle, PhD			
	Contact Telephone	301-451-3888			
	Contact Email	<a href="mailto:riddleme@mail.nih.gov">riddleme@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 06-Feb-2024 , 06-Mar-2024 , 07-May-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial Requirements for Grants and Contracts for guidance).</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110993	<a href="#">Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-121	07-Jan-2024	Not Specified
	<p>Contact Name   Leslie A. Frieden, PhD</p> <p>Contact Telephone   301-496-4263</p> <p>Contact Email   <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025</p> <p>Synopsis   The goal of the NIDCR Career Enhancement Award (K18) is to support mentored research experiences for established investigators who either wish to expand or augment their dental, oral, or craniofacial (DOC) research program, or to redirect their research by incorporating DOC research into their research program to advance fundamental knowledge about dental, oral, and craniofacial health and disease. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
101371	<a href="#">NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-101	15-Feb-2024	450,000 USD
	<p>Contact Name   Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone   301-594-4748</p> <p>Contact Email   <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Feb-2024</p> <p>Synopsis   NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.</p>			
115011	<a href="#">RFA-DK-22-028 -- Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-22-028	29-Jan-2024 [Optional][LOI/Pre-App]	1,050,000 USD
	Contact Name	Miranda M Broadney, MD, MPH			
	Contact Telephone	301-594-6841			
	Contact Email	<a href="mailto:Miranda.Broadney@nih.gov">Miranda.Broadney@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jan-2024 [Optional][LOI/Pre-App], 29-Feb-2024			
	Synopsis	<p>The purpose of this NIDDK Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials to test pragmatic interventions that include screening for adverse social determinants of health (SDoH) and referring or providing resource service linkages for social services within the healthcare setting for individuals living with type 1 diabetes. The pilot trials will determine 1) feasibility of screening for social risks and implementing referral service linkages (e.g., connecting persons in need to appropriate transportation, housing, food, etc. resources) within the context of a healthcare encounter, and 2) preliminary signals of the intervention’s impact on both the social risk(s) and type 1 diabetes (T1D) specific outcomes such as glycemic control. The overarching goal of this FOA is to stimulate collaborations between healthcare systems, community-based organizations, and social service entities for testing and advancing effective interventions which integrate social care and medical care to reduce health disparities in T1D.</p>			
116589	<a href="#">Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-23-086	05-Feb-2024	600,000 USD
	Contact Name	Aynur Unalp-Arida, M.D., M.Sc., Ph.D.			
	Contact Telephone	301-594-8879			
	Contact Email	<a href="mailto:aynur.unalp-arida@nih.gov">aynur.unalp-arida@nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>Synopsis This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.</p>				
108051	<a href="#">Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-096	05-Feb-2024	Not Specified
	<p>Contact Name Shilpa Hattangadi, M.D.</p> <p>Contact Telephone 301-594-7726</p> <p>Contact Email <a href="mailto:shilpam.hattangadi@nih.gov">shilpam.hattangadi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.</p>				
107685	<a href="#">Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-22-074	05-Feb-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Julie Barthold, MD</p> <p>Contact Telephone   301-594-9655</p> <p>Contact Email   <a href="mailto:julia.barthold@nih.gov">julia.barthold@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis   The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.</p>				
122082	<p><a href="#">RFA-DK-25-002 -- Single Source for Continuation of the Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)</a></p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-002	29-Jan-2024 [Optional][LOI/Pre-App]	10,000,000 USD
	<p>Contact Name   Xujing Wang, PhD</p> <p>Contact Telephone   301-451-2862</p> <p>Contact Email   <a href="mailto:xujing.wang@mail.nih.gov">xujing.wang@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024</p> <p>Synopsis   This is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement award to the University of Pennsylvania. The purpose of this Single Source is to extend the Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D). The HPAP-T2D is a resource-generation program that is tasked with: 1) identifying, collecting and intensively characterizing primary pancreatic tissues from patients with T2D and related forms of islet dysfunctions, as well as age-matched controls; and 2) curating, organizing, analyzing and sharing the data resulting from the study of these tissues through the PANC DB open-access resource database. HPAP-T2D is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.			
105892	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-21-024	07-Jan-2024	Not Specified
	<p>Contact Name   Terez Shea-Donohue, Ph.D.</p> <p>Contact Telephone   301 825-2314</p> <p>Contact Email   <a href="mailto:terez.shea-donohue@nih.gov">terez.shea-donohue@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute of Diabetes and Digestive and Kidney Diseases is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders. Interdisciplinary science in this area plays a pivotal role and projects are encouraged to include close collaboration between scientists with expertise in neurodevelopmental disorders and scientists with expertise in neurogastroenterology.</p>				
116446	<a href="#">Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-23-121	08-Jan-2024 [Optional][LOI/Pre-App]	6,250,000 USD
	<p>Contact Name   Hanyu Liang, M.D., Ph.D.</p> <p>Contact Telephone   301-443-8737</p> <p>Contact Email   <a href="mailto:hanyu.liang@nih.gov">hanyu.liang@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jan-2024 [Optional][LOI/Pre-App], 07-Feb-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, as well as new approaches to prevent, treat and cure these</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

diseases, including clinical research. A description of NIDDK scientific program areas can be found at <https://www.niddk.nih.gov/about-niddk/research-areas>.

122000	<a href="#">RFA-DK-25-003 -- Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-25-003	23-Jan-2024 [Optional][LOI/Pre-App]	3,750,000 USD
--------	---	---	---------------	--	---------------

	Contact Name	Peter J. Perrin, Ph.D.
	Contact Telephone	301-451-3759
	Contact Email	<a href="mailto:Peter.Perrin@nih.gov">Peter.Perrin@nih.gov</a>
	Sponsor Website	
	Program URL	<a href="#">Link to program URL</a>
	Deadline Dates (ALL)	23-Jan-2024 [Optional][LOI/Pre-App], 22-Feb-2024 , 23-Sep-2024 [Optional][LOI/Pre-App], 23-Oct-2024
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>

122206	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases (Defunct)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-21-022	06-Feb-2024	Not Specified
--------	--	---	---------------	-------------	---------------

	Contact Name	Hanyu Liang, MD/PhD
	Contact Telephone	301-443- 8737



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:hanyu.liang@nih.gov">hanyu.liang@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Feb-2024 , 06-Feb-2025</p> <p>Synopsis The purpose of the NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.</p>				
113279	<p><a href="#">Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a></p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-129	07-Jan-2024	150,000 USD
	<p>Contact Name Lisa M. Spain, Ph.D.</p> <p>Contact Telephone 301-451-9871</p> <p>Contact Email <a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 16-Mar-2024 , 07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 25-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
106814	<a href="#">RFA-ES-21-007 -- Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-007	02-Jan-2024 [Optional][LOI/Pre-App]	1,425,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Heather Henry, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">984-287-3268</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:heather.henry@nih.gov">heather.henry@nih.gov/</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">02-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement is encouraged.</td> </tr> </table>					Contact Name	Heather Henry, Ph.D.	Contact Telephone	984-287-3268	Contact Email	<a href="mailto:heather.henry@nih.gov">heather.henry@nih.gov/</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	02-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024	Synopsis	The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement is encouraged.
Contact Name	Heather Henry, Ph.D.																		
Contact Telephone	984-287-3268																		
Contact Email	<a href="mailto:heather.henry@nih.gov">heather.henry@nih.gov/</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	02-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024																		
Synopsis	The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research among basic (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward transdisciplinary/translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement is encouraged.																		
116073	<a href="#">RFA-ES-23-003 -- Maintaining and Enriching Environmental Epidemiology Cohorts to Support Scientific and Workforce Diversity (U24 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-23-003	14-Jan-2024 [Optional][LOI/Pre-App]	1,250,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Melissa M. Smarr, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">984-287-4507</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:melissa.smarr@nih.gov">melissa.smarr@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">14-Jan-2024 [Optional][LOI/Pre-App], 13-Feb-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to: (1) support the maintenance and resource infrastructure enrichment of existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations, while strengthening scientific and workforce diversity in environmental health.</td> </tr> </table>					Contact Name	Melissa M. Smarr, PhD	Contact Telephone	984-287-4507	Contact Email	<a href="mailto:melissa.smarr@nih.gov">melissa.smarr@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	14-Jan-2024 [Optional][LOI/Pre-App], 13-Feb-2024	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to: (1) support the maintenance and resource infrastructure enrichment of existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations, while strengthening scientific and workforce diversity in environmental health.
Contact Name	Melissa M. Smarr, PhD																		
Contact Telephone	984-287-4507																		
Contact Email	<a href="mailto:melissa.smarr@nih.gov">melissa.smarr@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	14-Jan-2024 [Optional][LOI/Pre-App], 13-Feb-2024																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to: (1) support the maintenance and resource infrastructure enrichment of existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations, while strengthening scientific and workforce diversity in environmental health.																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119809	<a href="#">RFA-ES-23-011 -- Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-23-011	01-Dec-2023	275,000 USD
	<p>Contact Name   Toccara Chamberlain, M.A.</p> <p>Contact Telephone   984-287-4482</p> <p>Contact Email   <a href="mailto:toccara.chamberlain@nih.gov">toccara.chamberlain@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Dec-2023 , 01-Feb-2024 , 01-Apr-2024 , 01-Apr-2024 , 03-Jun-2024 , 01-Aug-2024 , 01-Oct-2024 , 02-Dec-2024 , 03-Mar-2025 , 02-Jun-2025 , 01-Aug-2025 , 01-Oct-2025 , 01-Dec-2025</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 4-6 months.</p>				
102785	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-170	12-Feb-2024	375,000 USD
	<p>Contact Name   Carol Shreffler, PhD</p> <p>Contact Telephone   984-287-3322</p> <p>Contact Email   <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024</p> <p>Synopsis   The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.

102788	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-172	12-Feb-2024	375,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Carol Shreffler, PhD  
 Contact Telephone | 984-287-3322  
 Contact Email | [shreffl1@niehs.nih.gov](mailto:shreffl1@niehs.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Feb-2024

Synopsis | The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-171. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants”, should apply to the companion FOA PAR-21-170)

102787	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-21-171	12-Feb-2024	375,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | Carol Shreffler, PhD  
 Contact Telephone | 984-287-3322

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Feb-2024</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial trial, as part of their research and career development. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants", must apply to companion FOA, PAR-21-170. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-21-172.</p>				
113566	<a href="#">Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics</a>	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-23-002	07-Jan-2024	Not Specified
	<p>Contact Name Lingamanaidu V. Ravichandran, Ph.D</p> <p>Contact Telephone 984-287-3309</p> <p>Contact Email <a href="mailto:lingamanaidu.ravichandran@nih.gov">lingamanaidu.ravichandran@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 16-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 16-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 16-Oct-2027</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
117879	<a href="#">Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-23-145	01-Feb-2024	1,250,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sailaja Koduri, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:sailaja.koduri@nih.gov">sailaja.koduri@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>01-Feb-2024 , 03-Oct-2024 , 03-Feb-2025 , 03-Oct-2025 , 03-Feb-2026</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.</td> </tr> </table>					Contact Name	Sailaja Koduri, Ph.D.	Contact Telephone		Contact Email	<a href="mailto:sailaja.koduri@nih.gov">sailaja.koduri@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	01-Feb-2024 , 03-Oct-2024 , 03-Feb-2025 , 03-Oct-2025 , 03-Feb-2026	Synopsis	The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.
Contact Name	Sailaja Koduri, Ph.D.																		
Contact Telephone																			
Contact Email	<a href="mailto:sailaja.koduri@nih.gov">sailaja.koduri@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	01-Feb-2024 , 03-Oct-2024 , 03-Feb-2025 , 03-Oct-2025 , 03-Feb-2026																		
Synopsis	The Maximizing Investigators' Research Award (MIRA) under this FOA is a grant to provide support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this FOA will: Enable investigators to apply earlier in their independent research careers, allowing them to secure grant funding that will launch and sustain successful research careers. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors, which could lead to new scientific discoveries. Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively. Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs. Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research. Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.																		
108741	<a href="#">Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies</a>	National Institute of General Medical Sciences/NIH/DHHS	NOT-GM-22-021	08-Dec-2023	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Veerasamy (Ravi) Ravichandran, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:Veerasamy.ravichandra@nih.gov">Veerasamy.ravichandra@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> </table>					Contact Name	Veerasamy (Ravi) Ravichandran, Ph.D.	Contact Telephone		Contact Email	<a href="mailto:Veerasamy.ravichandra@nih.gov">Veerasamy.ravichandra@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>				
Contact Name	Veerasamy (Ravi) Ravichandran, Ph.D.																		
Contact Telephone																			
Contact Email	<a href="mailto:Veerasamy.ravichandra@nih.gov">Veerasamy.ravichandra@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 08-Dec-2024 , 07-Jan-2025

Synopsis | The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that incorporates economic factors. The Institute is particularly interested in mathematical and computational modeling studies of infectious disease spread and evolution, and of the effects of possible intervention strategies, that include consideration of economic influences and feedback.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121164	<a href="#">RFA-MH-25-125 -- Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R34 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-125	20-Jan-2024 [Optional][LOI/Pre-App]	450,000 USD

Contact Name | Stephen O'Connor, Ph.D.

Contact Telephone | 301-480-8366

Contact Email | [stephen.o'connor2@nih.gov](mailto:stephen.o'connor2@nih.gov)

Sponsor Website |

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 20-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024

Synopsis | This initiative supports pilot work for subsequent research to test the effectiveness of combined interventions to both detect and intervene to reduce risk of suicide and suicide ideation and behavior (SIB), and non-suicidal self-injury (NSSI) specifically among children and adolescents from underserved populations. Applications should focus on developmental work that would enhance the probability of success in subsequent larger scale R01 projects. Research generating new information about factors causing/reducing disparities is strongly encouraged, along with due consideration for the variation in developmental needs across children and youth. Applications proposing definitive tests of an intervention/implementation strategy should respond to the companion R01 announcement RFA-MH-21-187. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. This Funding Opportunity Announcement (FOA) invites development of service strategies that are designed to be delivered in typical service settings using commonly available personnel and resources, to enhance the future implementation of interventions that are proven effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social and contextual factors, the service strategy under development

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

should account for individual-, family, community-, provider-, and organizational-level factors necessary to optimize effectiveness, feasibility, and rapid uptake, implementation and sustained delivery, thereby accelerating the benefit to the population. The intervention should improve connections to preventive and treatment interventions with proven effectiveness in reducing suicide and suicidal ideation and behaviors, with the goal of making these more available, accessible, and more effectively delivered to underserved youth, in a sustained and coordinated way. This FOA encourages pilot research focused on the development of systems-level interventions and is not intended to support development or testing of new screening tools, assessment instruments, or pilot studies for the development of individual-level preventive or therapeutic interventions. This FOA is published in parallel to a companion R01 FOA (RFA-MH-21-187) supporting larger scale tests of effectiveness and/or implementation of the type of studies described here. This FOA is focused on services interventions for use in settings that primarily serve underserved youth; support for studies focused specifically on Black youth is provided via RFA-MH-21-185 (R01) and RFA-MH-21-186 (R34).

121165	<a href="#">RFA-MH-25-126 -- Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-25-126	20-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Stephen O'Connor, Ph.D.
Contact Telephone	301-480-8366
Contact Email	<a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024
Synopsis	<p>This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide and suicide ideation and behavior (SIB) and/or non-suicidal self-harm (NSSI) by youth from populations that are often underserved by the mental health system. Specifically, this Funding Opportunity Announcement (FOA) encourages services research aimed at testing easily implemented systems-level interventions and strategies that improve systematic risk identification, coordinated referral to, or engagement and retention in quality care for prevention of SIB and/or NSSI among adolescents and children from the targeted populations. Opportunities for detection and prevention in youth may occur at various points of contact across an array of mental health specialty and non-specialty settings. The service strategies to be tested under this announcement should be designed for delivery in typical service settings using commonly available personnel and resources, to enhance implementation and future uptake in diverse settings, and thereby reduce risk of suicide and self-harm. Given the importance of cultural, social, and contextual factors, the intervention strategies should account for individual-, family-, community-, provider-, and organizational-level factors to</p>



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>optimize effectiveness, feasibility, acceptability, rapid uptake and sustained delivery. The strategy should also improve connections to preventive and treatment interventions with proven effectiveness in reducing SIB or NSSI, with the goal of making these interventions more available, accessible, and more effectively delivered to youth, in a sustained and coordinated way. This FOA encourages research focused on systems-level interventions and is not intended to support the development or testing of new screening tools, assessment instruments, or individual-level preventive or therapeutic interventions. This FOA is published in parallel to a companion R34 FOA (RFA-MH-21-188) supporting pilot studies in preparation for the larger-scale studies described here. This FOA is focused on services interventions for use in settings that primarily serve underserved youth. Support for studies focused specifically on Black youth is provided via RFA-MH-21-185 (R01) and RFA-MH-21-186 (R34).A</p>			
103213	<a href="#">Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-210	05-Feb-2024	Not Specified
	<p>Contact Name   Adam Haim, Ph.D.</p> <p>Contact Telephone   301-435-3593</p> <p>Contact Email   <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024</p> <p>Synopsis   NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, PAR-21-211.</p>				
119702	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-024	05-Feb-2024	Not Specified
	<p>Contact Name   David Panchision</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Telephone	301-402-3969			
	Contact Email	<a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) encourages research on the biology of high-confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular, and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular, and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components, and processes. The resulting paradigms, component pathways, and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established. Applicants proposing exploratory research at the early and conceptual stages of project development should apply to the companion R21 NOFO PAR-24-025</p>			

119663	<a href="#">Schizophrenia and Related Disorders During mid- to Late-Life (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-023	05-Feb-2024	Not Specified
--------	--	--	------------	-------------	---------------

	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-480-8335			
	Contact Email	<a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R01 grant mechanism, while the companion NOFO (PAR-24-026), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.</p>			
118003	<a href="#">Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-235	07-Jan-2024	Not Specified
	Contact Name	Margaret Grabb, Ph.D.			
	Contact Telephone	301-443-3563			
	Contact Email	<a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026			
	Synopsis	<p>The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration’s (FDA’s) guidance on natural history studies for rare disorders).</p>			
118004	<a href="#">Notice of Special Interest (NOSI): Pre-Clinical Research on Gene Therapies for Rare Genetic Neurodevelopmental Disorders</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-236	07-Jan-2024	Not Specified
	Contact Name				
	Contact Telephone	301-443-3563			
	Contact Email	<a href="mailto:NIMHgenetherapies@nih.gov">NIMHgenetherapies@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026			
	Synopsis	The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to highlight interest in pre-clinical research aimed at developing novel approaches for somatic cell gene therapies to treat neurodevelopmental disorders with prominent cognitive, social and/or affective impairment.			
102908	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-175	05-Feb-2024	Not Specified
	Contact Name	Andrew Rossi, Ph.D.			
	Contact Telephone	301-443-1576			
	Contact Email	<a href="mailto:andrew.rossi@nih.gov">andrew.rossi@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024			
	Synopsis	A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-21-176, seeks shorter, higher-risk R21 grant applications.			
112309	<a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-170	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Jamie Driscoll</p> <p>301-443-5288</p> <p><a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>
---	--

107489	<a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-066	05-Feb-2024	2,500,000 USD
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Andrew Breeden, Ph.D.</p> <p>301-451-3185</p> <p><a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a></p> <p></p>
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-067, seeks shorter, higher-risk R21 grant applications.</p>				
117750	<a href="#">Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-168	07-Jan-2024	Not Specified
	<p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a “hit” is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.</p>				
115033	<a href="#">Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-093	05-Feb-2024	Not Specified
	Contact Name David McMullen, M.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-451-0180</p> <p>Contact Email   <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion R21 FOA, PAR-21-288, seeks grant applications encouraging shorter, higher-risk studies.</p>				
113136	<p><a href="#">RFA-MH-21-175 -- BRAIN Initiative: Engineering and Optimization of Molecular Technologies for Functional Dissection of Neural Circuits (UM1 Clinical Trial Not Allowed)</a></p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-245	16-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Douglas S. Kim, Ph.D.</p> <p>Contact Telephone   301-827-6463</p> <p>Contact Email   <a href="mailto:douglas.kim@nih.gov">douglas.kim@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 18-Sep-2024 [Optional][LOI/Pre-App], 17-Oct-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) is intended to support the creation of Centers for accelerated engineering and optimization of high-impact, molecular technologies to monitor and/or manipulate brain cell activity in experimental animals. The Centers will produce high-impact molecular probes such as, but not limited to, fluorescent protein indicators of neuronal state variables (e.g., intracellular calcium, membrane voltage, released neurotransmitters/neuromodulators, etc.), molecular integrators of neural activity, optogenetic, chemogenetic, sonogenetic, magnetogenetic actuators, and activity-dependent molecular switches. This FOA is part of the Brain Research through Advancing Innovative Neurotechnologies</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

(BRAIN Initiative Armamentarium project, whose goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple species. In this FOA, technology optimization is sought for existing tools for brain cell monitoring or manipulation that are beyond the proof-of-concept stage and that can be delivered selectively as payloads to cell types using newly developed brain cell access reagents. Each Molecular Payloads Center is expected to integrate: (1) sufficiently scaled molecular engineering, (2) in vivo validation of improvements seen in engineering assays in intact brains of experimental animals, (3) benchmarking throughout the technology development against existing best-in-class tools, and (4) adaptation of tools into easily produced and applied formats for neuroscience users. Molecular Payloads Centers may also include optional demonstration experiments that establish groundbreaking capabilities of improved molecular tools in vivo. This FOA will foster close interaction between technologists and neurobiologists in a research consortium including tool developers funded by other Armamentarium FOAs for brain cell access reagents. The Armamentarium consortium will promote rigorous technology design, benchmarking, validation, and distribution of monitoring and/or manipulation tools and associated brain cell access reagents.

103214	<a href="#">Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-211	16-Feb-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Adam Haim, Ph.D.  
 Contact Telephone | 301-435-3593  
 Contact Email | [haima@mail.nih.gov](mailto:haima@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Feb-2024

Synopsis | NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.			
102910	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-176	16-Feb-2024	275,000 USD
	Contact Name	Andrew Rossi, Ph.D.			
	Contact Telephone	301-443-1576			
	Contact Email	<a href="mailto:andrew.rossi@nih.gov">andrew.rossi@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024			
	Synopsis	<p>A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 exploratory grant mechanism, whereas its companion FOA, PAR-21-175, seeks R01 grant applications for larger research applications that have an established premise.</p>			
114549	<a href="#">Notice of Special Interest (NOSI): The Neural Mechanisms of Multi-Dimensional Emotional and Social Representation</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-23-120	07-Jan-2024	Not Specified
	Contact Name	Andrew Breeden, Ph.D.			
	Contact Telephone				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:andrew.breeden@nih.gov">andrew.breeden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research that incorporates a multi-dimensional perspective into studies of the neural mechanisms underlying emotional and/or social representations. The ability to integrate a broad array of emotional and social information is impaired in many mental disorders, yet the neural mechanisms underlying these processes are not well understood. This NOSI encourages studies in humans and animals investigating how diverse multi-dimensional emotional and/or social cues are represented across brain circuits that are important for mental health relevant cognitive, social, and affective behavioral functions. The term “multi-dimensional” refers to the consideration of multiple modalities (e.g., social, emotional, visual, and auditory), the effects of complex contexts and development, and/or dynamic processes that unfold over a variety of temporal scales.</p>				
102539	<a href="#">Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment and Cure</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-105	08-Dec-2023	Not Specified
	<p>Contact Name Collene Lawhorn, Ph.D.</p> <p>Contact Telephone 301-828-7186</p> <p>Contact Email <a href="mailto:collene.lawhorn@nih.gov">collene.lawhorn@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024</p> <p>Synopsis The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.</p>				
107450	<a href="#">Notice of Special Interest (NOSI): Secondary Analysis of Posttraumatic Psychopathology Data</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-045	15-Dec-2023	Not Specified
	<p>Contact Name Susan Borja, Ph.D.</p> <p>Contact Telephone 310-443-1252</p> <p>Contact Email <a href="mailto:susan.borja@nih.gov">susan.borja@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to analyze existing and accumulating data to aid in refining phenotypes of posttraumatic psychopathology(ies), markers of onset and change, and risk detection. NIMH is also interested in research using available data to identify potential prevention and treatment targets and to advance and refine measurement and validation of potential novel targets for future development in experimental therapeutics research.</p>				
115199	<a href="#">Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-087	21-Feb-2024	Not Specified
	<p>Contact Name Jamie Driscoll</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email <a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 21-Feb-2024 , 21-Jun-2024 , 21-Oct-2024 , 21-Feb-2025 , 20-Jun-2025</p> <p>Synopsis The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to pharmacologic manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.			
115061	<a href="#">Mood and Psychosis Symptoms During the Menopause Transition (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-097	05-Feb-2024	Not Specified
	Contact Name	Laura M. Rowland, Ph.D.			
	Contact Telephone	301-480-8335			
	Contact Email	<a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036 ) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.			
115058	<a href="#">Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-095	05-Feb-2024	Not Specified
	Contact Name	Michael C. Freed, Ph.D., EMT			
	Contact Telephone	301-443-3747			
	Contact Email	<a href="mailto:michael.freed@nih.gov">michael.freed@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.

115044	<a href="#">Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-094	05-Feb-2024	2,500,000 USD
--------	---	--	------------	-------------	---------------

Contact Name	Susan T. Azrin, Ph.D.
Contact Telephone	301-443-3267
Contact Email	<a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		services outcomes. This FOA is published in parallel to a companion R34 FOA, PAR-21-292 supporting pilot studies in preparation for the larger-scale studies described here.			
115030	<a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-091	07-Jan-2024	Not Specified
	Contact Name	Jamie Driscoll			
	Contact Telephone	301-443-5288			
	Contact Email	<a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025			
	Synopsis	<p>The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>			
115060	<a href="#">Laboratories to Optimize Digital Health (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-096	05-Feb-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Adam Haim, Ph.D.</p> <p>Contact Telephone   301-435-3593</p> <p>Contact Email   <a href="mailto:Haima@mail.nih.gov">Haima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025</p> <p>Synopsis   NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.</p>				
115032	<p><a href="#">Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)</a></p>	National Institute of Mental Health/NIH/DHHS	PAR-23-092	05-Feb-2024	Not Specified
	<p>Contact Name   Susan T. Azrin, Ph.D.</p> <p>Contact Telephone   301-443-3267</p> <p>Contact Email   <a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		including due consideration of the needs of individuals across the life span. This FOA is published in parallel to a companion R34, PAR-21-283, that supports pilot studies in preparation for the larger-scale studies described here.			
102513	<a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-135	15-Feb-2024	Not Specified
	Contact Name	Alexander Talkovsky, Ph.D.			
	Contact Telephone	301-827-7614			
	Contact Email	<a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>			
102530	<a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-137	15-Feb-2024	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Margaret Grabb, Ph.D.</p> <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Feb-2024</p> <p>Synopsis   NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				
102528	<a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-136	15-Feb-2024	Not Specified

	<p>Contact Name   Margaret Grabb, Ph.D.</p> <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Feb-2024</p> <p>Synopsis   NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials,</p>				
--	---	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, PAR-21-137or PAR-21-133.

115201	<a href="#">Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-102	16-Feb-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Laura M. Rowland, Ph.D.  
 Contact Telephone | 301-480-8335  
 Contact Email | [laura.rowland@nih.gov](mailto:laura.rowland@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. This FOA uses the R21 mechanism, while the companion FOA (PAR-23-097) uses the R01 grant mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.

115202	<a href="#">Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required )</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-103	16-Feb-2024	450,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | Susan T. Azrin, Ph.D.  
 Contact Telephone | 301-443-3267

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of individuals across the life span. Applications proposing definitive tests of an implementation strategy should respond to the companion R01 announcement PAR-23-092.</p>				
115200	<a href="#">Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-101	16-Feb-2024	275,000 USD
	<p>Contact Name Lizzy Ankudowich, Ph.D.</p> <p>Contact Telephone 301-480-8187</p> <p>Contact Email <a href="mailto:lizzy.ankudowich@nih.gov">lizzy.ankudowich@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This FOA aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to invasive recording modalities that have high translational potential. Development of new therapies is outside the scope of this FOA, though development of novel tools/methods to enable relevant mental health studies is encouraged. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-23-093, seeks R01 grant applications.

115204	<a href="#">Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-104	16-Feb-2024	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name | Susan T. Azrin, Ph.D.  
 Contact Telephone | 301-443-3267  
 Contact Email | [azrinst@mail.nih.gov](mailto:azrinst@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Feb-2024 , 16-Jun-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of existing family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and pilot test the navigator model’s ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and pilot test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA is published in parallel to a companion R01 FOA, PAR-23-094 which uses the R01 funding mechanism.

115209	<a href="#">Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-105	16-Feb-2024	450,000 USD
--------	---	--	------------	-------------	-------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Susan T. Azrin, Ph.D.</p> <p>Contact Telephone   301-443-3267</p> <p>Contact Email   <a href="mailto:azrinst@mail.nih.gov">azrinst@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Test the feasibility of integrating and analyzing large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches; Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.</p>				
119664	<a href="#">Schizophrenia and Related Disorders During mid- to Late-Life (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-026	16-Feb-2024	275,000 USD
	<p>Contact Name   Laura M. Rowland, Ph.D.</p> <p>Contact Telephone   301-480-8335</p> <p>Contact Email   <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions. This NOFO uses the R21 grant mechanism, while the companion NOFO (PAR-24-023) uses the R01 mechanism. Investigators proposing high</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.					
119705	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-24-025	16-Feb-2024	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	David Panchision 301-402-3969 <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>  <a href="#">Link to program URL</a> 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO , the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO (PAR-24-024).			
102507	<a href="#">Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-131	15-Feb-2024	450,000 USD
	Contact Name	Joel Sherrill, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-443-2477 <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>  <a href="#">Link to program URL</a> 15-Feb-2024  Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Support for fully-powered effectiveness studies is provided through separate FOAs that utilize the R01 mechanism for single-site effectiveness trials (PAR-21-130; "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01).") and collaborative R01 mechanism for multi-site effectiveness trials (PAR-21-129;"Clinical Trials to Test the Effectiveness of Treatment, Prevention, and Services Interventions (Collaborative R01 Clinical Trial Required)"). Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.
--	---

102505	<a href="#">Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-129	15-Feb-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Contact Telephone Contact Email	Joel Sherrill, Ph.D. 301-443-2477 <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024</p> <p>Synopsis</p> <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. Support for fully-powered effectiveness studies via a single R01 grant is provided through a separate FOA, PAR-21-130, "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)." This FOA is designed for applicants seeking funding for multi-site collaborative clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				
102506	<a href="#">Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-130	15-Feb-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Joel Sherrill, Ph.D.</p> <p>301-443-2477</p> <p><a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>15-Feb-2024</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102511	<p><a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)</a></p>	National Institute of Mental Health/NIH/DHHS	PAR-21-134	15-Feb-2024	Not Specified
	<p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. Support for multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation) is provided through a separate FOA, PAR-21-129 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)." This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p>				
	<p>Contact Name Alexander Talkovsky, Ph.D.</p> <p>Contact Telephone 301-827-7614</p> <p>Contact Email <a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024</p> <p>Synopsis NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102509	<a href="#">First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-133	15-Feb-2024	Not Specified

may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

Contact Name | Margaret Grabb, Ph.D.  
 Contact Telephone | 301-443-3563  
 Contact Email | [mgrabb@mail.nih.gov](mailto:mgrabb@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Feb-2024

Synopsis | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to “de-risk” novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion FOAs.</p>			
102508	<a href="#">Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-132	15-Feb-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Adam Haim, Ph.D.</p> <p>301-435-3593</p> <p><a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>15-Feb-2024</p>			
	Synopsis	<p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs</p>			
105330	<a href="#">NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-239	12-Feb-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Ashlee Van't Veer, PhD</p> <p>Contact Telephone   301-443-3107</p> <p>Contact Email   <a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbstrainingbranch@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis   The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (IRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
117821	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-23-149	12-Feb-2024	Not Specified
	<p>Contact Name   Ashlee Van't Veer</p> <p>Contact Telephone   301-443-3107</p> <p>Contact Email   <a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbstrainingbranch@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis   The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PAR-23-150.					
104058	<a href="#">NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-21-235	07-Jan-2024	275,000 USD
	Contact Name	Susan Koester, Ph.D.			
	Contact Telephone	301-443-3563			
	Contact Email	<a href="mailto:koesters@mail.nih.gov">koesters@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024			
	Synopsis	The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.			
107491	<a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-067	16-Feb-2024	275,000 USD
	Contact Name	Andrew Breeden, Ph.D.			
	Contact Telephone	301-451-3185			
	Contact Email	<a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity PAR-22-066 seeks R01 grant applications.

106895	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Feb-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | David McMullen, M.D.  
 Contact Telephone | 301-451-0180  
 Contact Email | [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024

Synopsis | The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.

106926	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-039	05-Feb-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name | David McMullen, M.D.  
 Contact Telephone | 301-451-0180

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis                      The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitting in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches.</p>				
114657	<a href="#">Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-23-050	07-Jan-2024	Not Specified
	<p>Contact Name Jonathan Pevsner, Ph.D</p> <p>Contact Telephone 301-728-5618</p> <p>Contact Email <a href="mailto:jonathan.pevsner@nih.gov">jonathan.pevsner@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis                      This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see <a href="https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html">https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html</a>). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.</p>				
108834	<a href="#">Notice of Special Interest (NOSI): Neuro-Glia Mechanisms Governing Complex Behaviors (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-090	07-Jan-2024	Not Specified
	<p>Contact Name   Michele Ferrante, Ph.D.            Contact Telephone   301-435-6782            Contact Email   <a href="mailto:michele.ferrante@nih.gov">michele.ferrante@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025            Synopsis   This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the role of neuro-glia activity coupling in modulating complex behaviors.</p>				
102537	<a href="#">Notice of Special Interest (NOSI): Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-090	07-Jan-2024	Not Specified
	<p>Contact Name   Andrea Horvath Marques, MD, MPH, PhD            Contact Telephone   301-646-7320            Contact Email   <a href="mailto:andrea.horvathmarques@nih.gov">andrea.horvathmarques@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The National Institute of Mental Health is issuing this Notice of Special Interest (NOSI) to highlight interest in developing and implementing prevention strategies to reduce suicide risk (suicide ideation and behavior, including acts of self-harm/suicide) and promote resilience among young people, age 10-24 years, in low-and middle-income countries (LMICs)and low-resources settings. NIMH welcomes applicants from LMICs and strongly encourages applicants from the United States or upper middle-income countries to partner with sites in LMICs.

106896	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Feb-2024	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name David McMullen, M.D.  
 Contact Telephone 301-451-0180  
 Contact Email [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024

Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
106927	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-22-038	16-Feb-2024	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>David McMullen, M.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-0180</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.</p> </td> </tr> </table>					Contact Name	David McMullen, M.D.	Contact Telephone	301-451-0180	Contact Email	<a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.</p>
Contact Name	David McMullen, M.D.																		
Contact Telephone	301-451-0180																		
Contact Email	<a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024																		
Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity, PAR-22-039, seeks R01 grant applications.</p>																		
117822	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)</a>	National Institute of Mental Health/NIH/DHHS	PA-23-150	12-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ashlee Van't Veer</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-3107</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a></td> </tr> </table>					Contact Name	Ashlee Van't Veer	Contact Telephone	301-443-3107	Contact Email	<a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>								
Contact Name	Ashlee Van't Veer																		
Contact Telephone	301-443-3107																		
Contact Email	<a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025 , 12-Feb-2026</p> <p>Synopsis The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-23-149.</p>				
122305	<a href="#">RFA-MH-24-181 -- Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-24-181	01-Feb-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Julia Zehr, Ph.D.</p> <p>Contact Telephone 301-443-1617</p> <p>Contact Email <a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Feb-2024 [Optional][LOI/Pre-App], 01-Mar-2024</p> <p>Synopsis Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental illness and risk for psychopathology. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology. This NOFO seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity RFA-MH-24-180 seeks R01 grant applications proposing longer term projects with supporting preliminary data.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122304	<a href="#">RFA-MH-24-180 -- Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-24-180	01-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Julia Zehr, Ph.D.</p> <p>Contact Telephone   301-443-1617</p> <p>Contact Email   <a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Feb-2024 [Optional][LOI/Pre-App], 01-Mar-2024</p> <p>Synopsis   Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental illness and risk for psychopathology. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental illness, psychiatric symptoms, and risk or resilience for psychopathology. This NOFO uses the R01 grant mechanism, whereas its companion NOFO, RFA-MH-24-181, seeks shorter, higher-risk R21 grant applications.</p>				
108843	<a href="#">Notice of Special Interest (NOSI): NIMH Priorities on Research on Aggression and Violence Against Others</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-22-095	08-Dec-2023	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:NIMHResearchOnAggres@mail.nih.gov">NIMHResearchOnAggres@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025</p> <p>Synopsis   NIMH is issuing this Notice of Special Interest (NOSI) to outline priorities for research on the etiology, risks for, and prevention of interpersonal aggression and violence against others.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117726	<a href="#">RFA-NS-23-026 -- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-23-026	14-Feb-2024	Not Specified
	<p>Contact Name   Natalie Trzcinski, Ph.D</p> <p>Contact Telephone   301-469-1779</p> <p>Contact Email   <a href="mailto:natalie.trzcinski@nih.gov">natalie.trzcinski@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Feb-2024 , 11-Oct-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) supports efforts to disseminate resources for integration into neuroscience research practice. The resource(s) should be relevant to the goals of the BRAIN Initiative as outlined in the "BRAIN 2025: A Scientific Vision" and "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures" and shared broadly to the neuroscience community. The resource(s) should address compelling needs of neuroscience researchers that are otherwise unavailable or impractical in their current form. Activities must include dissemination of an existing resource, and may include one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and/or specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications primarily focused on technology or software development and where broad dissemination is not planned to be initiated by year 2 are not responsive to this FOA.</p>				
100306	<a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-Jan-2024	Not Specified
	<p>Contact Name   Stephen Korn, Ph.D.</p> <p>Contact Telephone   301-496-4188</p> <p>Contact Email   <a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 09-Feb-2024 , 07-May-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

115920	<a href="#">NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-090	06-Feb-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Jeremy Brown, MD  
 Contact Telephone | 301-594-4481  
 Contact Email | [jeremy.brown@nih.gov](mailto:jeremy.brown@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 06-Feb-2024 , 10-Jun-2024 , 08-Oct-2024 , 07-Feb-2025 , 06-Jun-2025 , 07-Oct-2025 , 06-Feb-2026

Synopsis This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN.</p>				
110549	<a href="#">NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-142	08-Feb-2024	Not Specified
	<p>Contact Name   Jeremy Brown MD</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Feb-2024 , 10-Jun-2024 , 08-Oct-2024 , 10-Feb-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism.</p>				
107322	<a href="#">Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-030	08-Feb-2024	Not Specified
	<p>Contact Name   Ann-Marie Broome, PhD, MBA</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:ann-marie.broome@nih.gov">ann-marie.broome@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Feb-2024 , 07-Jun-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.			
111360	<a href="#">Notice of Special Interest (NOSI): Disease Mechanisms of Prenatal and Pediatric Hydrocephalus</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-004	07-Jan-2024	Not Specified
	Contact Name	Jill Morris, Ph.D.			
	Contact Telephone	301-496-5754			
	Contact Email	<a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025			
	Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis-driven research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.			
108301	<a href="#">RFA-NS-22-034 -- HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-034	07-Dec-2023	Not Specified
	Contact Name	Michael L. Oshinsky, PhD			
	Contact Telephone	301-496-9964			
	Contact Email	<a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Dec-2023 , 02-Feb-2024 , 09-Apr-2024 , 04-Jun-2024 , 07-Aug-2024 , 02-Oct-2024 , 06-Dec-2024			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

104258	<a href="#">NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-237	07-Jan-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Jeremy Brown, MD  
 Contact Telephone | 301-496-9135  
 Contact Email | [Jeremy.brown@nih.gov](mailto:Jeremy.brown@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2024 , 09-Feb-2024 , 07-May-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<https://www.ninds.nih.gov/>).

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
111120	<a href="#">Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-184	20-Feb-2024	3,750,000 USD
	<p>Contact Name: Glen H. Nuckolls, Ph.D.</p> <p>Contact Telephone: 301-496-5745</p> <p>Contact Email: <a href="mailto:glen.nuckolls@nih.gov">glen.nuckolls@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 20-Feb-2024 , 19-Aug-2024 , 19-Feb-2025</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS expects to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.</p>				
103724	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-234	07-Jan-2024	Not Specified
	<p>Contact Name: Michelle Jones-London, Ph.D.</p> <p>Contact Telephone: 301-451-7966</p> <p>Contact Email: <a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis: The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153).

109940	<a href="#">Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-076	07-Jan-2024	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Adam L. Hartman, MD
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 20-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 18-Oct-2024 , 07-Jan-2025 , 19-Feb-2025 , 07-May-2025
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

115793	<a href="#">Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-062	05-Jan-2024	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Amelie Gubitza, PhD
Contact Telephone	301-332-6453
Contact Email	<a href="mailto:gubitza@nih.gov">gubitza@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Deadline Dates (ALL)   05-Jan-2024 , 20-Feb-2024 , 22-Feb-2024 , 14-Mar-2024 , 05-Apr-2024 , 22-Jun-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to advance research activities relevant to strategic priorities for the ALS research community identified in a recent planning effort of NINDS.</p>					
102747	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 122	20-Feb-2024	750,000 USD
<p>Contact Name   Becky Roof, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 20-Jun-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.</p>					
102739	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21- 123	20-Feb-2024	750,000 USD
<p>Contact Name   Becky Roof, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 20-Jun-2024</p>					

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.</p>			
109299	<a href="#">Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-089	22-Feb-2024	Not Specified
	Contact Name	Carol Taylor-Burds Ph.D			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:carol.taylor-burds@nih.gov">carol.taylor-burds@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Feb-2024 , 07-May-2024 , 22-Jun-2024 , 07-Sep-2024 , 21-Feb-2025 , 07-May-2025			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of fit-for-purpose candidate biomarkers and biomarker signatures that enable more efficient clinical trials to advance therapeutic development or be used in clinical practice to help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarkers or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for a defined Context of Use(s). In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using carefully standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.</p>			
120765	<a href="#">RFA-NS-24-006 -- Community-Engaged Health Equity Research in Neuroscience Initiative (R01- CT Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-006	03-Jan-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Cheryse A. Sankar, PhD			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-318-2889</p> <p>Contact Email   <a href="mailto:cheryse.sankar@nih.gov">cheryse.sankar@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jan-2024 [Optional][LOI/Pre-App], 02-Feb-2024</p> <p>Synopsis   This NOFO solicits applications to establish clinical trial readiness for community-driven research interventions to decrease disparities in neurological disorders in NIH-designated populations that experience health disparities (HDPs). These clinical studies will utilize community-engaged research and collaborative, multidisciplinary teams to identify, develop, and evaluate strategies to improve outcomes related to neurological disorders in HDPs and fill gaps in clinical trial readiness. Expected outcomes include 1) Identifying and understanding drivers of health disparities and barriers for specific neurological disorders within HDP communities, 2) Identifying specific modifiable targets to prevent and/or decrease neurological morbidity/mortality and inequities among HDPs, and 3) Developing future community-driven research interventions to decrease disparities and gaps in neurological health among HDPs. The National Institute of Neurological Disorders and Stroke (NINDS) intends to enhance the quality and increase the likelihood of success of future clinical trials in neurological health disparities by supporting studies leading to trial readiness.</p>				
120785	<p><a href="#">RFA-NS-24-007 -- Community-Engaged Health Equity Research in Neuroscience Initiative (R34 – CT Not Allowed)</a></p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-24-007	03-Jan-2024 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name   Cheryse A. Sankar, Ph.D.</p> <p>Contact Telephone   301-318-2889</p> <p>Contact Email   <a href="mailto:cheryse.sankar@nih.gov">cheryse.sankar@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jan-2024 [Optional][LOI/Pre-App], 02-Feb-2024</p> <p>Synopsis   This NOFO solicits applications for planning grants to assess feasibility and/or determine best practices to conduct community-engaged health equity research in neurological disorders with populations that experience health disparities (HDPs). If successful, these planning grants would support, enable and/or lay the groundwork for future clinical studies or trials. In addition to posing a research question related to addressing health disparities in neurological disorders, applicants must also be filling a gap in 1) Engagement with one or more HDP communities; and/or 2) Multidisciplinary research team expertise in neurological disorders, health disparities research and/or community-engaged research. Expected outcomes</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	would advance understanding of drivers of health disparities and barriers to neurological health equity and establish collaborative research teams, including community partners, with appropriate expertise in community engagement with HDPs, health disparities research and neurological disorders.				
103817	<a href="#">RFA-NS-21-021 -- Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-021	20-Feb-2024	Not Specified
	Contact Name	Nick Langhals, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Feb-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.</p>			
103393	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-153	07-Jan-2024	Not Specified
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	<a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-152).</p>				
106266	<p><a href="#">NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a></p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-022	07-Jan-2024	Not Specified
	<p>Contact Name Amelie Gubitz, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email <a href="mailto:gubitza@ninds.nih.gov">gubitza@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024</p> <p>Synopsis The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.			
111323	<a href="#">Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-003	07-Jan-2024	Not Specified
	<p>Contact Name   Jill Morris, Ph.D.</p> <p>Contact Telephone   301-496-5754</p> <p>Contact Email   <a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.</p>				
103957	<a href="#">NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-223	05-Feb-2024	Not Specified
	<p>Contact Name   Codrin Lungu, MD</p> <p>Contact Telephone   301-496-9135</p> <p>Contact Email   <a href="mailto:lunguci@ninds.nih.gov">lunguci@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests ([www.ninds.nih.gov/funding/areas/index.htm](http://www.ninds.nih.gov/funding/areas/index.htm)). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

107186	<a href="#">Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-053	05-Feb-2024	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Codrin Lungu, MD  
 Contact Telephone 301-496-9135  
 Contact Email [lunguci@ninds.nih.gov](mailto:lunguci@ninds.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024

Synopsis Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

thus, prediction of aggregate treatment response has been difficult. This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. Projects involving biomarker discovery or early validation should apply to the relevant FOAs (PAR-19-315, PAR-21-056, PAR-21-057, PAR-21-058, PAR-21-059). The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).

106359	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-327	12-Feb-2024	Not Specified
--------	---	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen Korn, Ph.D.</p> <p><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>12-Feb-2024 , 12-Jun-2024</p> <p>This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-328.</p>
---	---

106361	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-328	12-Feb-2024	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Stephen Korn, Ph.D.</p> <p><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p>
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Feb-2024 , 12-Jun-2024</p> <p>Synopsis This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-327.</p>				
103680	<p><a href="#">Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees</a></p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-21-047	15-Feb-2024	Not Specified
	<p>Contact Name Roderick Corriveau, Ph.D.</p> <p>Contact Telephone 301-496-5680</p> <p>Contact Email <a href="mailto:roderick.corriveau@nih.gov">roderick.corriveau@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024 , 15-May-2024</p> <p>Synopsis This Notice encourages eligible NINDS awardees in the Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) research community to apply for administrative supplements in response to PA-21-071, "Research Supplements to Promote Diversity in Health-Related Research," or any reissues of this announcement through the expiration date of this Notice. The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031, "Notice of NIH's Interest in Diversity") and encourages institutions to diversify their student populations by enhancing the participation of individuals from groups that are underrepresented in the biomedical, clinical, behavioral, and social sciences. Goal 1 of the National Plan to Address Alzheimer's Disease is to prevent and effectively treat AD/ADRD by 2025. This initiative addresses the critical need to increase the number of health professionals and researchers who are trained to meet the expanding demand for cognitive impairment and dementia diagnosis, care, and research to meet Goal 1.</p>				
118319	<p><a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required)</a></p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-142	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Stephen Korn, PhD			
	Contact Telephone				
	Contact Email	<a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024			
	Synopsis	<p>The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-143).</p>			

118321	<a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-143	07-Jan-2024	Not Specified
--------	--	--	------------	-------------	---------------

	Contact Name	Stephen Korn, PhD			
	Contact Telephone				
	Contact Email	<a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PAR-23-142).</p>			
113257	<a href="#">NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-22-230	07-Jan-2024	Not Specified
	Contact Name	David L. Tilley, MPH, MS, CPH			
	Contact Telephone	301-827-6014			
	Contact Email	<a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Mar-2025 , 07-May-2025			
	Synopsis	<p>This funding announcement solicits R01 grant applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>			
113258	<a href="#">NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-22-231	07-Jan-2024	200,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone   301-827-6014</p> <p>Contact Email   <a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 16-Mar-2024 , 07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025</p> <p>Synopsis   This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.</p>				
118358	<a href="#">Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-24-017	02-Feb-2024	30,776,920 USD
	<p>Contact Name   Chhanda Dutta, Ph.D.</p> <p>Contact Telephone   301-496-4161</p> <p>Contact Email   <a href="mailto:duttac@mail.nih.gov">duttac@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Feb-2024</p> <p>Synopsis   The Longevity Consortium (LC), originally established in 2004, is part of an ongoing group of ongoing human longevity translational projects employing a variety of approaches for the identification and translation of protective factors (genomic and other) associated with exceptional longevity. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit a cooperative agreement (U19) application for the renewal of the LC. Proposed activities for the LC renewal should build upon the resources generated by previous project periods and incorporate new research resources, as appropriate, to address the following five main objectives: Evaluate the predictive value of human biologic factors for human longevity and related aging outcomes, the relationships of differing contexts to predictive value of these factors, and the biological mechanisms that account for predictive relationships. Evaluate the predictive value of cross-species differences in specific biologic and genetic factors for differences in species life span. Clarify the relationships between factors related to exceptional longevity in</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>humans and factors influencing cognitive function in old age and risk or severity of Alzheimer’s disease and related dementias. Assess the potential value of predictive factors for developing or repurposing drugs or other interventions to extend life span or health span. For factors with sufficient potential translational value, conduct studies to identify therapeutic targets and interventions, using defined milestones to guide decisions on their continuation or discontinuation. Develop methods to increase the interoperability of varied data types from differing human and comparative species studies and use these methods in integrative analyses combining data from multiple sources to improve understanding about factors influencing longevity and health span in differing contexts and their potential for development of interventions. Each of the above objectives must be addressed by at least one Specific Aim of the proposed U19 Cores and/or Projects.</p>				
108299	<a href="#">NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-22-362	01-Feb-2024	Not Specified
	<p>Contact Name   Ramesh Vemuri, Ph.D.            Contact Telephone   301-402-7700            Contact Email   <a href="mailto:ramesh.vemuri@nih.gov">ramesh.vemuri@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   01-Feb-2024 , 01-Oct-2024            Synopsis   This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for awarded U01 research project cooperative agreements focused on aging research.</p>				
102978	<a href="#">Limited Competition: Alzheimer’s Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-212	05-Feb-2024	Not Specified
	<p>Contact Name   Marilyn Miller, Ph.D.            Contact Telephone   301-496-9350            Contact Email   <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Feb-2024</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative (ADSP FUS 2.0).

121049	<a href="#">RFA-AG-24-027 -- Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-24-027	12-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name | Damali Martin, Ph.D., MPH  
 Contact Telephone |  
 Contact Email | [martinda@mail.nih.gov](mailto:martinda@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Jan-2024 [Optional][LOI/Pre-App], 14-Feb-2024

Synopsis | This notice of funding opportunity (NOFO) promotes collaborative research programs to support the development/enhancement of infrastructure (e.g., tools, surveys, biospecimens, data) for Alzheimer's disease (AD) and AD-related dementias (ADRD) neuroscience research in low- and middle-income countries (LMICs) in Africa, as defined by the World Bank. Specifically, the National Institute on Aging (NIA) seeks to support UG3/UH3 Exploratory/Developmental Phase Innovation Awards Cooperative Agreement projects to enable the following: (1) The formation of transformative collaborations between institutions/scientists in the US and LMICs in Africa; (2) The development, or enhancement, of research infrastructure and resources for studies of AD/ADRD neuroscience relevant to Africa, as well as to examine how social or behavioral factors influence AD/ADRD in Africa; and (3) The initiation of pilot or exploratory studies that may inform future research for AD/ADRD neuroscience in Africa. The research infrastructure programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience research capacity and research, with the aim of ultimately leading to prevention and mitigation strategies for AD/ADRD in Africa.

120974	<a href="#">RFA-AG-24-046 -- Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-24-046	07-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	---	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name | Maja Maric, Ph.D.  
 Contact Telephone | 301-496-9350

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:maja.maric@nih.gov">maja.maric@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 [Optional][LOI/Pre-App], 07-Feb-2024</p> <p>Synopsis This Notice of Funding Opportunity (NOFO) aims to provide a proof-of-principle for a novel strategy for Alzheimer's disease (AD) and AD-related dementias (ADRD) immunotherapies. Specifically, the goal is to examine whether a novel immunotherapeutic approach in cancer immunotherapy with chimeric antigen receptor (CAR) immune cells can be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.</p>				
100902	<a href="#">Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-20-309	05-Feb-2024	Not Specified
	<p>Contact Name Laurie Ryan, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.</p>				
108328	<a href="#">Early and Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Feb-2024	Not Specified
	<p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.			
105958	<a href="#">Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-21-307	13-Feb-2024	Not Specified
	Contact Name	Lisa Onken, Ph.D.			
	Contact Telephone	301-496-3136			
	Contact Email	<a href="mailto:lisa.onken@nih.gov">lisa.onken@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention's principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions. The principle-based interventions under development may target behavioral, psychological, interpersonal, social, or institutional processes and may be designed for use at the individual, family, dyad, group, community, or health-systems level. Applications may propose mechanism-focused intervention research for individuals living with dementia or for individuals or systems providing care for people at any stage of AD/ADRD. Applications proposing			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>the development of interventions that address the principles underlying the care needs and challenges for individuals from diverse racial, ethnic, and socioeconomic backgrounds are strongly encouraged. Applications that involve interdisciplinary expertise and translational expertise (e.g., basic behavioral, social, psychological, or neurobiological science expertise relevant to hypothesized intervention mechanisms; expertise in the AD/ADRD service delivery system; and clinical psychological science expertise in areas outside of aging or AD/ADRD, but potentially relevant to AD/ADRD caregiver research, etc.) are also strongly encouraged. Applications may propose to create, modify, and test AD/ADRD care and caregiver support interventions based upon hypothesized mechanisms of action and are encouraged to incorporate a test of essential components or mechanisms of change using an appropriate methodological approach.</p>			
105960	<a href="#">Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 – Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-21-308	13-Feb-2024	Not Specified
	Contact Name	Partha Bhattacharyya, Ph. D.			
	Contact Telephone	301-496-3136			
	Contact Email	<a href="mailto:bhattacharyyap@mail.nih.gov">bhattacharyyap@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer’s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care. This FOA will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials. The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the go/no-go criteria that are specified for the R61 phase.</p>			
107419	<a href="#">Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-22-047	05-Feb-2024	5,000,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Lorenzo M. Refolo, Ph.D.</p> <p>Contact Telephone   301-594-7576</p> <p>Contact Email   <a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p> <p>Synopsis   The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this FOA include: research on basic mechanisms of disease or mechanisms of drug action; development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.</p>				
120970	<p><a href="#">Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)</a></p>	National Institute on Aging/NIH/DHHS	PAR-23-274	21-Feb-2024	Not Specified
	<p>Contact Name   Akanni Clarke</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:akanni.clarke@nih.gov">akanni.clarke@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Feb-2024 , 20-Jun-2024 , 21-Oct-2024 , 21-Feb-2025 , 23-Jun-2025 , 20-Oct-2025 , 20-Feb-2026 , 22-Jun-2026 , 19-Oct-2026</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development.

104436	<a href="#">NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-220	12-Feb-2024	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name | Yuan Luo, Ph.D.  
 Contact Telephone | 301-496-9350  
 Contact Email | [yuan.luo@nih.gov](mailto:yuan.luo@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 12-Feb-2024 , 12-Jun-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This pathway to independence award will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This award will support early career investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery and transition to research independence.. The long-term goal of this program is to develop a diverse translational research workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care. This Funding Opportunity Announcement (FOA) is designed for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

112937	<a href="#">Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-22-228	21-Feb-2024	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name | Nandini Arunkumar, Ph.D.  
 Contact Telephone | 301-451-2313

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:nandini.arunkumar@nih.gov">nandini.arunkumar@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Feb-2024 , 25-Oct-2024 , 21-Feb-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108054	<a href="#">Notice of Special Interest (NOSI): Research on Pain, Pain Management, and Opioids in Aging</a>	National Institute on Aging/NIH/DHHS	NOT-AG-22-004	08-Dec-2023	Not Specified
	Contact Name	Devon Oskvig, Ph.D.			
	Contact Telephone	301-827-5899			
	Contact Email	<a href="mailto:devon.oskvig@nih.gov">devon.oskvig@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Dec-2023 , 12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 08-Dec-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight that the National Institute on Aging (NIA) is interested in receiving grant applications focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas. This NOSI invites research applications that focus on improving the understanding of mechanisms underlying pain experience with aging; enhancing assessment, prevention, and management strategies for pain in older adults; and improving health equity of aging populations suffering with pain. New applications, resubmissions, competing renewals, and competing revisions to existing awards are all encouraged through this NOSI. For administrative supplements focused on pain, pain management, and opioids related to aging or older adults and within NIA's mission areas, please see NOT-AG-22-005.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108329	<a href="#">Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-21-360	20-Feb-2024	650,000 USD
	<p>Contact Name   Laurie Ryan</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 18-Jun-2024 , 18-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
114865	<a href="#">Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-083	20-Feb-2024	650,000 USD
	<p>Contact Name   Laurie Ryan</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 18-Jun-2024 , 18-Oct-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
115099	<a href="#">Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-082	21-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Nandini Arunkumar, Ph.D.</td> </tr> <tr> <td>Contact Telephone</td> <td>301-451-2313</td> </tr> <tr> <td>Contact Email</td> <td><a href="mailto:nandini.arunkumar@nih.gov">nandini.arunkumar@nih.gov</a></td> </tr> <tr> <td>Sponsor Website</td> <td></td> </tr> <tr> <td>Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>21-Feb-2024 , 25-Oct-2024 , 21-Feb-2025</td> </tr> <tr> <td>Synopsis</td> <td>This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.</td> </tr> </table>					Contact Name	Nandini Arunkumar, Ph.D.	Contact Telephone	301-451-2313	Contact Email	<a href="mailto:nandini.arunkumar@nih.gov">nandini.arunkumar@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	21-Feb-2024 , 25-Oct-2024 , 21-Feb-2025	Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.
Contact Name	Nandini Arunkumar, Ph.D.																		
Contact Telephone	301-451-2313																		
Contact Email	<a href="mailto:nandini.arunkumar@nih.gov">nandini.arunkumar@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	21-Feb-2024 , 25-Oct-2024 , 21-Feb-2025																		
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain a comprehensive mechanistic understanding of the impact of sex differences on the molecular trajectories of brain aging on the phenotypes of risk and resilience to Alzheimer's disease (AD) and AD-related dementias (ADRD), and on the molecular determinants underlying responsiveness to pharmacologic and non-pharmacologic interventions.																		
108048	<a href="#">NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-22-077	15-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Suzana Petanceska, Ph.D.</td> </tr> <tr> <td>Contact Telephone</td> <td>301-594-7754</td> </tr> <tr> <td>Contact Email</td> <td><a href="mailto:petanceskas@nia.nih.gov">petanceskas@nia.nih.gov</a></td> </tr> <tr> <td>Sponsor Website</td> <td></td> </tr> <tr> <td>Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>15-Feb-2024 , 17-Oct-2024</td> </tr> <tr> <td>Synopsis</td> <td>This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer's and Related Dementias.</td> </tr> </table>					Contact Name	Suzana Petanceska, Ph.D.	Contact Telephone	301-594-7754	Contact Email	<a href="mailto:petanceskas@nia.nih.gov">petanceskas@nia.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	15-Feb-2024 , 17-Oct-2024	Synopsis	This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer's and Related Dementias.
Contact Name	Suzana Petanceska, Ph.D.																		
Contact Telephone	301-594-7754																		
Contact Email	<a href="mailto:petanceskas@nia.nih.gov">petanceskas@nia.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	15-Feb-2024 , 17-Oct-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54 Specialized Center cooperative agreements that support large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions, and will address one or more AD/ADRD implementation research milestones supporting the research goals of the National Plan to Address Alzheimer's and Related Dementias.																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
117878	<a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-179	16-Feb-2024	200,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Luci Roberts, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-496-9350</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p> </td> </tr> </table>					Contact Name	Luci Roberts, Ph.D.	Contact Telephone	301-496-9350	Contact Email	<a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026	Synopsis	<p>This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p>
Contact Name	Luci Roberts, Ph.D.																		
Contact Telephone	301-496-9350																		
Contact Email	<a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026																		
Synopsis	<p>This Small Research Grant Program (R03) will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply.</p>																		
101790	<a href="#">NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-106	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:NIAttraining@nih.gov">NIAttraining@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2024 , 12-Feb-2024 , 07-May-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;"> <p>The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve</p> </td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	<a href="mailto:NIAttraining@nih.gov">NIAttraining@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024	Synopsis	<p>The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve</p>
Contact Name																			
Contact Telephone																			
Contact Email	<a href="mailto:NIAttraining@nih.gov">NIAttraining@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024																		
Synopsis	<p>The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve</p>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.</p>			
114861	<a href="#">Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-081	05-Feb-2024	Not Specified
	<p>Contact Name   Laurie Ryan            Contact Telephone   301-496-9350            Contact Email   <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024            Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.</p>				
114469	<a href="#">NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-23-057	05-Feb-2024	Not Specified
	<p>Contact Name   Sergei Romashkan, M.D., Ph.D.            Contact Telephone   301-435-3047            Contact Email   <a href="mailto:romashks@mail.nih.gov">romashks@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025            Synopsis   This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106670	<a href="#">NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-351	12-Feb-2024	Not Specified
	<p>Contact Name   Saroj Regmi, Ph.D.</p> <p>Contact Telephone   301-480-8964</p> <p>Contact Email   <a href="mailto:saroj.regmi@nih.gov">saroj.regmi@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024</p> <p>Synopsis   The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty positions conducting research that advances the mission of NIA. This award will provide three years of protected time through salary and research support to conduct biomedical research at an extramural sponsoring institution/organization to which the individual has been recruited, been offered, and has accepted a tenure-track full-time assistant professor position (or equivalent). This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.</p>				
121996	<a href="#">RFA-AG-24-040 -- Microphysiological Systems to Advance Precision Medicine for AD/ADRD Treatment and Prevention (U54 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-24-040	15-Jan-2024 [Optional][LOI/Pre-App]	12,500,000 USD
	<p>Contact Name   Zane Martin, Ph.D.</p> <p>Contact Telephone   301-827-7130</p> <p>Contact Email   <a href="mailto:zane.martin@nih.gov">zane.martin@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Translational Centers for Microphysiological Systems (MPS) (AD/ADRD MPS Translational Centers). The overarching purpose of this Centers program is to develop 2D and 3D models of AD/ADRD as reproducible and scalable platforms that recapitulate key features of human AD/ADRD</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	pathophysiology to be used as precision medicine research tools to investigate the complex biology of AD/ADRD and to accelerate multiple aspects of drug discovery and preclinical drug development.																		
120843	<a href="#">Analytical and Clinical Validation of Biomarkers for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-23-258	05-Feb-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Yuan Luo, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-9350</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:Yuan.Luo@nih.gov">Yuan.Luo@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer's disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.</td> </tr> </table>					Contact Name	Yuan Luo, Ph.D.	Contact Telephone	301-496-9350	Contact Email	<a href="mailto:Yuan.Luo@nih.gov">Yuan.Luo@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Feb-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026	Synopsis	This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer's disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.
Contact Name	Yuan Luo, Ph.D.																		
Contact Telephone	301-496-9350																		
Contact Email	<a href="mailto:Yuan.Luo@nih.gov">Yuan.Luo@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Feb-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Oct-2025 , 05-Feb-2026																		
Synopsis	This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer's disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.																		
113465	<a href="#">Notice of Special Interest (NOSI): Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)</a>	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	05-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Lorenzo M. Refolo, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-7576</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jan-2024 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 11-Mar-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025</td> </tr> </table>					Contact Name	Lorenzo M. Refolo, Ph.D.	Contact Telephone	301-594-7576	Contact Email	<a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Jan-2024 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 11-Mar-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025		
Contact Name	Lorenzo M. Refolo, Ph.D.																		
Contact Telephone	301-594-7576																		
Contact Email	<a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Jan-2024 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 11-Mar-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 09-Jul-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 05-Sep-2025																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration.			
122532	<a href="#">Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-24-052	16-Feb-2024	Not Specified
	Contact Name	Jamie Lahvic, Ph.D.			
	Contact Telephone				
	Contact Email	<a href="mailto:NIATraining@mail.nih.gov">NIATraining@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 , 16-Jul-2024 , 16-Oct-2024 , 16-Nov-2024 , 16-Feb-2025 , 16-Mar-2025 , 16-Jun-2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-2026 , 16-Jun-2026 , 16-Jul-2026 , 16-Oct-2026 , 16-Nov-2026			
	Synopsis	This Notice of Funding Opportunity (NOFO) invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within NIA's strategic priorities.			
107782	<a href="#">Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-001	05-Jan-2024	Not Specified
	Contact Name	Bradley Kerridge, Ph.D.			
	Contact Telephone	301-827-7493			
	Contact Email	<a href="mailto:bradley.kerridge@nih.gov">bradley.kerridge@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.			
116584	<a href="#">Notice of Special Interest (NOSI): Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-23-003	07-Jan-2024	Not Specified
	Contact Name	Robert Freeman, Ph.D.			
	Contact Telephone	301-443-8820			
	Contact Email	<a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026			
	Synopsis	In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA's interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term "domestic violence" will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).			
120718	<a href="#">Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-249	16-Feb-2024	450,000 USD
	Contact Name	Brett T. Hagman, Ph.D.			
	Contact Telephone	301-443-0638			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.</p>				
120721	<a href="#">Alcohol Health Services Research (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-252	16-Feb-2024	450,000 USD
	<p>Contact Name Laura E. Kwako, Ph.D.</p> <p>Contact Telephone 301-451-8507</p> <p>Contact Email <a href="mailto:laura.kwako@nih.gov">laura.kwako@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.</p>				
104867	<a href="#">Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-250	16-Feb-2024	1,775,000 USD
	<p>Contact Name Elizabeth M Powell, PhD</p> <p>Contact Telephone 301-443-0786</p> <p>Contact Email <a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a></p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.</p>				
105028	<a href="#">Notice of Special Interest (NOSI): Genetics of Alcohol Sensitivity and Tolerance</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-21-029	07-Jan-2024	Not Specified
	<p>Contact Name Hemin Chin, PhD</p> <p>Contact Telephone 301-443-1282</p> <p>Contact Email <a href="mailto:hemin.chin@nih.gov">hemin.chin@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tolerance, and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both experimental and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to provide insights into genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genomic, epigenetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to consider model systems in which these complex relationships can be better studied under defined genetic backgrounds and well-controlled environmental conditions.</p>				
110811	<a href="#">Notice of Special Interest (NOSI): Research on Alcohol and Coronavirus Disease (COVID-19) within the Mission of NIAAA</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-22-012	07-Jan-2024	Not Specified
	Contact Name Kathy Jung, PhD				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-8744</p> <p>Contact Email   <a href="mailto:kathy.jung@nih.gov">kathy.jung@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) solicits grant applications that advance understanding of critical interactions between alcohol use, SARS-CoV-2, and COVID-19. A central focus is research that can improve public health by informing responses to the evolving COVID-19 pandemic and its consequences.</p>				
101458	<a href="#">Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-024	07-Jan-2024	Not Specified
	<p>Contact Name   Li Lin</p> <p>Contact Telephone   301-827-7749</p> <p>Contact Email   <a href="mailto:linli@mail.nih.gov">linli@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.</p>				
120716	<a href="#">Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-250	05-Feb-2024	2,500,000 USD
	<p>Contact Name   Brett T. Hagman, Ph.D.</p> <p>Contact Telephone   301-443-0638</p> <p>Contact Email   <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.			
120720	<a href="#">Alcohol Health Services Research (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-23-251	05-Feb-2024	Not Specified
	Contact Name	Laura E. Kwako, Ph.D.			
	Contact Telephone	301-451-8507			
	Contact Email	<a href="mailto:laura.kwako@nih.gov">laura.kwako@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.			
122632	<a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-067	16-Feb-2024	450,000 USD
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			
	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (PAR-24-068, the R61/R33 option).</p>			
122636	<a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-24-068	16-Feb-2024	Not Specified
	Contact Name	William Dunty, PhD			
	Contact Telephone	301-443-7351			
	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 17-Jun-2024 , 16-Oct-2024 , 17-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (PAR-24-067, the R34 option).</p>			
106846	<a href="#">NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-22-025	06-Feb-2024	7,500,000 USD
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Feb-2024 , 06-Jun-2024 , 09-Oct-2024</p> <p>Synopsis The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a low risk clinical trial but are not required to (optional).</p>				
122102	<a href="#">Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R01-Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAS-24-058	05-Feb-2024	Not Specified
	<p>Contact Name Nancy Freeman, Ph.D</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email <a href="mailto:freemann@mail.nih.gov">freemann@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.					
122020	<a href="#">NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-050	27-Feb-2024	Not Specified
	<p>Contact Name   Trinh T. Ly, M.D.</p> <p>Contact Telephone   301-435-4085</p> <p>Contact Email   <a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Feb-2024 , 27-Jun-2024 , 28-Oct-2024 , 27-Feb-2025 , 27-Jun-2025 , 28-Oct-2025 , 27-Feb-2026 , 29-Jun-2026 , 27-Oct-2026</p> <p>Synopsis   The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this funding opportunity. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-24-051. Investigators are strongly encouraged to contact Dr. Trinh Ly, prior to submission, to ensure this is the correct NOFO for their proposed research.</p>				
122021	<a href="#">NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24-051	05-Feb-2024	2,499,995 USD
	<p>Contact Name   Trinh T. Ly, M.D.</p> <p>Contact Telephone   301-435-4085</p> <p>Contact Email   <a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</p>				
122103	<a href="#">Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R21-Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAS-24-057	16-Feb-2024	Not Specified
	<p>Contact Name Nancy Freeman, Ph.D</p> <p>Contact Telephone 301-402-3458</p> <p>Contact Email <a href="mailto:freemann@mail.nih.gov">freemann@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.

104661	<a href="#">Notice of Special Interest (NOSI): NIDCD Health Disparities and Inequities Research</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-003	08-Dec-2023	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Kelly King, Au.D, Ph.D.
Contact Telephone	301-402-3458
Contact Email	<a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Apr-2024 , 07-May-2024
Synopsis	This Notice of Special Interest (NOSI) encourages applications that advance the understanding or reduce the impact of health disparities and inequities in communication disorders among racial/ethnic minority and other underrepresented populations. Applications that address the influence or reduction of racism or discrimination in causing or sustaining health disparities and inequities are also encouraged. The research must address one or more of the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.

102240	<a href="#">Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-001	05-Jan-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Kelly King, Au.D, Ph.D.
Contact Telephone	301-402-3458
Contact Email	<a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.

117406	<a href="#">Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-009	12-Dec-2023	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Holly L. Storkel, Ph.D.
Contact Telephone	301-496-5061
Contact Email	<a href="mailto:holly.storkel@nih.gov">holly.storkel@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 05-Apr-2026 , 07-May-2026 , 05-Jun-2026
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research to promote language and communication in autistic individuals who are minimally verbal/non-speaking. Further research is needed to evaluate and tailor existing interventions, develop novel interventions, develop and apply new research designs and methods to intervention efforts, and identify meaningful outcome measures.

114999	<a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-001	07-Jan-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Merav Sabri, Ph.D.
Contact Telephone	301-827-0908
Contact Email	<a href="mailto:merav.sabri@nih.gov">merav.sabri@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities from its new strategic plan, in basic and mechanistic research on neural circuits underlying sensory processing in hearing, balance, taste and smell. NIDCD encourages multidisciplinary and innovative projects, from diverse teams, to advance a mechanistic understanding of the behavior of neural circuits at cellular and sub-second temporal resolution by integrating cutting-edge technologies and approaches for recording and modulation of cells and circuits (e.g., electrophysiology, optical imaging, optogenetics, chemogenetics, sonogenetics, magnetogenetics, pharmacologic modulation). Applications are expected to integrate appropriate domains of expertise, including but not limited to biological, chemical and physical sciences, engineering, computational modeling, statistical analysis, and bioethics, as appropriate. Mechanistic human studies and comparative, cross-species projects are highly encouraged.			
117259	<a href="#">Notice of Special Interest (NOSI): Encouraging Women’s Health Research within the NIDCD Mission Areas</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-23-006	07-Jan-2024	Not Specified
	Contact Name	Christopher Myers			
	Contact Telephone	301-435-0713			
	Contact Email	<a href="mailto:myersc@nidcd.nih.gov">myersc@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 25-Feb-2026 , 07-May-2026			
	Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD’s mission. NIDCD’s mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan   NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural,			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's quality of life.

101297	<a href="#">NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-107	27-Feb-2024	375,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Bracie Watson, Jr.  
 Contact Telephone | 301-402-3458  
 Contact Email | [watsonb@nidcd.nih.gov](mailto:watsonb@nidcd.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 27-Feb-2024

Synopsis | The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

122439	<a href="#">RFA-DC-24-004 -- In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-004	01-Feb-2024	2,499,995 USD
--------	--	---	---------------	-------------	---------------

Contact Name | Amy Poremba, Ph.D.  
 Contact Telephone | 301-997-3152  
 Contact Email | [amy.poremba@nih.gov](mailto:amy.poremba@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 01-Feb-2024 , 03-Jun-2024 , 01-Oct-2024 , 03-Feb-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to the development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in mammalian animal models may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This notice of funding opportunity announcement (NOFO) also supports investigator initiated low-risk clinical trials addressing the development or improvement of human in vivo structural and functional imaging technologies. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not be an NIH-defined Phase III Clinical Trial, have low risks to subjects, and intend to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low-risk trials determined to be Basic Experimental Studies with Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each application. High-risk clinical trials not meeting all the criteria above are referred to the companion U01 Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (Clinical Trial required) NOFO RFA-DC-24-005.

122441	<a href="#">RFA-DC-24-005 -- Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	RFA-DC-24-005	01-Feb-2024	2,499,995 USD
--------	--	---	---------------	-------------	---------------

Contact Name	Amy Poremba, Ph.D.
Contact Telephone	301-997-3152
Contact Email	<a href="mailto:amy.poremba@nih.gov">amy.poremba@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024 , 03-Jun-2024 , 01-Oct-2024 , 03-Feb-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this funding opportunity is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop, advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans. This funding opportunity supports a cooperative agreement between an NIDCD Project Scientist and an Investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has potentially higher risks to participants. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed per application submitted to this funding opportunity. Low risk clinical trials not meeting any of the criteria above are referred to the companion In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 - Clinical Trial Optional) RFA-DC-24-004. Investigators are strongly encouraged to contact the scientific/research contact, prior to submission, to ensure this is the correct NOFO for their proposed research.

115928	<a href="#">RFA-DA-24-027 -- Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-027	08-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Vani Pariyadath, Ph.D.
Contact Telephone	301-443-3209
Contact Email	<a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Jan-2024 [Optional][LOI/Pre-App], 08-Feb-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>workforce to meet the nation’s biomedical, behavioral and clinical research needs. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support training and educational activities for responsible analyses of complex large-scale data involving brain, behavioral, genomic, and socioenvironmental data that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs. Courses for Skills Development Curriculum or Methods Development</p>			
121604	<a href="#">RFA-DA-24-006 -- Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Basic Experimental Studies with Humans (BESH) Required)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-006	15-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Holly Moore, PhD</p> <p>Contact Telephone: 301-827-7376</p> <p>Contact Email: <a href="mailto:holly.moore@nih.gov">holly.moore@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 15-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024</p>	<p>Synopsis: The purpose of this notice of funding opportunity (NOFO) is to solicit applications for basic science experiments involving humans (BESH) aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on neurobehavioral function and risk for substance use disorders (SUD) and co-occurring psychiatric disorders in people living with HIV (PLWH). As referred to in NOT-OD-18-212, BESH are “prospective basic science studies involving human participants” that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Such studies prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental processes or principles. Applicants proposing projects involving animal models or observational studies in humans should use the companion NOFO, RFA-DA-24-005. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
121603	<a href="#">RFA-DA-24-005 -- Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-005	15-Jan-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Sunila Nair, PhD</p> <p>Contact Telephone   301-827-6832</p> <p>Contact Email   <a href="mailto:sunila.nair@nih.gov">sunila.nair@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to solicit applications for research aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on substance use disorders (SUDs) and co-occurring psychiatric disorders in people living with HIV (PLWH). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material</p>				
120064	<p><a href="#">RFA-DA-24-064 -- HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)</a></p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-064	01-Jan-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name   Sam Ananthan, Ph.D.</p> <p>Contact Telephone   301-435-2199</p> <p>Contact Email   <a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. For information about Novel Therapeutic Options for Opioid Use Disorder and Overdose, see <a href="https://heal.nih.gov/research/medication-options">https://heal.nih.gov/research/medication-options</a> This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

106312	<a href="#">RFA-DA-22-040 -- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-040	15-Feb-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Richard A. Jenkins, Ph.D.
Contact Telephone	301-443-1923
Contact Email	<a href="mailto:jenkinsri@nida.nih.gov">jenkinsri@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Feb-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

103015	<a href="#">Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-028	07-Jan-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Pamela G. Fleming
Contact Telephone	301-480-1159
Contact Email	<a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024
Synopsis	This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
102988	<a href="#">Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-033	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Pamela G. Fleming</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-480-1159</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.</td> </tr> </table>					Contact Name	Pamela G. Fleming	Contact Telephone	301-480-1159	Contact Email	<a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024	Synopsis	This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.
Contact Name	Pamela G. Fleming																		
Contact Telephone	301-480-1159																		
Contact Email	<a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024																		
Synopsis	This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.																		
106339	<a href="#">Notice of Special Interest (NOSI): Evaluation of Sex Differences on HIV-Associated Comorbidities in the Context of Stimulant Use</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-020	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Da-Yu Wu, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-4649</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:wudy@nida.nih.gov">wudy@nida.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged.</td> </tr> </table>					Contact Name	Da-Yu Wu, PhD	Contact Telephone	301-435-4649	Contact Email	<a href="mailto:wudy@nida.nih.gov">wudy@nida.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024	Synopsis	The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged.
Contact Name	Da-Yu Wu, PhD																		
Contact Telephone	301-435-4649																		
Contact Email	<a href="mailto:wudy@nida.nih.gov">wudy@nida.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024																		
Synopsis	The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged.																		
120062	<a href="#">RFA-DA-24-063 -- HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-063	01-Jan-2024 [Optional][LOI/Pre-App]	2,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sam Ananthan, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-2199</td> </tr> </table>					Contact Name	Sam Ananthan, Ph.D.	Contact Telephone	301-435-2199										
Contact Name	Sam Ananthan, Ph.D.																		
Contact Telephone	301-435-2199																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. For information about Novel Therapeutic Options for Opioid Use Disorder and Overdose, see <a href="https://heal.nih.gov/research/medication-options">https://heal.nih.gov/research/medication-options</a> This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>				
107619	<a href="#">Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002	07-Jan-2024	Not Specified
	<p>Contact Name Kiran Vemuri, Ph.D.</p> <p>Contact Telephone 301-435-4446</p> <p>Contact Email <a href="mailto:kiran.vemuri@nih.gov">kiran.vemuri@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 12-Feb-2025</p> <p>Synopsis The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research on all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, and determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.			
103071	<a href="#">Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	07-Jan-2024	Not Specified
	Contact Name	Shang-Yi Anne Tsai, Ph.D			
	Contact Telephone	301-827-5842			
	Contact Email	<a href="mailto:stsai@nih.gov">stsai@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024			
	Synopsis	National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.			
103870	<a href="#">Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-003	07-Jan-2024	Not Specified
	Contact Name	Holly Moore			
	Contact Telephone	301-827-7376			
	Contact Email	<a href="mailto:Holly.Moore@nih.gov">Holly.Moore@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024			
	Synopsis	NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged.			
104862	<a href="#">Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	07-Jan-2024	Not Specified
	Contact Name	Yu (Woody) Lin			
	Contact Telephone	301-435-1318			
	Contact Email	<a href="mailto:ylin1@mail.nih.gov">ylin1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025			
	Synopsis	This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA's mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.			
121950	<a href="#">RFA-DA-25-013 --Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-013	13-Feb-2024 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Shang-Yi Anne Tsai, PhD			
	Contact Telephone	301-827-5842			
	Contact Email	<a href="mailto:stsai@nih.gov">stsai@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024 , 13-Mar-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.</p>			
121948	<a href="#">RFA-DA-25-012 --Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-012	13-Feb-2024 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Shang-Yi Anne Tsai, PhD			
	Contact Telephone	301-827-5842			
	Contact Email	<a href="mailto:stsai@nih.gov">stsai@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024 , 13-Mar-2025			
	Synopsis	<p>The goal of this notice of funding opportunity (NOFO) is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.</p>			
101989	<a href="#">Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-018	07-Jan-2024	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	301-480-2541			
	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.</p>				
105778	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Basic Experimental Studies with Humans Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-309	07-Jan-2024	150,000 USD
	<p>Contact Name John Fedota, PhD</p> <p>Contact Telephone 301-402-0812</p> <p>Contact Email <a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.</p>				
105780	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-310	07-Jan-2024	150,000 USD
	<p>Contact Name John Fedota, PhD</p> <p>Contact Telephone 301-402-0812</p> <p>Contact Email <a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.
109484	<a href="#">Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance use Prevention and Treatment</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-006	07-Jan-2024	Not Specified
	Contact Name	Janet Kuramoto-Crawford, PhD			
	Contact Telephone	301-443-8856			
	Contact Email	<a href="mailto:janet.kuramoto-crawford@nih.gov">janet.kuramoto-crawford@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).			
109268	<a href="#">Notice of Special Interest (NOSI): Epidemiology of Drug Abuse</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-004	07-Jan-2024	Not Specified
	Contact Name	Marsha Lopez, PhD, MHS			
	Contact Telephone	301-443-6504			
	Contact Email	<a href="mailto:Marsha.Lopez@nih.gov">Marsha.Lopez@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025			
	Synopsis	The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.</p>																		
114151	<a href="#">Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Raul Mandler, MD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-281-0569</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.</td> </tr> </table>					Contact Name	Raul Mandler, MD	Contact Telephone	240-281-0569	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.
Contact Name	Raul Mandler, MD																		
Contact Telephone	240-281-0569																		
Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026																		
Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.																		
115450	<a href="#">Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A Jump Into Precision Medicine.</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-001	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Guifang Lao, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-5931</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:laog@nih.gov">laog@nih.gov</a></td> </tr> </table>					Contact Name	Guifang Lao, Ph.D.	Contact Telephone	301-827-5931	Contact Email	<a href="mailto:laog@nih.gov">laog@nih.gov</a>								
Contact Name	Guifang Lao, Ph.D.																		
Contact Telephone	301-827-5931																		
Contact Email	<a href="mailto:laog@nih.gov">laog@nih.gov</a>																		



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>				
117405	<a href="#">Notice of Special Interest (NOSI): Leveraging Glial Cells to Treat Addiction</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-006	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	Shang-Yi Anne Tsai, Ph.D.			
119295	<a href="#">Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-23-194	07-Jan-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	Marsha F. Lopez, Ph.D., M.H.S.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026 , 16-Jun-2026 , 07-Sep-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message   National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				
121946	<p><a href="#">RFA-DA-24-030 -- Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed)</a></p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-030	08-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Olivier Berton, PhD</p> <p>Contact Telephone 301-827-7771</p> <p>Contact Email <a href="mailto:olivier.berton@nih.gov">olivier.berton@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jan-2024 [Optional][LOI/Pre-App], 08-Feb-2024</p> <p>Synopsis This notice of funding opportunity (NOFO) aims to support the development and application of innovative ex-vivo imaging technologies, along with necessary coordinated pipelines encompassing tissue procurement, histological processing and computation to enable spatial analysis and in situ molecular annotation of cell populations involved in central nervous system (CNS) HIV infection, persistence, and neuropathogenesis. The pipelines developed and validated during the R61 phase should be applicable to freshly collected or banked CNS tissues with well-preserved structure (whole brains, slices or explants) from humans or animal models. The utility of the pipelines should be demonstrated during the R33 phase, through test-cases investigating intercellular communication mechanisms in HIV-associated neurocognitive disorders (HAND), antiretroviral therapy (ART) response and/or substance use.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113995	<a href="#">Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-012	07-Jan-2024	Not Specified
	<p>Contact Name   Tisha Wiley, Ph.D.</p> <p>Contact Telephone   301-594-4381</p> <p>Contact Email   <a href="mailto:tisha.wiley@nih.gov">tisha.wiley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.</p>				
114003	<a href="#">Notice of Special Interest (NOSI): Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	08-Dec-2023	Not Specified
	<p>Contact Name   Sam Ananthan, Ph.D.</p> <p>Contact Telephone   301-435-2199</p> <p>Contact Email   <a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.			
114150	<a href="#">Notice of Special Interest (NOSI): Chemsex and HIV: Prevalence, Medical/Psychosocial Consequences, and Treatment</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Jan-2024	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	240-281-0569			
	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The purpose of this notice is to support research on the epidemiology, medical/psychosocial impact, and preventive and therapeutic measures for chemsex in people with HIV and HIV-vulnerable populations including sexual minorities (SM) e.g. lesbian, gay, bisexual.			
114048	<a href="#">Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	08-Dec-2023	Not Specified
	Contact Name	Sam Ananthan, Ph.D.			
	Contact Telephone	301-435-2199			
	Contact Email	<a href="mailto:sam.ananthan@nih.gov">sam.ananthan@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 08-Dec-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.</p>				
103874	<a href="#">Notice of Special Interest (NOSI): Leveraging Transformative Connectome Resources in Model Organisms to Elucidate the Neurobiology of Substance Abuse Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-006	07-Jan-2024	Not Specified
	<p>Contact Name   Olivier Berton, Ph.D.            Contact Telephone   301-827-7771            Contact Email   <a href="mailto:olivier.berton@nih.gov">olivier.berton@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024            Synopsis   The purpose of this notice is to encourage research project submissions that leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD).</p>				
104182	<a href="#">Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-004	07-Jan-2024	Not Specified
	<p>Contact Name   Susan Wright, Ph.D.            Contact Telephone   301-402-6683            Contact Email   <a href="mailto:susan.wright@nih.gov">susan.wright@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025            Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning, 2) supercomputing/parallel computing, and/or 3) quantum computing.
106007	<a href="#">Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-064	07-Jan-2024	Not Specified
	Contact Name	Steve Gust, Ph.D.			
	Contact Telephone	301-402-1118			
	Contact Email	<a href="mailto:sgust@nida.nih.gov">sgust@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science.			
102446	<a href="#">Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-007	07-Jan-2024	Not Specified
	Contact Name	Richard A. Jenkins PhD			
	Contact Telephone	301-443-1923			
	Contact Email	<a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.

101829	<a href="#">Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-011	07-Jan-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Raul Mandler, MD; FAAN; FANA
Contact Telephone	301-480-2541
Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.

102016	<a href="#">Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-017	07-Jan-2024	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Raul Mandler, MD
Contact Telephone	301-480-2541
Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.			
102120	<a href="#">Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-019	07-Jan-2024	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	301-480-2541			
	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).			
111673	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058	07-Jan-2024	Not Specified
	Contact Name	Olivier Berton, Ph.D.			
	Contact Telephone	301-827-7771			
	Contact Email	<a href="mailto:Olivier.berton@nih.gov">Olivier.berton@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation.</p>				
122293	<a href="#">RFA-DA-25-058 -- Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-058	28-Jan-2024	Not Specified
	Contact Name	Tanya Ramey, M.D., Ph.D			
	Contact Telephone	301-827-5944			
	Contact Email	<a href="mailto:tanya.ramey@nih.gov">tanya.ramey@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-Jan-2024 , 28-Feb-2024			
	Synopsis	<p>The purpose of this notice of funding opportunity (NOFO) is to support the development of classic psychedelics (e.g., psilocybin, LSD), empathogens (e.g., MDMA), dissociatives (e.g., ketamine and related compounds), and other hallucinogens (e.g., ibogaine and its analogues) (henceforth “psychedelics”) as new treatment options for Substance Use Disorder (SUD). There is an urgent need to develop novel treatments for SUD in light of the escalating rates of substance use, addiction, and overdose. Psychedelics may offer a new potential therapeutic use in SUD. Applications may include the evaluation of an existing psychedelic, a new formulation, or a new psychedelic compound. The application can be at a preclinical and/or clinical phase of medication development. This NOFO utilizes the UG3/UH3 Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this funding opportunity should present a research plan that will cover both the UG3 and UH3 phases. In the 2-year UG3 phase, the project will have a set of milestones to be completed by the end of this period. Once the UG3 phase has been successfully completed, the project may transition to the UH3 phase and may be funded for up to three additional years. The ultimate goal is to advance the development of safe and effective treatments for SUDs with psychedelics in the FDA approval pathway. Investigators submitting to this NOFO must address both UG3 and UH3 phases.</p>			
122557	<a href="#">RFA-DA-25-030 -- Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-030	13-Feb-2024 [Optional][LOI/Pre-App]	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Sean Lynch, PhD, LCSW</p> <p>Contact Telephone   301-594-4596</p> <p>Contact Email   <a href="mailto:sean.lynch@nih.gov">sean.lynch@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024</p> <p>Synopsis   This notice of funding opportunity (NOFO) encourages exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among adolescents at high risk for overdose (i.e., intentional, unintentional, fatal, and/or non-fatal). Research studies should identify targets for overdose prevention and substance use disorder (SUD) treatment and recovery. Research studies may use a variety of approaches (e.g., leveraging existing data sources, survey research, social network analysis, development of new methods, feasibility research). Outcomes of interest include, but are not limited to, prevalence of overdose and reduction in substance use, particularly fentanyl use or use of substances that are commonly laced with fentanyl; unintentional use/overdose, use/overdose by risk group, stigma, family and environmental risk and protective factors, treatment engagement, adolescents' perceptions of substance use, and optimistic bias. Research studies involving services delivery or interventions are encouraged to consider the companion NOFO, RFA-DA-25-031, Adolescent Overdose Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional).</p>				
122413	<a href="#">RFA-DA-25-029 -- National Drug Early Warning System Coordinating Center (U01 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-029	20-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   MeLisa R. Creamer, PhD, MPH</p> <p>Contact Telephone   301-402-1933</p> <p>Contact Email   <a href="mailto:melisa.creamer@mail.nih.gov">melisa.creamer@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024</p> <p>Synopsis   This notice of funding opportunity (NOFO) seeks applications for a single Coordinating Center to support research on the identification and dissemination of signals of emerging drug use patterns in communities across the United States. The Coordinating Center will provide operational, administrative, and logistical support by executing the following: Establish a Scientific Advisory Group to provide guidance and direction. Engage an Early Warning Network composed of two</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

components: local health experts on drug use from selected communities (Sentinel Sites) and a broader network of community-based health researchers, to support the bi-directional sharing of information and insights into drug use patterns in their communities and to support the ongoing monitoring, interpretation, and dissemination of data. Identify, compile, analyze, and triangulate research data and resources from multiple sources to assess and contextualize emerging drug threats. Disseminate contextualized research findings, data, and resources to key audiences who can use the data to inform their response.

122412	<a href="#">RFA-DA-25-027 -- The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-027	13-Feb-2024 [Optional][LOI/Pre-App]	2,500,000 USD
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Betty Tai, Ph.D.
Contact Telephone	301-443-2397
Contact Email	<a href="mailto:btai@nida.nih.gov">btai@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024
Synopsis	National Institute on Drug Abuse (NIDA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network's capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and healthcare institutions. This FOA will use the NIH Clinical Research Cooperative Agreements - Single Project (UG1) award mechanism.

122558	<a href="#">RFA-DA-25-031 -- Adolescent Overdose Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-031	13-Feb-2024 [Optional][LOI/Pre-App]	225,000 USD
--------	--	---	---------------	-------------------------------------	-------------

Contact Name	Sean Lynch, PhD, LCSW
Contact Telephone	301-594-4596
Contact Email	<a href="mailto:sean.lynch@nih.gov">sean.lynch@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This notice of funding opportunity (NOFO) encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials that will guide the expansion of effective, non-stigmatizing overdose prevention, substance use disorder (SUD) treatment, and recovery services for adolescents. Outcomes of interest include, but are not limited to, harm reduction, recovery, treatment retention and effectiveness, quality of care, patient-centered outcomes, and implementation factors. The goal of this NOFO is to improve the availability of interventions for adolescents at high risk of overdose (i.e., intentional, unintentional, fatal, and/or non-fatal) that are effective, practical, cost-effective, scalable, and sustainable. Developmental and exploratory research studies whose purpose is to better understand adolescent illicit fentanyl use and overdose patterns among youth at high risk in order to identify targets for overdose prevention and SUD treatment and recovery are encouraged to consider the companion NOFO, RFA-DA-25-030, Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed).

110056	<a href="#">RFA-DA-23-021 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-021	15-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Leonardo Angelone, PhD
Contact Telephone	301-827-5946
Contact Email	<a href="mailto:leonardo.angelone@nih.gov">leonardo.angelone@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jan-2024 [Optional][LOI/Pre-App], 14-Feb-2024 , 14-Jul-2024 [Optional][LOI/Pre-App], 13-Aug-2024 , 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025
Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117771	<a href="#">RFA-DA-24-038 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-24-038	15-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Leonardo Angelone, PhD</p> <p>Contact Telephone   301-827-5946</p> <p>Contact Email   <a href="mailto:leonardo.angelone@nih.gov">leonardo.angelone@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jan-2024 [Optional][LOI/Pre-App], 14-Feb-2024 , 14-Jul-2024 [Optional][LOI/Pre-App], 13-Aug-2024 , 15-Jan-2025 [Optional][LOI/Pre-App], 14-Feb-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.</p>				
115679	<a href="#">NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23-111	07-Jan-2024	275,000 USD
	<p>Contact Name  </p> <p>Contact Telephone   301-402-1366</p> <p>Contact Email   <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026			
	Synopsis	NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.			
107524	<a href="#">Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-072	05-Feb-2024	Not Specified
	Contact Name	Nancy L. Jones, PhD, MS			
	Contact Telephone	301-594-8945			
	Contact Email	<a href="mailto:nancy.jones@nih.gov">nancy.jones@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.			
107817	<a href="#">RFA-EY-21-003 -- BRAIN Initiative-Related Research Education: Short Courses (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-EY-21-003	15-Feb-2024	1,250,000 USD
	Contact Name	Neeraj Agarwal, PhD			
	Contact Telephone	301-435-8155			
	Contact Email	<a href="mailto:agarwalnee@nei.nih.gov">agarwalnee@nei.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development The			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>purpose of this FOA is to encourage applications for the continuation of ongoing and creation of new courses for skills development that will significantly advance the educational goals of the BRAIN Initiative as described in The BRAIN Initiative®2.0: From Cells to Circuits, Toward Cures including neuroethics and opportunities to increase the workforce diversity in BRAIN Initiative research areas. Proposed programs are expected to offer hands-on research experiences, an in-depth conceptual understanding of the techniques and tools employed, and the knowledge to apply appropriate analytic approaches to the resulting data. Participants are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty with an emphasis on diversity as defined by NIH (NOT-OD-20-031). Proposed programs will facilitate the development of a sophisticated cadre of future investigators with the knowledge and skills to apply BRAIN Initiative techniques and approaches and data resources to research questions about brain function and behavior. Programs appropriate for this FOA must include participants from a regionally/nationally recruited cohort.</p>																		
114369	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements to Prepare Data Assets for Infectious and Immune-mediated Diseases for Inclusion into the NIAID Data Ecosystem</a>	National Institutes of Health/DHHS	NOT-AI-23-009	13-Feb-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-761-7328</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:datascience-FOA@niaid.nih.gov">datascience-FOA@niaid.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>13-Feb-2024 , 13-Feb-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for infectious- and immune-mediated disease research for inclusion in the NIAID Data Ecosystem. Research may include studies that strive to generate a better understanding of mechanisms for the prevention, diagnosis, and treatment of infectious- and immune mediated diseases. Relevant data must already have been collected and applicants must demonstrate that the data assets have value to other researchers for studies of infectious- and immune-mediated disease. The supplemental funding will enable applicants to prepare their data assets for meeting technical specifications for inclusion in the NIAID Data Ecosystem. The proposed supplemental activities must be within the scope of the approved aims of the parent award.</p> </td> </tr> </table>					Contact Name		Contact Telephone	301-761-7328	Contact Email	<a href="mailto:datascience-FOA@niaid.nih.gov">datascience-FOA@niaid.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	13-Feb-2024 , 13-Feb-2025	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for infectious- and immune-mediated disease research for inclusion in the NIAID Data Ecosystem. Research may include studies that strive to generate a better understanding of mechanisms for the prevention, diagnosis, and treatment of infectious- and immune mediated diseases. Relevant data must already have been collected and applicants must demonstrate that the data assets have value to other researchers for studies of infectious- and immune-mediated disease. The supplemental funding will enable applicants to prepare their data assets for meeting technical specifications for inclusion in the NIAID Data Ecosystem. The proposed supplemental activities must be within the scope of the approved aims of the parent award.</p>
Contact Name																			
Contact Telephone	301-761-7328																		
Contact Email	<a href="mailto:datascience-FOA@niaid.nih.gov">datascience-FOA@niaid.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	13-Feb-2024 , 13-Feb-2025																		
Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting supplemental funding applications for award recipients currently funded by participating NIH Institutes and Centers to prepare data assets relevant for infectious- and immune-mediated disease research for inclusion in the NIAID Data Ecosystem. Research may include studies that strive to generate a better understanding of mechanisms for the prevention, diagnosis, and treatment of infectious- and immune mediated diseases. Relevant data must already have been collected and applicants must demonstrate that the data assets have value to other researchers for studies of infectious- and immune-mediated disease. The supplemental funding will enable applicants to prepare their data assets for meeting technical specifications for inclusion in the NIAID Data Ecosystem. The proposed supplemental activities must be within the scope of the approved aims of the parent award.</p>																		
114457	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements for R25 Data Science Training for Infectious and Immune-Mediated Disease Research</a>	National Institutes of Health/DHHS	NOT-AI-23-010	13-Feb-2024	100,000 USD														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-761-7328</p> <p>Contact Email <a href="mailto:datascience-FOA@niaid.nih.gov">datascience-FOA@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Feb-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of participating NIH institutes and centers (ICs) to enhance existing NIH research Education (R25) awards with data science training relevant to infectious- and immune-mediated disease research. Data science is a rapidly evolving field in infectious- and immune-mediated diseases. Some of the most impactful data science takes place in transdisciplinary collaborations between biomedical, behavioral, clinical, and computational scientists. The supplemental work supported by this NOSI will enable existing R25 training programs to offer data science mentoring and training to engage a broader community in data science by improving training programs and transdisciplinary collaboration between biomedical, behavioral, clinical, and computational scientists for research on infectious- and immune-mediated diseases, consistent with the NIH Strategic Plan for Data Science.</p>				
111642	<p><a href="#">Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain</a></p>	National Institutes of Health/DHHS	NOT-NS-22-087	15-Feb-2024	100,000 USD
	<p>Contact Name Rebecca Hommer, MD</p> <p>Contact Telephone 301-827-2257</p> <p>Contact Email <a href="mailto:rebecca.hommer@nih.gov">rebecca.hommer@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024</p> <p>Synopsis The NIH Helping to End Addiction Long TermSM (HEAL) Initiative aims to improve our understanding, management, and treatment of pain by funding high quality scientific research in this relatively understudied area of medicine. For the HEAL Initiative and NIH to meet their long-term goals of providing effective non-opioid options for the treatment of pain conditions and innovative approaches for treating opioid use disorders, it will be necessary to train a new generation of clinical pain researchers. Leveraging HEAL Initiative clinical research programs to train novice researchers and investigators new to pain research in the mechanics, techniques, and best practices of clinical pain research will maximize the impact of</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

HEAL funding for both current and future research endeavors. Increasing the number of individuals trained in high quality clinical pain research is a critical step toward ensuring the highest impact of HEAL, with studies that encompass a broad range of pain conditions and have the potential to include, address the needs of, and positively impact diverse and traditionally under-served patient populations.

114886	<a href="#">RFA-MH-23-335 -- BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-MH-23-335	16-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Lizzy Ankudowich, Ph.D.
Contact Telephone	301-480-8187
Contact Email	<a href="mailto:lizzy.ankudowich@nih.gov">lizzy.ankudowich@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors. This R61/R33 FOA is intended to support biphasic applications for novel tools development (i.e., hardware/software) in the R61 phase, followed by the integration/synchronization of these novel tools with established methods for recording human brain activity in the R33 phase. Applications must propose one or more milestones, which clearly define the criteria for the success of the R61 project objectives. Transition to the R33 phase will depend on demonstration of milestone completion. Applications should be submitted by multi-disciplinary teams with expertise spanning behavior and behavioral measurement, neurobiology, social systems, computer/data systems, engineering, biostatistics, neuroethics, and artificial intelligence. Applicants pursuing brain-behavior quantification and synchronization tool development in non-human animals, or pursuing comparative animal studies including humans, are not responsive to this FOA and should consider related Brain-Behavior Quantification and Synchronization (BBQS) opportunities listed on the BRAIN Initiative website, or reach out to the contacts (see Section VII: Agency Contacts) for guidance on relevant opportunities.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
117252	<a href="#">RFA-NS-23-022 -- Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-23-022	03-Jan-2024 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name   Lumy Sawaki-Adams, MD, PhD</p> <p>Contact Telephone   301-827-1457</p> <p>Contact Email   <a href="mailto:lumy.sawaki-adams@nih.gov">lumy.sawaki-adams@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jan-2024 [Optional][LOI/Pre-App], 02-Feb-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory and innovative research applications focused on the neurological and neuropsychiatric manifestations of COVID-19 (neuro-COVID) and Post-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments for PASC-related neurological complications are of particular interest for this NOFO.</p>				
117236	<a href="#">RFA-NS-23-021 -- Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-23-021	03-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Lumy Sawaki-Adams, MD, PhD</p> <p>Contact Telephone   301-827-1457</p> <p>Contact Email   <a href="mailto:lumy.sawaki-adams@nih.gov">lumy.sawaki-adams@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jan-2024 [Optional][LOI/Pre-App], 02-Feb-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications focused on the neurological and neuropsychiatric manifestations of COVID-19 (neuro-COVID) and Post-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments for PASC-related neurological complications are of particular interest for this NOFO.			
103967	<a href="#">Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-229	05-Feb-2024	2,499,995 USD
	<p>Contact Name   Mahua Mukhopadhyay, Ph.D.</p> <p>Contact Telephone   301-435-6886</p> <p>Contact Email   <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Feb-2025</p> <p>Synopsis   Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.</p>				
107429	<a href="#">Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-064	05-Feb-2024	Not Specified
	<p>Contact Name   Larissa Aviles-Santa, MD, MPH</p> <p>Contact Telephone   301-827-6924</p> <p>Contact Email   <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support innovative multi-disciplinary and multi-level (e.g., patient, clinician, interpersonal, health care system, community) research designed to understand how optimizing patient-clinician communication and relationship affects health care outcomes in patients from populations with health care disparities. In addition, this initiative will support research to (1) gain an understanding of how the Patient-Clinician Relationship (PCR) in the primary care and chronic disease care settings affects clinical and non-clinical health outcomes in populations that experience health disparities, and (2) identify best practices and interventions that build and improve PCR leading to better health outcomes and increased health equity.</p>				
107447	<a href="#">RFA-HL-23-008 -- NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HL-23-008	28-Feb-2024	3,000,000 USD

Contact Name	Marc Rigas, PhD
Contact Telephone	301-496-0091
Contact Email	<a href="mailto:marc.rigas@nih.gov">marc.rigas@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	28-Feb-2024
Synopsis	<p>The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations. Proposed projects MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope) and require ultimate approval/clearance by a Federal regulatory agency. NCATS intends to co-fund applications that meet the NCATS mission to develop innovations that reduce,</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>remove or bypass costly and time-consuming bottlenecks in the translational science process, to speed the development and delivery of new drugs, diagnostics, medical devices and behavioral interventions to patients. For a description of the NCATS SBIR/STTR research priorities, please refer to <a href="http://ncats.nih.gov/smallbusiness/priorities?">http://ncats.nih.gov/smallbusiness/priorities?</a>(<a href="http://ncats.nih.gov/smallbusiness/priorities">http://ncats.nih.gov/smallbusiness/priorities</a>). This FOA is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that address a rare disease or young pediatric populations (aged 0-12 years and defined in Section IV, part 7). The primary indication of the product under development would: Address a rare disease as defined in the Orphan Drug Act Amendment of 1984 as any disease or condition that affects less than 200,000 persons in the United States; or Qualify as a Humanitarian Use Device, defined as a medical device intended to benefit patients in the treatment or diagnosis of a disease or condition that affects or is manifested in fewer than 4,000 persons in the United States per year; OR be targeted at a young pediatric population, defined as including neonates (0-28 days), infants (&lt;2 years), and/or children (2-12 years of age), as indicated in the FDA Premarket Assessment of Pediatric Medical Devices. This FOA will give competitive preference and funding priority to applications deemed likely to result in a commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed one-third of the requested NHLBI funds (total costs) being requested for the entire project period of the Phase IIB Small Market Award.</p>				

113623	<a href="#">RFA-MH-22-292 -- BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-MH-22-292	02-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Yong Yao, Ph.D.
Contact Telephone	301-443-6102
Contact Email	<a href="mailto:yyao@mail.nih.gov">yyao@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	02-Jan-2024 [Optional][LOI/Pre-App], 01-Feb-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, mouse, and other species in coordination and collaboration with other BRAIN Initiative Cell Atlas Network (BICAN) projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
107506	<a href="#">RFA-HL-23-009 -- NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HL-23-009	28-Feb-2024	3,000,000 USD
	<p>Contact Name   Marc Rigas, PhD</p> <p>Contact Telephone   301-496-0091</p> <p>Contact Email   <a href="mailto:marc.rigas@nih.gov">marc.rigas@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Feb-2024</p> <p>Synopsis   The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Funding Opportunity Announcement (FOA) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this FOA MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope). This FOA is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency. This FOA will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant's ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds (total costs).</p>				
119458	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials</a>	National Institutes of Health/DHHS	NOT-CA-23-071	28-Feb-2024	100,000 USD
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Feb-2024 , 30-Jun-2025</p> <p>Synopsis The Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) announces this Notice of Special Interest to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials - by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.</p>				
120869	<p><a href="#">Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for Alcohol, Tobacco, and Other Drugs (ATOD) Use and Misuse in Adult Populations That Experience Health Disparities (R01, Clinical Trial Required)</a></p>				
	<p>National Institutes of Health/DHHS PAR-23-270 05-Feb-2024 Not Specified</p>				
	<p>Contact Name Denise Stredrick, Ph.D.</p> <p>Contact Telephone 301-402-9749</p> <p>Contact Email <a href="mailto:denise.stredrick@nih.gov">denise.stredrick@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026 , 05-Feb-2027</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within.

120817	<a href="#">Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-244	05-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	David Berrigan
Contact Telephone	240-276-6752
Contact Email	<a href="mailto:berrigad@mail.nih.gov">berrigad@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026
Synopsis	This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

121563	<a href="#">Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-302	05-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Alexander Arguello, Ph.D.
Contact Telephone	240-731-3753
Contact Email	<a href="mailto:alexander.arguello@mail.nih.gov">alexander.arguello@mail.nih.gov</a>
Sponsor Website	



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.</p>				
121564	<a href="#">Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-301	16-Feb-2024	275,000 USD
	<p>Contact Name Alexander Arguello, Ph.D.</p> <p>Contact Telephone 240-731-3753</p> <p>Contact Email <a href="mailto:alexander.arguello@mail.nih.gov">alexander.arguello@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026 , 16-Oct-2026</p> <p>Synopsis The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.</p>				
121638	<a href="#">RFA-DA-25-047 -- Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-DA-25-047	13-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Morris Flood, DHSc</p> <p>Contact Telephone 301-496-6144</p> <p>Contact Email <a href="mailto:morris.flood@nih.gov">morris.flood@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024 , 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025 , 12-Feb-2026 [Optional][LOI/Pre-App], 13-Mar-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBCs) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder.</p>				
121634	<a href="#">RFA-DA-25-048 -- Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-DA-25-048	13-Feb-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Morris Flood, DHSc</p> <p>Contact Telephone 301-496-6144</p> <p>Contact Email <a href="mailto:morris.flood@nih.gov">morris.flood@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024 , 12-Feb-2025 [Optional][LOI/Pre-App], 13-Mar-2025 , 12-Feb-2026 [Optional][LOI/Pre-App], 13-Mar-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder</p>				
110353	<a href="#">Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-161	28-Feb-2024	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6970</p> <p>Contact Email <a href="mailto:lamt@nih.gov">lamt@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Feb-2024 , 29-Jul-2024 , 28-Feb-2025</p> <p>Synopsis Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts” PAR. This funding opportunity announcement</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement.</p>																		
120238	<a href="#">Notice of Special Interest (NOSI): BRAIN Initiative: Mentored Clinician Scientist Research Career Development Program to Develop Expertise in Intracranial Human Neuroscience Research (K08)</a>	National Institutes of Health/DHHS	NOT-AA-23-015	12-Feb-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ivana Grakalic, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-7600</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:igrakalic@mail.nih.gov">igrakalic@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>12-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Special Interest (NOSI) is to promote the availability of Mentored Clinician Scientist Research Career Development Awards (K08) applications in research areas covered by the NIH BRAIN Initiative®. This program will provide support and protected time (3-5 years) for clinicians to develop new and/or expand their expertise in intracranial human neuroscience research. The goal of the program is to build an interdisciplinary and diverse research workforce dedicated to capitalizing on intracranial neural recording and/or stimulating technologies to answer high-impact questions in human neuroscience.</td> </tr> </table>					Contact Name	Ivana Grakalic, PhD	Contact Telephone	301-443-7600	Contact Email	<a href="mailto:igrakalic@mail.nih.gov">igrakalic@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	12-Feb-2024	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote the availability of Mentored Clinician Scientist Research Career Development Awards (K08) applications in research areas covered by the NIH BRAIN Initiative®. This program will provide support and protected time (3-5 years) for clinicians to develop new and/or expand their expertise in intracranial human neuroscience research. The goal of the program is to build an interdisciplinary and diverse research workforce dedicated to capitalizing on intracranial neural recording and/or stimulating technologies to answer high-impact questions in human neuroscience.
Contact Name	Ivana Grakalic, PhD																		
Contact Telephone	301-443-7600																		
Contact Email	<a href="mailto:igrakalic@mail.nih.gov">igrakalic@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	12-Feb-2024																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote the availability of Mentored Clinician Scientist Research Career Development Awards (K08) applications in research areas covered by the NIH BRAIN Initiative®. This program will provide support and protected time (3-5 years) for clinicians to develop new and/or expand their expertise in intracranial human neuroscience research. The goal of the program is to build an interdisciplinary and diverse research workforce dedicated to capitalizing on intracranial neural recording and/or stimulating technologies to answer high-impact questions in human neuroscience.																		
120876	<a href="#">RFA-NS-24-027 -- VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in AD/DR (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-24-027	15-Dec-2023 [Optional][LOI/Pre-App]	6,000,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Roderick A. Corriveau</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:roderick.corriveau@nih.gov">roderick.corriveau@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Dec-2023 [Optional][LOI/Pre-App], 01-Feb-2024</td> </tr> </table>					Contact Name	Roderick A. Corriveau	Contact Telephone		Contact Email	<a href="mailto:roderick.corriveau@nih.gov">roderick.corriveau@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	15-Dec-2023 [Optional][LOI/Pre-App], 01-Feb-2024		
Contact Name	Roderick A. Corriveau																		
Contact Telephone																			
Contact Email	<a href="mailto:roderick.corriveau@nih.gov">roderick.corriveau@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	15-Dec-2023 [Optional][LOI/Pre-App], 01-Feb-2024																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this notice of funding opportunity (NOFO) is to support research designed to, in parallel in human-based and model-based studies, advance fundamental understanding of basic disease-related molecular mechanisms of vascular contributions to cognitive impairment and dementia (VCID). Specifically, this NOFO solicits applications focused on molecular mechanisms of small cerebral vessel diseases, including one or more of arteriolosclerosis, cerebral amyloid angiopathy (CAA), and atherosclerosis (direct impact or downstream effects on small vessels) that contribute to dementia diagnoses. Proposed research will use team-based and multi-faceted approaches to understand these small vessel disorders both cross-sectionally and over time (prodromal and after phenotypic disease first develops), as well as their relationship to VCID phenotypic and clinical outcomes. In addition to standard NIH sharing requirements, the program will highlight Center Without Walls (CWOW) sharing of pre-publication ideas, data, methods, and results. The overall goal is to generate, via a collaborative CWOW framework, foundational knowledge in the emerging field of VCID that is needed for future development of interventions including for prevention and better clinical outcomes.

105617	<a href="#">Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-287	07-Jan-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025
Synopsis	<p>The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth). The goals of this FOA are to support multidisciplinary research that investigates the effectiveness of SBHCs as a health services care delivery model to detect, manage, and prevent chronic illnesses that disproportionately burden underserved youth. The mechanisms of impact by which SBHCs improve the health of at-risk populations such as sexual and gender minority youth, immigrant youth, and youth who reside in rural areas are also a relevant focus for understanding effective models of SBHCs. Applications are expected to provide a conceptual model that describes hypothesized causal pathways by which SBHCs engage underserved youth to improve health outcomes and how SBHCs may complement (or reduce) the use of other services. Lessons learned through this initiative can help determine whether SBHCs can be adopted as a best practice care model to address the health services needs of underserved youth and if so, whether SBHCs given their accessibility to students can be an effective site of</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

intervention to address disparities in chronic conditions, and behavioral, oral, and reproductive health of youth from underserved communities who lack access to health care.

103723	<a href="#">Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-233	09-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Ann-Marie Broome PhD MBA  
 Contact Telephone | 301-496-1779  
 Contact Email | [ann-marie.broome@nih.gov](mailto:ann-marie.broome@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 09-Feb-2024 , 05-Apr-2024

Synopsis | The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

103168	<a href="#">Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-201	05-Feb-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name | Lisa Gilotty, Ph.D.  
 Contact Telephone | 301-443-3825  
 Contact Email | [gilottyl@mail.nih.gov](mailto:gilottyl@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Feb-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199.

103023	<a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-166	05-Feb-2024	2,495,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Miguel Ossandon MS  
 Contact Telephone 240-276-5714  
 Contact Email [ossandom@mail.nih.gov](mailto:ossandom@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-Feb-2024

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.

103050	<a href="#">Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)</a>	National Institutes of Health/DHHS	NOT-HL-21-008	07-Jan-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Denis Buxton, PhD</p> <p>301-435-0515</p> <p><a href="mailto:buxtond@nhlbi.nih.gov">buxtond@nhlbi.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Postural Orthostatic Tachycardia Syndrome (POTS) can be a debilitating condition that affects routine activities such as working or attending school. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. The peak incidence is at age 14 years, but half of all individuals with POTS develop it in adulthood. While there are no precise data on the prevalence of POTS, it is estimated to affect 0.2-1% of the U.S. population. There is thus a compelling need to stimulate research to understand the causes of POTS in order to inform the development of treatments. Improving the diagnosis of POTS through the development of biomarkers or improved diagnostic tools represents another major need. Translational studies and mechanistic clinical trials to guide the development of better treatments are also important goals. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.</p>
---	---

109791	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-137	07-Jan-2024	1,250,000 USD
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Julia Zehr, Ph.D.</p> <p>301-443-1617</p> <p><a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p>
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (<a href="http://www.abcdstudy.org">www.abcdstudy.org</a>). This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-138, seeks shorter, higher-risk R21 grant applications.</p>			
109172	<a href="#">Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-085	05-Feb-2024	Not Specified
	Contact Name	Avi Rasooly, PhD			
	Contact Telephone	240-276-6196			
	Contact Email	<a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.</p>			
112472	<a href="#">Notice of Special Interest (NOSI): Respiratory Complications of the Muscular Dystrophies (R01)</a>	National Institutes of Health/DHHS	NOT-HL-22-025	07-Jan-2024	Not Specified
	Contact Name	Aruna Natarajan, MD, PhD			
	Contact Telephone	301-827-0180			
	Contact Email	<a href="mailto:aruna.natarajan@nih.gov">aruna.natarajan@nih.gov</a>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of this NOSI is to encourage research grant applications focused on respiratory complications of the muscular dystrophies. This includes further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies.</p>				
119254	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-207	05-Feb-2024	Not Specified
	<p>Contact Name Laura M. Rowland, Ph.D.</p> <p>Contact Telephone 301-480-8335</p> <p>Contact Email <a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026</p> <p>Synopsis The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R01 mechanism, while the companion announcement PAR-23-208 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
117793	<a href="#">Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities (R01, Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-23-170	05-Feb-2024	Not Specified
	<p>Contact Name JoyAnn Courtney, Ph.D.</p> <p>Contact Telephone 301-402-3911</p> <p>Contact Email <a href="mailto:joyann.courtney@nih.gov">joyann.courtney@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.</p>				
114402	<a href="#">Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-037	07-Jan-2024	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-480-2619</p> <p>Contact Email <a href="mailto:NICHD-Network-ClinicalResearch@nih.gov">NICHD-Network-ClinicalResearch@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice NOT-HD-19-034: To enhance the rigor and reproducibility of clinical trial protocols To promote greater availability of multisite clinical trial infrastructure to support trials from a wider range of investigators To facilitate data sharing and access to biospecimens to efficiently expand research capacity for all</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>investigators To facilitate greater involvement of diverse populations in multisite clinical trials. Consequently, multisite clinical trials and observational studies conducted by and within the participating NICHD-supported Clinical Research Networks will be submitted as investigator-initiated, multi-Principal Investigator (PI) grant applications by any qualified investigator in the extramural community (including NICHD Network investigators) in conjunction with the respective NICHD Network Data Coordinating Center (DCC). It is the intent of this initiative to utilize the NICHD Clinical Research Network infrastructure in a manner that will promote the funding and support of the best science in a timely, transparent, equitable and cost-effective manner.</p>			
116476	<a href="#">Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-130	05-Feb-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Katie M. Vance, Ph.D.</p> <p>301-435-6640</p> <p><a href="mailto:Katie.Vance@nih.gov">Katie.Vance@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026</p> <p>The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.</p>			
116310	<a href="#">Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy</a>	National Institutes of Health/DHHS	NOT-HL-23-003	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Anthony Agresti</p> <p>301-827-8014</p> <p><a href="mailto:agrestia@nhlbi.nih.gov">agrestia@nhlbi.nih.gov</a></p> <p></p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
102638	<a href="#">New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAS-21-150	07-Jan-2024	600,000 USD
	<p>Contact Name Shilpa Hattangadi, M.D.</p> <p>Contact Telephone 301-594-7726</p> <p>Contact Email <a href="mailto:shilpam.hattangadi@nih.gov">shilpam.hattangadi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.</p>				
102694	<a href="#">Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health</a>	National Institutes of Health/DHHS	NOT-HD-20-032	07-Jan-2024	Not Specified
	<p>Contact Name Regina M. Bures, Ph.D.</p> <p>Contact Telephone 301-496-9485</p> <p>Contact Email <a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-disciplinary scientific teams proposing research using systems science approaches to address persistent public health challenges. Systems science refers to multi-level methodologies addressing complex behavioral and social phenomena. This initiative encourages applications for both basic and applied research, including methodological and measurement development, with a focus on human behavioral and/or social science. This initiative also seeks to promote interdisciplinary collaboration among health researchers and experts in mathematical modelling.			
108001	<a href="#">Notice of Special Interest (NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	NOT-HL-23-001	07-Jan-2024	Not Specified
	Contact Name	Robb Rowley, MD			
	Contact Telephone	301-827-9126			
	Contact Email	<a href="mailto:Robb.Rowley@nih.gov">Robb.Rowley@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate novel epidemiological research to address key knowledge gaps within and between subpopulations of Asian Americans, Native Hawaiians, and Pacific Islanders. These populations are frequently aggregated in research, potentially masking important social and health differences. Given clear heterogeneity in ancestry, culture, immigration patterns among Asian Americans, socioeconomic position, and acculturation into American life, a critical need exists for epidemiological research to enhance our understanding of the interplay of environmental exposures, lifestyle, behavioral, genomics, social, neighborhood, and biological factors that impact the health of Asian American, Native Hawaiian, and Pacific Islander subpopulations.			
112441	<a href="#">Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-210	05-Feb-2024	2,500,000 USD
	Contact Name	Liam O'Fallon			
	Contact Telephone	984-287-3298			
	Contact Email	<a href="mailto:ofallon@niehs.nih.gov">ofallon@niehs.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings. Projects supported under this program will employ community-engaged research methods to conduct research and to translate research findings into public health action. This announcement reflects NIEHS' and NIMHD's commitment to environmental health disparities and environmental justice research. This FOA also advances efforts to nurture and sustain trust and bi-directional communication between academic researchers and affected communities. The Research to Action program is part of the National Institute of Environmental Health Sciences (NIEHS) "Partnerships for Environmental Public Health" (PEPH) network (<https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm>).

093897	<a href="#">Research Project Grant (Parent R01 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-183	07-Jan-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024

Synopsis | The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)

093907	<a href="#">Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-184	07-Jan-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-4000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
093908	<a href="#">NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-185	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs)</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>					
099859	<a href="#">Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)</a>	National Institutes of Health/DHHS	NOT-HL-20-814	07-Jan-2024	Not Specified
	<p>Contact Name   Guofei Zhou, PhD            Contact Telephone   301-827-7825            Contact Email   <a href="mailto:guofei.zhou@nih.gov">guofei.zhou@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).</p>				
108364	<a href="#">Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care towards Health Equity (R01 - Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-22-092	07-Jan-2024	Not Specified
	<p>Contact Name   Larissa Avilés-Santa, MD, MPH            Contact Telephone   301-827-6924            Contact Email   <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024            Synopsis   This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The goal of this initiative is attainment of optimal treatment and health outcomes goals to advance health care towards health equity.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108571	<a href="#">Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy</a>	National Institutes of Health/DHHS	NOT-HL-23-003	07-Jan-2024	Not Specified
	<p>Contact Name   Anthony Agresti</p> <p>Contact Telephone   301-827-8014</p> <p>Contact Email   <a href="mailto:agrestia@nhlbi.nih.gov">agrestia@nhlbi.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis   This Notice of Special Interest (NOSI) aims to accelerate a comprehensive understanding of the mechanisms of COVID-19-Associated Coagulopathy (CAC) which are provoked by vascular endothelial cell injury, hyperimmune responses, and hypercoagulability at genomic, molecular, and cellular levels. Knowledge obtained from such studies may be applied to the future design of early diagnostics and effective treatment for high-risk patients as well as enable CAC research findings to be applied to on-going COVID-19 clinical trials.</p>				
114120	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-046	07-Jan-2024	Not Specified
	<p>Contact Name   David M. Panchision, Ph.D.</p> <p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This FOA is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 FOA (PAR-23-047).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
116616	<a href="#">Notice of Special Interest (NOSI): Research Project Grants in Valvular Heart Disease (CAROL Act)</a>	National Institutes of Health/DHHS	NOT-HL-23-079	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Frank Evans, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-0510</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:evansf@nhlbi.nih.gov">evansf@nhlbi.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.</td> </tr> </table>					Contact Name	Frank Evans, PhD	Contact Telephone	301-435-0510	Contact Email	<a href="mailto:evansf@nhlbi.nih.gov">evansf@nhlbi.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026	Synopsis	As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.
Contact Name	Frank Evans, PhD																		
Contact Telephone	301-435-0510																		
Contact Email	<a href="mailto:evansf@nhlbi.nih.gov">evansf@nhlbi.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026																		
Synopsis	As part of the National Heart, Lung, and Blood Institute's implementation of the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking R01 applications that propose research in valvular heart disease.																		
107608	<a href="#">Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-031	05-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Enrique Michelotti, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-443-5415</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</td> </tr> </table>					Contact Name	Enrique Michelotti, PhD	Contact Telephone	301-443-5415	Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024	Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.
Contact Name	Enrique Michelotti, PhD																		
Contact Telephone	301-443-5415																		
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.																		
115307	<a href="#">Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research</a>	National Institutes of Health/DHHS	NOT-HL-22-040	07-Jan-2024	Not Specified														

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Kristin M. Burns, MD</p> <p>Contact Telephone   301-594-6859</p> <p>Contact Email   <a href="mailto:kristin.burns@nih.gov">kristin.burns@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb-2027 , 07-May-2027 , 05-Jun-2027 , 07-Sep-2027 , 05-Oct-2027 , 07-Jan-2028</p> <p>Synopsis   This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere to the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.</p>				
111805	<a href="#">Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-181	07-Jan-2024	Not Specified
	<p>Contact Name   Albert Avila, Ph.D.</p> <p>Contact Telephone   301-496-8804</p> <p>Contact Email   <a href="mailto:aavila@nida.nih.gov">aavila@nida.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 09-Jan-2024 , 06-Feb-2024 , 06-May-2024 , 07-May-2024 , 06-Jun-2024 , 06-Sep-2024 , 07-Sep-2024 , 08-Oct-2024 , 07-Jan-2025 , 08-Jan-2025 , 06-Feb-2025 , 05-May-2025 , 07-May-2025 , 06-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH's Interest in Diversity), are encouraged to work with their</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	institutions to apply for support under this program. Investigators from categories A and B are particularly encouraged to work with their institutions to apply.																		
105957	<a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-305	11-Dec-2023	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Mary Evans, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-4578</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</td> </tr> </table>					Contact Name	Mary Evans, Ph.D.	Contact Telephone	301-594-4578	Contact Email	<a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024	Synopsis	This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.
Contact Name	Mary Evans, Ph.D.																		
Contact Telephone	301-594-4578																		
Contact Email	<a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024																		
Synopsis	This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.																		
104854	<a href="#">Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV</a>	National Institutes of Health/DHHS	NOT-AI-21-054	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Rosemary McKaig, M.P.H, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3214</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:rm434n@nih.gov">rm434n@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024</td> </tr> </table>					Contact Name	Rosemary McKaig, M.P.H, Ph.D.	Contact Telephone	240-627-3214	Contact Email	<a href="mailto:rm434n@nih.gov">rm434n@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024		
Contact Name	Rosemary McKaig, M.P.H, Ph.D.																		
Contact Telephone	240-627-3214																		
Contact Email	<a href="mailto:rm434n@nih.gov">rm434n@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. Further, because this field can reveal unexpected associations through analysis of diverse data, BDS approaches may reveal events that are unseen or transient in traditional analysis of datasets. Discovery of these events will considerably advance research on HIV networks of transmission and the care continuum. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research.</p>			
104500	<a href="#">Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to Improve Use of Evidence-Based Practices for HLBS Conditions</a>	National Institutes of Health/DHHS	NOT-HL-21-010	07-Jan-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Rebecca A. Roper, MS, MPH 301-496-1051 <a href="mailto:Rebecca.Roper@nih.gov">Rebecca.Roper@nih.gov</a>  <a href="#">Link to program URL</a> 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			
	Synopsis	<p>This Notice of Special Interest (NOSI) is intended to stimulate the use of behavioral economics strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. NHLBI encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. Applications that focus on the use of behavioral economics to develop implementation strategies for user-driven, sustainable interventions that may be simplified and minimally disruptive when possible are encouraged. Applications may propose either a clinical trial or non-clinical trial design, as appropriate to the research objectives.</p>			
111616	<a href="#">Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</a>	National Institutes of Health/DHHS	NOT-OD-22-123	28-Dec-2023	Not Specified
	Contact Name	Charlene Schramm, PhD			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-402-3739</p> <p>Contact Email   <a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>				
117550	<p><a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-23-164	07-Jan-2024	Not Specified
	<p>Contact Name   Enrique Michelotti, Ph.D.</p> <p>Contact Telephone   301-443-5415</p> <p>Contact Email   <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</p> <p>Synopsis   This Funding Opportunity Announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (PAR-23-164).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
117551	<a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-165	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Enrique Michelotti, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-5415</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).</td> </tr> </table>					Contact Name	Enrique Michelotti, Ph.D.	Contact Telephone	301-443-5415	Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026	Synopsis	This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).
Contact Name	Enrique Michelotti, Ph.D.																		
Contact Telephone	301-443-5415																		
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026																		
Synopsis	This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to NOFO (PAR-23-164).																		
113055	<a href="#">RFA-EB-22-002 -- HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-EB-22-002	21-Jan-2024 [Optional][LOI/Pre-App]	2,250,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Moria F. Bittmann</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-7699</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:moria.bittmann@nih.gov">moria.bittmann@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024 , 15-Sep-2024 [Optional][LOI/Pre-App], 15-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage</td> </tr> </table>					Contact Name	Moria F. Bittmann	Contact Telephone	301-496-7699	Contact Email	<a href="mailto:moria.bittmann@nih.gov">moria.bittmann@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024 , 15-Sep-2024 [Optional][LOI/Pre-App], 15-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage
Contact Name	Moria F. Bittmann																		
Contact Telephone	301-496-7699																		
Contact Email	<a href="mailto:moria.bittmann@nih.gov">moria.bittmann@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024 , 15-Sep-2024 [Optional][LOI/Pre-App], 15-Oct-2024 , 18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025																		
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.				
094250	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-206	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094234	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-202	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-496-8580</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			
115095	<a href="#">Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-073	07-Jan-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:AITraininghelpdesk@niaid.nih.gov">AITraininghelpdesk@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024 , 07-Jan-2025 , 12-Feb-2025 , 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and "protected time" (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

103180	<a href="#">Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-200	16-Feb-2024	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	Lisa Gilotty, Ph.D.
Contact Telephone	301-443-3825
Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.

103183	<a href="#">Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-199	16-Feb-2024	100,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	Lisa Gilotty, Ph.D.
Contact Telephone	301-443-3825
Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.

107609	<a href="#">Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-032	16-Feb-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024

Synopsis | This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH, NIA, NIAAA and NIDA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).

114377	<a href="#">Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)</a>	National Institutes of Health/DHHS	NOT-AI-23-013	05-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Samuel Perdue, Ph.D.
--------------	----------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-627-3341</p> <p>Contact Email   <a href="mailto:sperdue@nih.gov">sperdue@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines, vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.</p>				
113804	<a href="#">Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest</a>	National Institutes of Health/DHHS	NOT-HD-22-038	07-Jan-2024	Not Specified
	<p>Contact Name   Elyse R. Grossman</p> <p>Contact Telephone   240-551-3628</p> <p>Contact Email   <a href="mailto:elyse.grossman@nih.gov">elyse.grossman@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see <a href="https://nida.nih.gov/about-nida/strategic-plan/nidas-mission">https://nida.nih.gov/about-nida/strategic-plan/nidas-mission</a> .			
114675	<a href="#">Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA)</a>	National Institutes of Health/DHHS	NOT-GM-23-015	08-Dec-2023	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 16-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 16-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 16-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 25-Feb-2025 , 05-Apr-2025 , 12-Apr-2025 , 07-May-2025 , 16-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 25-Jun-2025 , 08-Aug-2025 , 05-Sep-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 25-Oct-2025 , 08-Dec-2025			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform the scientific community of the interest of NIGMS, NLM, and ODSS in supporting efficiency optimization and cost reduction for Sequence Read Archive (SRA) data storage and utilization.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
121246	<a href="#">Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-292	05-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>David Dean Jr., Ph.D., M.S.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-276-8703</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:bconnole@mail.nih.gov">bconnole@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.</td> </tr> </table>					Contact Name	David Dean Jr., Ph.D., M.S.	Contact Telephone	240-276-8703	Contact Email	<a href="mailto:bconnole@mail.nih.gov">bconnole@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026	Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.
Contact Name	David Dean Jr., Ph.D., M.S.																		
Contact Telephone	240-276-8703																		
Contact Email	<a href="mailto:bconnole@mail.nih.gov">bconnole@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026																		
Synopsis	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) intends to support the rigorous assessment of barriers to quality cancer treatment and follow-up care for sexual and gender minority (SGM) cancer survivors. This funding opportunity is intended to address a critical need for improved care delivery and outcomes for SGM cancer survivors. The goal is to address the disease burden in an underserved and understudied population that is at higher risk of poorer health outcomes. The NCI solicits proposals for observational and/or interventional studies of SGM survivors designed to understand barriers and/or improve care and outcomes for SGM people with cancer, using interoperable sexual orientation and gender identity (SOGI) data collection in cancer care settings, where appropriate.																		
122108	<a href="#">RFA-AI-23-061 -- Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-23-061	07-Jan-2024	5,450,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Tania B. Lombo Rodriguez, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-761-7612</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:tania.lombo@mail.nih.gov">tania.lombo@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities</td> </tr> </table>					Contact Name	Tania B. Lombo Rodriguez, Ph.D.	Contact Telephone	301-761-7612	Contact Email	<a href="mailto:tania.lombo@mail.nih.gov">tania.lombo@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities
Contact Name	Tania B. Lombo Rodriguez, Ph.D.																		
Contact Telephone	301-761-7612																		
Contact Email	<a href="mailto:tania.lombo@mail.nih.gov">tania.lombo@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025																		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.			
122034	<a href="#">RFA-NS-24-013 -- Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-NS-24-013	20-Jan-2024 [Optional][LOI/Pre-App]	46,900,000 USD
	<p>Contact Name   Rebecca Hommer, MD</p> <p>Contact Telephone   301-827-2257</p> <p>Contact Email   <a href="mailto:rebecca.hommer@nih.gov">rebecca.hommer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p> <p>Synopsis   This RFA is soliciting applications proposing placebo-controlled, phase 3 clinical trials to determine the efficacy and safety of FDA approved monoclonal antibody therapies directed against amyloid compared to placebo in diverse "mixed dementia" populations with a focus on vascular contributions to cognitive impairment and dementia (VCID). In this NOFO the mixed-etiology dementias (MED) that are of interest and that are in scope are cognitive impairment and dementia cases positive for 1) canonical Alzheimer's pathology biomarkers (for example, amyloid deposition assessed using positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) with evidence of vascular contributions based on imaging (for example, white matter disease and/or subclinical infarction). Bayesian approaches with response adaptive randomization to examine specific subgroups are encouraged. Successful applications will be powered to determine efficacy in diverse populations representative of the distribution of the disease in the United States by sex, race/ethnicity, and geographic distribution. Applications must include elements of patient and community engagement that are incorporated into all stages of program development and at all levels of the organizational structure.</p>				
108357	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-060	07-Jan-2024	300,000 USD
	<p>Contact Name   Lisa Chadwick</p> <p>Contact Telephone   301-435-7275</p> <p>Contact Email   <a href="mailto:lisa.chadwick@nih.gov">lisa.chadwick@nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108327	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 25-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or <a href="https://grants.nih.gov/grants/funding/r15.htm">https://grants.nih.gov/grants/funding/r15.htm</a>.</p>	National Institutes of Health/DHHS	PAR-21-357	07-Jan-2024	300,000 USD

<p>Contact Name Mahua Mukhopadhyay, Ph.D.</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 25-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or <a href="https://grants.nih.gov/grants/funding/r15.htm">https://grants.nih.gov/grants/funding/r15.htm</a>. This REAP funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this FOA, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>
--



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108347	<a href="#">Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration</a>	National Institutes of Health/DHHS	NOT-EY-22-002	05-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024</p> <p>Synopsis The National Eye Institute (NEI) is issuing this Notice of Special Interest (NOSI) to encourage novel research that incorporates newly identified factors into new or existing models of visual system regeneration. These factors were identified by a consortium of research teams as part of the Audacious Goal Initiative (AGI) and are being shared broadly with the research community. Applicants beyond the original consortium are strongly encouraged to apply.</p>				
112751	<a href="#">Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech</a>	National Institutes of Health/DHHS	NOT-NS-23-002	20-Feb-2024	Not Specified
	<p>Contact Name Eric Hudak, Ph.D.</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 20-Jun-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Helping to End Addiction Long-Term (HEAL) Initiative and overseen by the NIH Blueprint MedTech program. Academic institutions and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies of medical devices for the diagnosis and treatment of pain and opioid use disorder (OUD). Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the HEAL Initiative are encouraged.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
116056	<a href="#">Notice of Special Interest (NOSI): Mortality of Adolescents, Young Adults, and Other NICHD Priority Populations in the United States</a>	National Institutes of Health/DHHS	NOT-HD-23-001	07-Jan-2024	Not Specified
	<p>Contact Name   Juanita J. Chinn, PhD</p> <p>Contact Telephone   301-827-4901</p> <p>Contact Email   <a href="mailto:juanita.chinn@nih.gov">juanita.chinn@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to invite applications to: Identify mechanisms, causes, correlates, and modifiable risk factors underlying recent trends in mortality during adolescence and young adulthood. Trends to be examined include the growing inequalities in overall mortality and by cause of death and manner of death (natural, unintentional and intentional injuries, including suicide and homicide, and undetermined), with attention to race, ethnicity, sex, gender, age, disability status, as well as family structure and living arrangements, income, education, and geographic location. Examine trends in mortality among individuals with intellectual and physical disabilities with a particular interest in studies that identify mechanisms, explanations, and modifiable risk factors. Improve the accuracy and granularity of cause of death coding, especially for individuals with intellectual and physical disabilities, and to improve the accuracy of manner of death coding, particularly across unintentional and intentional injuries, including suicide and homicide, for adolescents and young adults as well as for individuals with intellectual and physical disabilities. Improve research on mortality among youth populations of all sexual orientations and gender identities –especially for suicide and homicide, and other intentional and unintentional injuries. Examine the impact of rising mortality among adolescents, adolescents transitioning to adulthood and young adults on the health and development of the population, including demographic factors such as fertility and nuptiality, on the health and development of decedents' offspring and other family members, and on the health, development, and well-being of populations of interest to the NICHD is of high program priority. The NICHD populations of interest that are the focus of this Notice are adolescents, young adults, and individuals with intellectual, developmental, or physical disabilities. For information on the NICHD Strategic Plan 2020 (<a href="https://www.nichd.nih.gov/about/org/strategicplan">https://www.nichd.nih.gov/about/org/strategicplan</a>)</p>				
122019	<a href="#">Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-24-046	07-Feb-2024	275,000 USD
	<p>Contact Name   Holly Storkel, PhD, CCC-SLP</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-451-6842</p> <p>Contact Email   <a href="mailto:holly.storkel@nih.gov">holly.storkel@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Feb-2024 , 19-Jul-2024 , 19-Nov-2024</p> <p>Synopsis   The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Community engaged research combined with rigorous qualitative research and diverse research teams are needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children.</p>				
122024	<a href="#">Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-059	05-Feb-2024	Not Specified
	<p>Contact Name   Rada K. Dagher, PhD, MPH</p> <p>Contact Telephone   301-451-2187</p> <p>Contact Email   <a href="mailto:rada.dagher@nih.gov">rada.dagher@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis</p>				
112393	<a href="#">Notice of Special Interest (NOSI): HEAL Initiative--Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery</a>	National Institutes of Health/DHHS	NOT-NS-22-095	20-Feb-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 20-Feb-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to improve the translational application of animal models and/or outcome measures for the development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.</p>				
102740	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-124	20-Feb-2024	750,000 USD
	<p>Contact Name Becky Roof, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 20-Jun-2024</p> <p>Synopsis This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.</p>				
110865	<a href="#">Notice of Special Interest (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy</a>	National Institutes of Health/DHHS	NOT-CA-22-063	28-Dec-2023	Not Specified
	<p>Contact Name Yin Liu, Ph.D.</p> <p>Contact Telephone 240-276-6251</p> <p>Contact Email <a href="mailto:liuy@mail.nih.gov">liuy@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024</p> <p>Synopsis   The overall goal of this Notice of Special Interest (NOSI) is to promote mechanistic research aimed at better understanding the pathophysiology of immune-related adverse events (irAEs). It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. The proposed research can be basic or translational but should be focused on revealing the mechanisms underlying irAEs. Single investigators and/or multidisciplinary teams with relevant expertise in the research area proposed and/or patient characterization and selection are encouraged to apply.</p>				
111618	<p><a href="#">Notice of Special Interest (NOSI): Developing Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) for Institutions With an Emphasis On Down Syndrome Research (R15 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	NOT-OD-22-136	07-Jan-2024	Not Specified
	<p>Contact Name   Sujata Barhan, Ph.D.</p> <p>Contact Telephone   301-435-0471</p> <p>Contact Email   <a href="mailto:sujata.bardhan@nih.gov">sujata.bardhan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 25-Feb-2024 , 07-May-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for development of Academic Research Enhancement Award (AREA) and Research Enhancement Award Program (REAP) applications to support small scale basic and translational research grants that meet programmatic objectives of the INCLUDE project at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate and/or graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than \$6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system. The goal of this NOSI is also to build a pathway of meritorious undergraduate and graduate students engaged in Down syndrome research.</p>				
112471	<p><a href="#">Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis</a></p>	National Institutes of Health/DHHS	NOT-DE-22-003	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Kathryn Stein, PhD</p> <p>Contact Telephone   301-827-4653</p> <p>Contact Email   <a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025</p> <p>Synopsis   The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput 'omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo.</p>				
111545	<p><a href="#">FCO-- AMENDMENT -- Research Opportunity Announcement (ROA): NIH All of Us Engagement, Communications, and Enrollment Partnerships</a></p>	National Institutes of Health/DHHS	OTA-22-006	30-Nov-2023	Not Specified
	<p>Contact Name   All of Us ROA Inquiries</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:AOU-ROA@nih.gov">AOU-ROA@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Nov-2023 , 29-Feb-2024 , 31-May-2024 , 30-Aug-2024 , 29-Nov-2024 , 28-Feb-2025 , 23-May-2025</p> <p>Synopsis   Research Opportunity Announcement (ROA) Title: All of Us Engagement, Communications, and Enrollment Partnerships ROA Number: OTA-22-006 ROA Open Period: May 26, 2022 to May 23, 2025 (Note: open period includes multiple white paper deadlines) Overview: The All of Us Research Program, within the Office of the Director (OD) at the National Institutes of Health (NIH), has issued a research opportunity announcement to solicit white papers supporting various Areas of Interest (AOIs). A ROA is a method of solicitation that announces the anticipated availability of Other Transactions (OT) awards, a special type of legal instrument other than contracts, grants, or cooperative agreements. Purpose: The All of Us Research Program is a historic effort to gather data from at least 1 million people, with the goal of accelerating health research and medical breakthroughs, and enabling individualized prevention, treatment, and care. The program is creating a national research resource to inform thousands of studies, covering a wide variety of health conditions. Researchers will use data from the program to learn more about how individual differences in lifestyle,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

environment, and biological makeup can influence health and disease. The purpose of this announcement is to fund organizations who can help All of Us build its cohort of volunteers who reflect the rich diversity of the United States and are actively engaged as partners. These funded organizations will help design and implement strategies to raise awareness of the program through community and health care provider organizations, drive increased enrollment of participants, foster regular communication with participants, and engage the research community to use the data being gathered. Award Project Duration: Award periods are anticipated to be up to five (5) years but may be shortened or extended as needed. Pre-Submission Webinar: A webinar will be conducted on June 27, 2022 at [Time TBD]. Registration information will be posted here once it is available. White Paper Deadlines: This ROA will remain open for three (3) years from its issue date, unless otherwise updated via an amendment, and includes multiple white paper (WP) submission deadlines. All WP deadline times are 3:00 PM Eastern Time: Calendar Year 2022 WP Deadlines August 31, 2022 November 30, 2022 Calendar Year 2023 WP Deadlines February 28, 2023 May 31, 2023 August 31, 2023 November 30, 2023 Calendar Year 2024 WP Deadlines February 29, 2024 May 31, 2024 August 30, 2024 November 29, 2024 Calendar Year 2025 WP Deadlines February 28, 2025 May 23, 2025 Documents and Related Links: The full ROA package is attached in the 'Attachments/Links' section. Potential offerors are encouraged to carefully review the announcement before submitting questions and/or preparing a white paper submission. A link to the All of Us Research Program webpage has been provided for additional information about our program.

116911	<a href="#">Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-122	07-Jan-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Alison Gammie
Contact Telephone	
Contact Email	<a href="mailto:alison.gammie@nih.gov">alison.gammie@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026
Synopsis	The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.

102724	<a href="#">Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-163	09-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Ann-Marie Broome, Ph.D. MBA  
 Contact Telephone | 301-496-1779  
 Contact Email | [ann-marie.broome@nih.gov](mailto:ann-marie.broome@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 09-Feb-2024 , 07-May-2024

Synopsis | The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

105002	<a href="#">The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-21-275	07-Jan-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Rada K. Dagher, PhD, MPH  
 Contact Telephone | 301-451-2187  
 Contact Email | [rada.dagher@nih.gov](mailto:rada.dagher@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.			
104359	<a href="#">Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-232	07-Jan-2024	2,500,000 USD
	Contact Name	Larissa Aviles-Santa, MD, MPH			
	Contact Telephone	301-827-6924			
	Contact Email	<a href="mailto:avilessantal@mail.nih.gov">avilessantal@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024			
	Synopsis	This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.			
107841	<a href="#">Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-358	07-Jan-2024	Not Specified
	Contact Name	Deborah E. Linares, PhD, MA			
	Contact Telephone	301-402-2516			
	Contact Email	<a href="mailto:Deborah.Linares@nih.gov">Deborah.Linares@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
102069	<a href="#">Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-115	05-Feb-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Melissa Parisi, MD, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-435-6880</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p> </td> </tr> </table>					Contact Name	Melissa Parisi, MD, PhD	Contact Telephone	301-435-6880	Contact Email	<a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Feb-2024	Synopsis	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p>
Contact Name	Melissa Parisi, MD, PhD																		
Contact Telephone	301-435-6880																		
Contact Email	<a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Feb-2024																		
Synopsis	<p>This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p>																		
105755	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-254	05-Feb-2024	2,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Daniel Gilchrist, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Feb-2024 , 05-Jun-2024</td> </tr> </table>					Contact Name	Daniel Gilchrist, Ph.D.	Contact Telephone		Contact Email	<a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024		
Contact Name	Daniel Gilchrist, Ph.D.																		
Contact Telephone																			
Contact Email	<a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>			
109941	<a href="#">Focused Technology Research and Development (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-127	07-Jan-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p>Fei Wang, Ph.D.</p> <p><a href="#">wangf@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>This Funding Opportunity Announcement (FOA) supports projects relevant to the NIGMS mission or those of other NIH institutes or Centers (ICs) participating in the FOA that focus solely on the development of technologies with the potential to enable acquisition of biomedical knowledge. Projects should be justified in terms of technical innovation and utility of such technical innovation for impacting future biomedical research. Outcomes or products of the proposed project should significantly advance the current state of the art and be sufficiently characterized for application in addressing a broad range of biomedical research questions. These outcomes may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.</p>			
110513	<a href="#">Notice of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior</a>	National Institutes of Health/DHHS	NOT-DA-23-004	07-Jan-2024	Not Specified
	Contact Name	Jonathan D. Pollock, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-1309</p> <p>Contact Email   <a href="mailto:jpollock@mail.nih.gov">jpollock@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD).</p>				
114710	<p><a href="#">RFA-NS-22-024 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	RFA-NS-22-024	09-Feb-2024	Not Specified
	<p>Contact Name   DP Mohapatra, Ph.D.</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Feb-2024 , 11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis   The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
114711	<a href="#">RFA-NS-22-025 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-025	09-Feb-2024	Not Specified
	<p>Contact Name: DP Mohapatra, Ph.D.            Contact Telephone: 301-496-9964            Contact Email: <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 09-Feb-2024 , 11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis: The purpose of this NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting Pain and/or SUD research, in order to promote a diverse pool of available independent investigators working in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-024).</p>				
114707	<a href="#">RFA-NS-22-023 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	RFA-NS-22-023	09-Feb-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name | DP Mohapatra, Ph.D.  
 Contact Telephone | 301-496-9964  
 Contact Email | [dp.mohapatra@nih.gov](mailto:dp.mohapatra@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 09-Feb-2024 , 11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025

Synopsis | The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

114700	<a href="#">RFA-NS-22-022 -- HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-022	09-Feb-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | DP Mohapatra, Ph.D.  
 Contact Telephone | 301-496-9964  
 Contact Email | [dp.mohapatra@nih.gov](mailto:dp.mohapatra@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Feb-2024 , 11-Jun-2024 , 11-Oct-2024 , 11-Feb-2025</p> <p>Synopsis The purpose of the NIH HEAL Initiative® Pathway to Independence Award (K99/R00) program is to support a cohort of new and well-trained independent investigators conducting Pain and/or SUD research, in order to increase the independent investigator workforce in research areas supported by the NIH HEAL Initiative®. This program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative®. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, an ancillary study to a clinical trial, or an independent Basic Experimental Studies with Humans (BESH). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing an independent BESH as lead investigator, should apply to the companion FOA (RFA-NS-22-023).</p>				
094033	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-195	07-Jan-2024	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
094032	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-194	07-Jan-2024	275,000 USD
	Contact Name				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis                      The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
094050	<a href="#">NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-200	07-Jan-2024	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis                      The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

094034	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-196	07-Jan-2024	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	<a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024

Synopsis

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105756	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-255	16-Feb-2024	275,000 USD
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.</p>				
105478	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders</a>	National Institutes of Health/DHHS	NOT-NS-22-003	07-Jan-2024	Not Specified
	<p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email <a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024</p> <p>Synopsis The National Institute of Neurological Disorders and Stroke is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders.</p>				
105732	<a href="#">Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts</a>	National Institutes of Health/DHHS	NOT-AI-21-059	07-Jan-2024	Not Specified
	<p>Contact Name Qian "Joy" Liu, M.D., MSc.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-761-6621</p> <p>Contact Email   <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understand the immunologic events in the vertebrate host that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly supported by NIAID through the expired FOA, PAR-18-860, "Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed). The intent of this NOSI is to indicate continued NIAID support for research in this area as described below through applications to the parent R01 and R21 FOAs.</p>				
105363	<a href="#">Notice of Special Interest (NOSI): Integration of Individual Residential Histories in Cancer Research</a>	National Institutes of Health/DHHS	NOT-CA-21-092	07-Jan-2024	Not Specified
	<p>Contact Name   Zaria Tatalovich, Ph.D.</p> <p>Contact Telephone   240-276-6976</p> <p>Contact Email   <a href="mailto:tatalovichzp@mail.nih.gov">tatalovichzp@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Control and Population Sciences to support investigation of the role of individual Residential Histories - a record of an individual's places of residence over the life course - relative to cancer risk, etiology, prevention, treatment, and outcomes.</p>				
109792	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-138	07-Jan-2024	275,000 USD
	<p>Contact Name   Julia Zehr, Ph.D.</p> <p>Contact Telephone   301-443-1617</p> <p>Contact Email   <a href="mailto:Zehrj@mail.nih.gov">Zehrj@mail.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (<a href="http://www.abcdstudy.org">www.abcdstudy.org</a>). This FOA seeks shorter, higher-risk</p>				
109181	<a href="#">Notice of Special Interest (NOSI): Public Health Research on Cannabis</a>	National Institutes of Health/DHHS	NOT-DA-22-003	07-Jan-2024	Not Specified
	<p>Contact Name Marsha Lopez, PhD</p> <p>Contact Telephone (301) 402-1846</p> <p>Contact Email <a href="tel:3014021846">(301) 402-1846</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.</p>				
103419	<a href="#">Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</a>	National Institutes of Health/DHHS	NOT-OD-21-100	07-Jan-2024	Not Specified
	<p>Contact Name Wendy Nelson, PhD, MPH</p> <p>Contact Telephone 240-276-6971</p> <p>Contact Email <a href="mailto:nelsonw@mail.nih.gov">nelsonw@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.</p>				
106126	<p><a href="#">Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations</a></p>	National Institutes of Health/DHHS	NOT-MH-21-330	07-Jan-2024	Not Specified
	<p>Contact Name   Adam Haim, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   NIH Institutes, Centers, and Offices participating in the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Populations initiative are issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the understanding and response to the Coronavirus Disease 2019 (COVID-19) pandemic and help us prepare more effectively for future public health emergencies. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, there are additional urgent public health needs, particularly in populations who experience health disparities and in vulnerable populations. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts (including vaccinations, masking, and physical distancing to inform the public health response) on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies.			
114596	<a href="#">Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-067	16-Feb-2024	275,000 USD
	Contact Name	Sige Zou, PhD			
	Contact Telephone	301-435-0749			
	Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025			
	Synopsis	<p>The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.</p>			
114857	<a href="#">Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-075	16-Feb-2024	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.			
	Contact Telephone	301-451-1390			
	Contact Email	<a href="mailto:CoulombeJ@mail.nih.gov">CoulombeJ@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.</p>			
115062	<a href="#">Notice of Special Interest (NOSI): argeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases</a>	National Institutes of Health/DHHS	NOT-DA-22-048	07-Jan-2024	Not Specified
	Contact Name	Yu (Woody) Lin, PhD			
	Contact Telephone	301-435-1318			
	Contact Email	<a href="mailto:ylin1@mail.nih.gov">ylin1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 13-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 10-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 13-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 25-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 25-Sep-2025 , 05-Oct-2025 , 12-Oct-2025 , 16-Oct-2025 , 07-Jan-2026			
	Synopsis	<p>This Notice of Special Interest (NOSI) encourages studies of the endocannabinoid system (ECS) and its roles in brain health and acute and chronic disease, substance use, and substance use disorder (SUD). The desired outcomes of research will be a mechanistic understanding of how cannabinoids and manipulation of the ECS can elicit both therapeutic and deleterious effects as well as the role of cannabinoids and ECS in symptom management.</p>			
116487	<a href="#">Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-131	16-Feb-2024	275,000 USD
	Contact Name	Katie M. Vance, Ph.D.			
	Contact Telephone	301-435-6640			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Katie.Vance@nih.gov">Katie.Vance@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026</p> <p>Synopsis The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.</p>				
120102	<a href="#">Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-239	16-Feb-2024	275,000 USD
	<p>Contact Name Jovier Evans, Ph.D.</p> <p>Contact Telephone 301-443-6328</p> <p>Contact Email <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R21 applications, while the companion announcement PAR-23-238 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism, PAR-23-238.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
119255	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-208	16-Feb-2024	275,000 USD

Contact Name	Laura M. Rowland, Ph.D.
Contact Telephone	301-480-8335
Contact Email	<a href="mailto:laura.rowland@nih.gov">laura.rowland@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	The goal of this Notice of Funding Opportunity (NOFO) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This NOFO uses the R21 mechanism, while the companion PAR-23-207 uses the R01 grant mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism, while applicants with preliminary data who seek longer-term funding should apply using the R01 mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120393	<a href="#">Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-255	16-Feb-2024	275,000 USD

Contact Name	Melissa Rotunno, Ph.D.
Contact Telephone	240-276-7245
Contact Email	<a href="mailto:rotunnom@mail.nih.gov">rotunnom@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025 , 16-Jun-2025 , 16-Oct-2025 , 16-Feb-2026 , 16-Jun-2026
Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
121941	<a href="#">Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-24-045	07-Feb-2024	275,000 USD
	<p>Contact Name: Holly Storkel, PhD, CCC-SLP            Contact Telephone: 301-451-6842            Contact Email: <a href="mailto:holly.storkel@nih.gov">holly.storkel@nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 07-Feb-2024 , 19-Jul-2024 , 19-Nov-2024            Synopsis: The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequelae.</p>				
104041	<a href="#">RFA-NS-21-023 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-023	21-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Brooks Gross, PhD            Contact Telephone: 301-496-1447            Contact Email: <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-024 or this FOA. The BRAIN PPP includes agreements with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <a href="https://braininitiative.nih.gov/brain-programs/public-private-partnerships">https://braininitiative.nih.gov/brain-programs/public-private-partnerships</a></p>			

106107	<a href="#">Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-282	20-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Leonardo Angelone, Ph.D
Contact Telephone	
Contact Email	<a href="mailto:Blueprint-MedTech@nih.gov">Blueprint-MedTech@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Feb-2024 , 20-Jun-2024
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations (CROs) that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. SBCs developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: <https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech>

104043	<a href="#">RFA-NS-21-024 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-024	21-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Brooks Gross, PhD
Contact Telephone	301-496-1447
Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024

**Synopsis** The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue first-in-human or early stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Only Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide data to answer key questions about the function or final design of a device and is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is part of a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <https://braininitiative.nih.gov/brain-programs/public-private-partnerships> Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-023 or this FOA.

106116	<a href="#">Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-315	20-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Nick Langhals, PhD  
 Contact Telephone | 301-496-1779  
 Contact Email | [NINDS-Devices@nih.gov](mailto:NINDS-Devices@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 20-Feb-2024 , 20-Jun-2024

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website: <https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
108288	<a href="#">Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech</a>	National Institutes of Health/DHHS	NOT-NS-22-052	20-Feb-2024	Not Specified
	<p>Contact Name   Nick Langhals, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 , 20-Jun-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) encourages the translation of the novel neurotechnologies, funded through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative and overseen by the NIH Blueprint MedTech program. Academic and Small Business Concerns (SBCs) are encouraged to submit grant applications that propose non-clinical validation for subsequent clinical feasibility studies. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the BRAIN Initiative are encouraged.</p>				
121337	<a href="#">NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-275	07-Jan-2024	Not Specified
	<p>Contact Name   Diane Adger-Johnson, MPH</p> <p>Contact Telephone   240-669-2924</p> <p>Contact Email   <a href="mailto:Altraininghelpdesk@niaid.nih.gov">Altraininghelpdesk@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025</p> <p>Synopsis   The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094248	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-205	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
112444	<a href="#">HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAS-22-207	12-Feb-2024	Not Specified
	<p>Contact Name Lori Ducharme, Ph.D.</p> <p>Contact Telephone 301-827-6331</p> <p>Contact Email <a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025</p> <p>Synopsis The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled clinician researchers with expertise in implementation science, who can help move these interventions into routine clinical practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world clinical settings, and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent clinician researchers with dual expertise in substance use and implementation science, limiting the field’s capacity to address persistent gaps in this area. There is a pressing need for a deeper bench of clinician researchers who can be called upon to meet ongoing and emerging implementation challenges in the substance use field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational clinical training in substance use prevention or treatment and/or co-occurring mental illness, and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to patient-oriented research in one or more of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.

106064	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))</a>	National Institutes of Health/DHHS	PAR-21-273	07-Jan-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Lanay M. Mudd, Ph.D., FACSM
Contact Telephone	301-594-9346
Contact Email	<a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

106063	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-21-272	07-Jan-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Lanay M. Mudd, Ph.D., FACSM
Contact Telephone	301-594-9346
Contact Email	<a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-271.

106062	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-271	07-Jan-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Kenneth D. Gibbs, Jr., Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:kenneth.gibbs@nih.gov">kenneth.gibbs@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-21-272.</p>					
104714	<a href="#">Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAS-21-245	16-Feb-2024	450,000 USD
	<p>Contact Name   Hung Tseng PhD</p> <p>Contact Telephone   301-496-0810</p> <p>Contact Email   <a href="mailto:tsengh@mail.nih.gov">tsengh@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Feb-2024 , 16-Jun-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for countermeasure development.</p>				
104784	<a href="#">Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies</a>	National Institutes of Health/DHHS	NOT-AI-21-056	05-Jan-2024	Not Specified
	<p>Contact Name   Usha Sharma, PhD</p> <p>Contact Telephone   240-292-4809</p> <p>Contact Email   <a href="mailto:usharma@niaid.nih.gov">usharma@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) is to inform potential applicants of NIAID's interest in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. This is needed to improve the guidance available to treatment and prevention programs for both individuals and populations.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Research responsive to this NOSI could include the development of: (i) highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations (ii) point of care (POC) DR assays, or (iii) strategies for rapid acquisition, curation and analysis of these HIV DR data and timely dissemination to healthcare providers and public health decision makers. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.

108358	<a href="#">Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-090	16-Feb-2024	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Miguel R. Ossandon, Ph.D.  
 Contact Telephone | 240-276-5714  
 Contact Email | [ossandom@mail.nih.gov](mailto:ossandom@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024

Synopsis | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility

108065	<a href="#">Notice of Special Interest (NOSI): Pediatric COVID-19 and Respiratory Viral Co-infection</a>	National Institutes of Health/DHHS	NOT-HL-22-004	07-Jan-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name |  
 Contact Telephone |  
 Contact Email |  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112644	<a href="#">Notice of Special Interest (NOSI): Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes</a>	National Institutes of Health/DHHS	NOT-AT-22-027	07-Jan-2024	Not Specified

Synopsis | This NOSI is intended to support projects that will employ existing and new clinical trial cohorts/observational cohorts to screen for co-infection, phenotype and collect biospecimens to answer some of these questions and to encourage investigator-initiated applications for basic, translational and human subject research (not clinical trials) in this space.

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024

Synopsis | This Notice of Special Interest (NOSI) is being issued by the National Center for Complementary and Integrative Health (NCCIH) with participation from multiple NIH Institutes, Centers, and Offices (ICOs). This NOSI aims to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than Δ9-tetrahydrocannabinol (Δ9-THC). Cannabinoids of particular interest include the following: Δ8-THC, Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), cannabichromevarin (CBDV), tetrahydrocannabivarin (THCV), Tetrahydrocannabivarin acid (THCVA), tetrahydrocannabinolic acid (THCA), carmagerol, cannabicitran, sesquicannabigerol. Terpenes of particular interest include the following: Myrcene, β-caryophyllene, Limonene, α -terpineol, Linalool, α-phellandrene, α-pinene, β-pinene, β-terpinene, and α-humulene. This NOSI intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the impact of minor cannabinoids and terpenes on mechanisms underlying their therapeutic effects. Preclinical studies of combinations of minor cannabinoids with terpenes or other natural products that may enhance their therapeutic benefits and/or abate unwanted effects are encouraged. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to symptoms relief and functional restoration may be very broad encompassing different pathological conditions and diseases. This NOSI encourages interdisciplinary collaborations among experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112791	<a href="#">Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities With a Focus on Addressing Diverse Representation in Research On Down Syndrome (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	NOT-OD-22-142	07-Jan-2024	Not Specified
	<p>Contact Name   Sujata Bardhan, Ph.D.</p> <p>Contact Telephone   301-435-0471</p> <p>Contact Email   <a href="mailto:sujata.bardhan@nih.gov">sujata.bardhan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025</p> <p>Synopsis   The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project.</p>				
114123	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-047	07-Jan-2024	275,000 USD
	<p>Contact Name   David M. Panchision, Ph.D.</p> <p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may instead wish to apply to the companion R01 mechanism (PAR-23-046).</p>				
114061	<a href="#">Notice of Special Interest (NOSI): Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior</a>	National Institutes of Health/DHHS	NOT-MH-23-110	07-Jan-2024	Not Specified
	<p>Contact Name: Mauricio Rangel-Gomez, Ph.D.            Contact Telephone: 301-435-6908            Contact Email: <a href="mailto:mauricio.rangel-gomez@nih.gov">mauricio.rangel-gomez@nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026            Synopsis: This Notice of Special Interest (NOSI) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This NOSI encourages collaborations between computationally and experimentally focused investigators. This NOSI seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate.</p>				
114367	<a href="#">Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics</a>	National Institutes of Health/DHHS	NOT-AI-23-001	05-Jan-2024	Not Specified
	<p>Contact Name: Julie Dyall, PhD            Contact Telephone: 301-631-7296            Contact Email: <a href="mailto:dyallj@niaid.nih.gov">dyallj@niaid.nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Sep-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Jan-2026 , 07-Jan-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest is to announce that the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Cancer Institute (NCI) are encouraging applications in the area of translational research and development of rapid Point-of-Care diagnostics that will diagnose active viremic HCV infections.			
121869	<a href="#">Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-23-304	05-Feb-2024	Not Specified
	Contact Name	Larissa Avilés-Santa, MD, MPH, Director			
	Contact Telephone	301-827-6924			
	Contact Email	<a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027			
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.			
093932	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-188	07-Jan-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-Sep-2024			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093931	<p><a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	PA-20-187	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p>				
093214	<p><a href="#">Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	PA-20-173	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
093210	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-171	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p>				
093225	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-174	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis</p> <p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>				
104076	<a href="#">Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-180	07-Jan-2024	450,000 USD
	<p>Contact Name Keisher Highsmith, DrPH</p> <p>Contact Telephone</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:duffys@nida.nih.gov">duffys@nida.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.</p>				
104057	<a href="#">Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-219	07-Jan-2024	275,000 USD
	<p>Contact Name Karrah Benson</p> <p>Contact Telephone 301-496-0838</p> <p>Contact Email <a href="mailto:Karrah.benson@nih.gov">Karrah.benson@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103983	<a href="#">Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes</a>	National Institutes of Health/DHHS	NOT-AA-21-028	07-Jan-2024	Not Specified
	<p>Contact Name: Gregory Bloss, M.A., M.P.P.</p> <p>Contact Telephone:</p> <p>Contact Email: <a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis: This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.</p>				
107543	<a href="#">Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research</a>	National Institutes of Health/DHHS	NOT-AI-22-004	07-Jan-2024	Not Specified
	<p>Contact Name: Annette L. Rothermel, Ph.D.</p> <p>Contact Telephone: 240-627-3477</p> <p>Contact Email: <a href="mailto:arothermel@niaid.nih.gov">arothermel@niaid.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2024 , 13-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Sep-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Institutes of Health (NIH) of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.</p>				
107449	<a href="#">Notice of Special Interest (NOSI): Reducing Stigma Related to Drug Use in Human Service Settings</a>	National Institutes of Health/DHHS	NOT-DA-21-060	07-Jan-2024	Not Specified
	<p>Contact Name   Richard A. Jenkins PhD</p> <p>Contact Telephone   301-443-1923</p> <p>Contact Email   <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The National Institute on Drug Abuse (NIDA) recognizes that stigma is pervasive in clinic, social service and other settings related to HIV prevention and care. Stigma contributes to a lack of attention to drug use screening, inadequate outreach to people who use drugs (PWUD) and insufficient uptake of services to prevent, treat, or mitigate HIV infection (and related consequences of drug use) among PWUD. Stigmas of interest include: internalized stigma among drug users, stigma associated with providing services to PWUD, and stigma toward PWUD by providers or service settings. Policies and practices that create or augment stigma also are of interest here, as well as stigma experienced by providers who might otherwise broaden their services to PWUD. Stigma reduction interventions for HIV service settings have been developed and, in some cases, implemented on a wide scale, but generally target sexual transmission as the primary behavioral risk; however, knowledge from this work can inform stigma among PWUD. Large literatures on stigma also exist in a variety of other conditions (e.g., cancer, mental illness) which also can provide conceptual and programmatic bases to speed the development of new interventions addressing PWUD.</p>				
107483	<a href="#">Notice of Special Interest (NOSI): Mechanistic Studies on the Impact of Substance Use in Sex and Gender Differences in HIV-Associated Neurocognitive Disorders</a>	National Institutes of Health/DHHS	NOT-DA-22-047	07-Jan-2024	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email  </p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis Compared to men, women are often more likely to develop HIV-associated neurocognitive impairments. The purpose of this notice is to inform potential applicants of NIDA's special interest in understanding the neurobiological bases for sex or gender-specific differences in HIV-associated neurocognitive disorders. This information can be used for targeted therapeutics and optimization of treatment options in HIV positive individuals with substance use disorders.</p>				
107484	<a href="#">Notice of Special Interest (NOSI): The Functional Oral Microbiome</a>	National Institutes of Health/DHHS	NOT-DE-21-015	07-Jan-2024	Not Specified
	<p>Contact Name Tamara McNealy, PhD.</p> <p>Contact Telephone 202-430-1474</p> <p>Contact Email <a href="mailto:tamara.mcnealy@nih.gov">tamara.mcnealy@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.</p>				
110578	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Research of Emerging and Existing Issues of COVID-19 Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities</a>	National Institutes of Health/DHHS	NOT-HD-22-003	07-Jan-2024	Not Specified
	<p>Contact Name Robert Tamburro, MD, MSc</p> <p>Contact Telephone 301-480-2619</p> <p>Contact Email <a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The purpose of this funding opportunity is to provide an opportunity for funded researchers in these various fields to pursue supplemental funding to conduct research addressing these emerging and other existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. The goal of this NOSI is to not replace or to compete with the various COVID-related funding opportunities currently available. Instead, the purpose is to complement them by offering a funding opportunity for currently funded investigators to address key issues not currently covered by available COVID-related funding announcements among these populations. It is hoped that the use of administrative supplements will foster research in these key areas in the most timely manner. Research projects addressing issues that are the focus of currently available or future COVID funding opportunity announcements will be encouraged to submit to those announcements. Also, applicants responding to this NOSI are strongly encouraged to describe plans for the rapid sharing of data and results as well as innovative data analytics approaches. The sharing of COVID-related data and resources and the effective communication of results are a high priority of the NIH.</p>				
110057	<a href="#">Notice of Special Interest (NOSI): Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities</a>	National Institutes of Health/DHHS	NOT-HD-22-002	07-Jan-2024	Not Specified
	<p>Contact Name   Robert Tamburro, MD, MSc            Contact Telephone   301-480-2619            Contact Email   <a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024            Synopsis   The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these and other emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities.</p>				
109942	<a href="#">Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-126	07-Jan-2024	275,000 USD
	<p>Contact Name   Fei Wang, Ph.D.            Contact Telephone              Contact Email   <a href="mailto:wangf@mail.nih.gov">wangf@mail.nih.gov</a>            Sponsor Website  </p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. The goal of this FOA is to support proof of concept, high-risk and potentially high-reward studies for feasibility and exploratory technology development. Due to the constraints that would be imposed on broad utility, this FOA does not support technology development that is narrowly focused on addressing specific biological questions. Rather, applications should propose development of innovative tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this FOA and will be administratively withdrawn without review.</p>				
110102	<p><a href="#">Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings</a></p>	National Institutes of Health/DHHS	NOT-AT-22-004	07-Jan-2024	Not Specified
	<p>Contact Name Beda Jean-Francois, Ph.D.</p> <p>Contact Telephone 202-313-2144</p> <p>Contact Email <a href="mailto:Beda.Jean-Francois@nih.gov">Beda.Jean-Francois@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children’s mental, emotional, and behavioral (MEB) health in school settings. This NOSI encourages applications which focus on dissemination</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and implementation research to deliver interventions in the school setting that will promote healthy MEB development and/or prevent MEB disorders. Applications should include a focus on one of the following: (1) primary/universal prevention MEB programs designed to promote healthy MEB development by decreasing risk factors and increasing protective factors to prevent onset of an MEB disorder; or (2) secondary/selective prevention programs designed to support screening and early identification of MEB disorders to slow progression with early intervention. Applications focused on tertiary/indicated treatment of MEB disorders will be considered non-responsive to this Notice.

108898	<a href="#">Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services</a>	National Institutes of Health/DHHS	NOT-MH-22-110	07-Jan-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen O'Connor, Ph.D.</p> <p>301-480-8366</p> <p><a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum, including the effectiveness of these components: call center capabilities to address distress and coordinate care, deployed mobile crisis outreach and support, and crisis services that can diagnose and provide short term stabilization.</p>
---	--

108483	<a href="#">Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research</a>	National Institutes of Health/DHHS	NOT-MH-22-100	07-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Pim Brouwers, Ph.D.</p> <p>240-627-3863</p> <p><a href="mailto:ebrouwer@mail.nih.gov">ebrouwer@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p>
---	---

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.</p>				
110034	<p><a href="#">Notice of Special Interest (NOSI): Research Using Implementation Science To Support the Delivery of Evidence-Based Practices in Community-Based Mental or General Medical Healthcare Settings</a></p>	National Institutes of Health/DHHS	NOT-MH-22-170	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis   This Notice of Special Interest (NOSI) highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program.</p>				
117692	<p><a href="#">RFA-MH-23-331 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	RFA-MH-23-331	13-Feb-2024	Not Specified
	<p>Contact Name   James Churchill, Ph.D.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-326-8800</p> <p>Contact Email   <a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Feb-2024 , 13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>Synopsis   The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this Notice of Funding Opportunity (NOFO) are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (RFA-MH-22-330).</p>				
101367	<a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a>	National Institutes of Health/DHHS	NOT-MH-21-175	07-Jan-2024	Not Specified
	<p>Contact Name   Yvonne Bennett, Ph.D.</p> <p>Contact Telephone   301-222-7094</p> <p>Contact Email   <a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <a href="https://www.humanconnectome.org/">https://www.humanconnectome.org/</a> and at the NIMH Data Archive (NDA) <a href="http://www.nda.nih.gov">www.nda.nih.gov</a>.</p>				
101300	<a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a>	National Institutes of Health/DHHS	NOT-MH-21-075	07-Jan-2024	Not Specified
	<p>Contact Name   Yvonne Bennett, Ph.D.            Contact Telephone   301-222-7094            Contact Email   <a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024            Synopsis   NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <a href="https://www.humanconnectome.org/">https://www.humanconnectome.org/</a> and at the NIMH Data Archive (NDA) <a href="http://www.nda.nih.gov">www.nda.nih.gov</a>.</p>				
106119	<a href="#">Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-313	07-Jan-2024	375,000 USD
	<p>Contact Name   Katrina J. Serrano, Ph.D.            Contact Telephone   301-480-7855            Contact Email   <a href="mailto:katrina.serrano@nih.gov">katrina.serrano@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

105890	<a href="#">Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions</a>	National Institutes of Health/DHHS	NOT-DE-21-010	07-Jan-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Zhong Chen, MD, PhD
Contact Telephone	301-529-7083
Contact Email	<a href="mailto:zhong.chen@nih.gov">zhong.chen@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.

110996	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-160	07-Jan-2024	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Gila Neta, PhD
Contact Telephone	240-276-6785

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Gila.Neta@nih.gov">Gila.Neta@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
110813	<a href="#">Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection</a>	National Institutes of Health/DHHS	NOT-AI-22-043	05-Jan-2024	Not Specified
	<p>Contact Name Chris Lambros, PhD</p> <p>Contact Telephone 240-627-3093</p> <p>Contact Email <a href="mailto:clambros@niaid.nih.gov">clambros@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 05-Sep-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 05-Jan-2025 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 05-Apr-2025 , 07-May-2025</p> <p>Synopsis The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics.</p>				
115289	<a href="#">Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services</a>	National Institutes of Health/DHHS	NOT-MH-23-140	07-Jan-2024	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Stephen O'Connor, Ph.D.</p> <p>Contact Telephone   301-480-8366</p> <p>Contact Email   <a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis   The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women's Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.</p>				
103986	<a href="#">Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life</a>	National Institutes of Health/DHHS	NOT-CA-21-074	07-Jan-2024	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email  </p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to stimulate research focused on the roles of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.</p>				
107763	<a href="#">Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects</a>	National Institutes of Health/DHHS	NOT-OD-22-023	07-Jan-2024	Not Specified
	Contact Name   Rachel Grana Mayne, PhD, MPH				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-5899</p> <p>Contact Email   <a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024</p> <p>Synopsis   The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research on electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-combustible nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.</p>				
107248	<a href="#">Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity</a>	National Institutes of Health/DHHS	NOT-CA-22-001	07-Jan-2024	Not Specified
	<p>Contact Name   Crystal Wolfrey</p> <p>Contact Telephone   240-276-6277</p> <p>Contact Email   <a href="mailto:wolfreyc@mail.nih.gov">wolfreyc@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 08-Oct-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management.</p>				
111858	<a href="#">Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities</a>	National Institutes of Health/DHHS	NOT-OD-22-154	07-Jan-2024	Not Specified
	<p>Contact Name   Jennifer Alvidrez, PhD</p> <p>Contact Telephone   301-827-0071</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Jennifer.alvidrez@nih.gov">Jennifer.alvidrez@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis The purpose of this NOSI is to solicit projects on preventive interventions that address cardiometabolic risk factors in populations that experience health disparities.</p>				
108832	<a href="#">Notice of Special Interest (NOSI): Addressing Cancer-Related Financial Hardship to Improve Patient Outcomes</a>	National Institutes of Health/DHHS	NOT-CA-22-045	25-Jan-2024	Not Specified
	<p>Contact Name Kathleen Castro, RN, MS, AOCN</p> <p>Contact Telephone 240-276-6834</p> <p>Contact Email <a href="mailto:kathleen.castro@mail.nih.gov">kathleen.castro@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote intervention research through investigator-initiated applications that aim to study ways to mitigate financial hardship for individuals impacted by a cancer diagnosis, including patients receiving cancer treatment, survivors, and caregivers.</p>				
106925	<a href="#">Notice of Special Interest (NOSI): Promoting Research To Understand Vascular Contributions to Cognitive Impairment and Dementia (VCID)</a>	National Institutes of Health/DHHS	NOT-HL-23-002	07-Jan-2024	Not Specified
	<p>Contact Name Jue Chen, Ph.D.</p> <p>Contact Telephone 301-435-0550</p> <p>Contact Email <a href="mailto:jue.chen@nih.gov">jue.chen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice is to inform potential applicants about an area of special interest to NHLBI, NINDS and NIA in research to understand mechanisms of vascular contributions to cognitive impairment and dementia (VCID) and to develop new approaches for the treatment of VCID.			
110794	<a href="#">Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)</a>	National Institutes of Health/DHHS	NOT-AI-22-042	07-Jan-2024	Not Specified
	Contact Name	Marina Protopopova, Ph.D.			
	Contact Telephone	301-761-7653			
	Contact Email	<a href="mailto:marina.protopopova@niaid.nih.gov">marina.protopopova@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.			
120387	<a href="#">Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-254	05-Feb-2024	1,750,000 USD
	Contact Name	Melissa Rotunno, Ph.D.			
	Contact Telephone	240-276-7245			
	Contact Email	<a href="mailto:rotunnom@mail.nih.gov">rotunnom@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026			
	Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.</p>				
120101	<a href="#">Social Disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-238	05-Feb-2024	Not Specified
	<p>Contact Name   Jovier Evans, Ph.D.            Contact Telephone   301-443-6328            Contact Email   <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 02-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026            Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental. This NOFO solicits R01 applications, while the companion announcement PAR-23-239 solicits R21 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.</p>				
120715	<a href="#">Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-245	05-Feb-2024	1,000,000 USD
	<p>Contact Name   Allison Dennis, PhD            Contact Telephone   301-827-9721            Contact Email   <a href="mailto:allison.dennis@nih.gov">allison.dennis@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.

120775	<a href="#">NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-229	06-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Kimberly LeBlanc, Ph.D
Contact Telephone	301-827-4102
Contact Email	<a href="mailto:kimberly.leblanc@nih.gov">kimberly.leblanc@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Feb-2024 , 06-May-2024 , 06-Oct-2024 , 06-Feb-2025 , 05-May-2025 , 07-Oct-2025 , 06-Feb-2026 , 05-May-2026
Synopsis	The Adolescent Brain Cognitive Development <sup>SM</sup> (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows investigators to apply for access to biological samples from the ABCD Study <sup>®</sup> . More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094235	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-203	07-Jan-2024	Not Specified

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	301-496-8580 <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>  <a href="#">Link to program URL</a> 07-Jan-2024 , 12-Feb-2024 , 07-May-2024
Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094235	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-201	07-Jan-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	    <a href="#">Link to program URL</a> 07-Jan-2024 , 12-Feb-2024 , 07-May-2024
--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			
094244	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)</a>		National Institutes of Health/DHHS	PA-20-204 07-Jan-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024			
	Synopsis	<p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093955	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-193	07-Jan-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name  
 Contact Telephone  
 Contact Email [grantinfo@nih.gov](mailto:grantinfo@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024

Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094044	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-199	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis</p>	<p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-20-197). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			
093953	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-186	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094026	<a href="#">Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-191	07-Jan-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024

Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093954	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-192	07-Jan-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL  
 Deadline Dates (ALL)

[Link to program URL](#)

07-Jan-2024 , 12-Feb-2024 , 07-May-2024

Synopsis

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

112443	<a href="#">HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAS-22-206	12-Feb-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Lori Ducharme, Ph.D.
Contact Telephone	301-827-6331
Contact Email	<a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Feb-2024 , 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025 , 12-Oct-2025
Synopsis	<p>The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use Prevention and Treatment (K01) is to provide support and “protected time” (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. Realizing the return on public investment in the development of evidence-based treatments and preventive interventions to address the ongoing overdose crisis depends on a cadre of skilled researchers with expertise in implementation science, who can help move these interventions into routine practice. Implementation science focuses on identifying modifiable barriers to the uptake and sustained use of evidence-based practices in real world settings and developing replicable and scalable strategies to overcome those barriers. While this field has grown rapidly over the past 15 years, there remain a limited number of independent researchers with dual expertise in addiction research and implementation science, constraining the field’s capacity to respond to continued calls for research in this area. There is a pressing need for a deeper bench of researchers who can be called upon to meet ongoing and emerging implementation challenges in the addiction field. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science. Development and execution of an independent NIH-defined clinical trial applying implementation science methods to one of the four domains of the HHS Overdose Prevention Strategy (prevention; evidence-based addiction treatment; harm reduction; or recovery research) is required. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, should consult the NIH Research Career Development Awards website for alternative funding opportunities.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
111464	<a href="#">Notice of Special Interest (NOSI): Mentored Career Development Awards to Foster the Careers of Investigators Pursuing Research Related to Down syndrome as Part of the INCLUDE Project</a>	National Institutes of Health/DHHS	NOT-OD-22-124	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Charlene Schramm, PhD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-402-3793</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS.</td> </tr> </table>					Contact Name	Charlene Schramm, PhD	Contact Telephone	301-402-3793	Contact Email	<a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024	Synopsis	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS.
Contact Name	Charlene Schramm, PhD																		
Contact Telephone	301-402-3793																		
Contact Email	<a href="mailto:schrammc@nih.gov">schrammc@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024 , 12-Oct-2024																		
Synopsis	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with training, resources, and mentorship, the NIH intends to support the career development of junior investigators in DS who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS.																		
103312	<a href="#">Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being</a>	National Institutes of Health/DHHS	NOT-OD-21-087	07-Jan-2024	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Bramaramba Kowtha MS, RDN, LDN</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">301-435-8052</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:bramaramba.kowtha@nih.gov">bramaramba.kowtha@nih.gov</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary</td> </tr> </table>					Contact Name	Bramaramba Kowtha MS, RDN, LDN	Contact Telephone	301-435-8052	Contact Email	<a href="mailto:bramaramba.kowtha@nih.gov">bramaramba.kowtha@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024	Synopsis	The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary
Contact Name	Bramaramba Kowtha MS, RDN, LDN																		
Contact Telephone	301-435-8052																		
Contact Email	<a href="mailto:bramaramba.kowtha@nih.gov">bramaramba.kowtha@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024																		
Synopsis	The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions.			
103732	<a href="#">Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence</a>	National Institutes of Health/DHHS	NOT-DA-21-012	07-Jan-2024	Not Specified
	Contact Name	Keisher Highsmith, DrPH			
	Contact Telephone				
	Contact Email	<a href="mailto:highsmithks@nih.gov">highsmithks@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.			
109173	<a href="#">Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-086	16-Feb-2024	275,000 USD
	Contact Name	Avi Rasooly, PhD			
	Contact Telephone	240-276-6196			
	Contact Email	<a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024 , 16-Jun-2024 , 16-Oct-2024 , 16-Feb-2025			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis This funding opportunity is part of a broader NCI-sponsored research on microbial based cancer therapy.

109009	<a href="#">Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities</a>	National Institutes of Health/DHHS	NOT-EY-22-004	08-Dec-2023	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Jimmy Le, Sc.D.
Contact Telephone	301-435-8160
Contact Email	<a href="mailto:Jimmy.Le@nih.gov">Jimmy.Le@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 08-Aug-2024 , 05-Sep-2024 , 07-Sep-2024 , 25-Sep-2024 , 08-Dec-2024 , 05-Jan-2025 , 07-Jan-2025 , 25-Jan-2025
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to highlight interest in supporting research that aims to promote health equity in the prevention, treatment, and management of eye and vision conditions. Applications that target reduction of health disparities experienced by people who are visually impaired or blind are encouraged, as well as applications that investigate the impact of bias, structural racism, and discrimination in causing or sustaining eye or vision health inequities.

109066	<a href="#">Notice of Special Interest (NOSI): Research on Drowning Prevention</a>	National Institutes of Health/DHHS	NOT-HD-21-048	07-Jan-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Cinnamon A. Dixon, DO, MPH
Contact Telephone	301-827-6189
Contact Email	<a href="mailto:cinnamon.dixon@nih.gov">cinnamon.dixon@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 07-May-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | Though epidemiologic research has helped identify drowning risk factors, little is known about what intervention strategies have the greatest efficacy to prevent drowning and/or improve outcomes after a drowning event. Thus, the goal of this NOSI is to encourage and facilitate scientific discovery for drowning prevention, specifically aimed at reducing drowning risk and improving outcomes in three primary domains. Domain 1: Understanding drowning disparities and developing drowning interventions to address these disparities. Rates of drowning vary significantly. Reasons contributing to drowning risks among certain populations are multifaceted and likely related to access and exposure to water, knowledge and skills around water, and behaviors and beliefs. Research evaluating both structural and/or systemic forces which contribute to disparities in drowning risk among children, parents and communities is needed. Development of effective interventions aimed at addressing these factors as they pertain to drowning prevention is critical. Domain 2: Studying the effects of swim instruction on swim skills to prevent drowning. Swim skills, which are often obtained through swim instruction, can decrease drowning risk; however tremendous variability among types and techniques of swim instruction exists. Validated measures which consistently assess swim skill efficacy to prevent drowning at differing ages and developmental abilities are lacking. Metrics which help to identify effective, quality swim instruction to prevent drowning are needed. The development of evidence-based best practices as to when and how to instruct populations most at risk for drowning (such as children of young age, of certain races/ethnicities, with intellectual or developmental disabilities, or those with linguistic or cultural differences), is essential. Domain 3: The adoption, integration and sustainable scale-up of the drowning chain of survival. The five steps of drowning chain of survival can reduce drowning mortality. These steps include: (1) preventing drowning, (2) recognizing distress, (3) providing flotation, (4) removal from water and (5) providing care as needed. Depending on the water source, interventions which constitute these layers of drowning protection exist. Research to advance the adoption, integration and sustainable scale-up of evidence-based drowning prevention interventions and the drowning chain of survival across families and communities is needed.

108897	<a href="#">Notice of Special Interest (NOSI): Assessment of Suicide Thoughts and Behaviors among Children and Preteens</a>	National Institutes of Health/DHHS	NOT-MH-22-086	07-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Eric R. Murphy, PhD
Contact Telephone	301-443-9230
Contact Email	<a href="mailto:eric.murphy@nih.gov">eric.murphy@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage advance research that addresses outstanding questions related to the developmentally and culturally appropriate characterization and assessment of STB in children/preteens. For



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

purposes of this NOSI, children/preteens are defined as youth 12 years old and younger. NIMH encourages applications that consider issues relevant to the assessment of diverse youth, including the acceptability and cultural relevance of the strategies for assessment among youth from minoritized backgrounds and/or sexual and gender minority youth.

093935	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-189	07-Jan-2024	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024

Synopsis

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
094015	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-176	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 12-Feb-2024 , 07-May-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> </td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024	Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>
Contact Name																			
Contact Telephone																			
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 12-Feb-2024 , 07-May-2024																		
Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>																		
094038	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-197	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>				
Contact Name																			
Contact Telephone																			
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094020	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-190	07-Jan-2024	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094040	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-198	07-Jan-2024	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p>	<p>Synopsis</p> <p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements</p>
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

101780	<a href="#">Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease</a>	National Institutes of Health/DHHS	NOT-AT-21-002	07-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Wen G. Chen, M.MSc, Ph.D.</p> <p>301-451-3989</p> <p><a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOSI, interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological processes of interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manipulate interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational models, or artificial intelligence models relevant to interoception and its impact on health and disease.</p>
---	--

101555	<a href="#">Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-109	16-Feb-2024	400,000 USD
--------	--	------------------------------------	------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Manuel Moro, DVM, Ph.D.</p> <p>301-480-1796</p> <p><a href="mailto:manuel.moro@nih.gov">manuel.moro@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Feb-2024</p>
---	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research using nonhuman primate (NHP) models performed by early-stage investigators who are within 10 years of their terminal degree or residency training and have at least two years of postdoctoral experience. This FOA is designed specifically for applicants proposing to develop new research directions using NHP models in basic science or translational research.			
106848	<a href="#">Notice of Special Interest (NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities</a>	National Institutes of Health/DHHS	NOT-DE-21-013	07-Jan-2024	Not Specified
	Contact Name	Hiroko Iida, DDS, MPH			
	Contact Telephone	301-594-7404			
	Contact Email	<a href="mailto:hiroko.iida@nih.gov">hiroko.iida@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies designed to identify and understand the mechanisms by which biologic factors (microbial, immune, genetic) contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence.			
106966	<a href="#">Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes</a>	National Institutes of Health/DHHS	NOT-AI-21-080	07-Jan-2024	Not Specified
	Contact Name	Nasrin Nabavi, Ph.D.			
	Contact Telephone	240-627-3538			
	Contact Email	<a href="mailto:nnabavi@mail.nih.gov">nnabavi@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025			
	Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use.

112267	<a href="#">Notice of Special Interest (NOSI): Advancing Research on Early Pregnancy Loss</a>	National Institutes of Health/DHHS	NOT-HD-22-026	07-Jan-2024	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Clara Cheng, PhD
Contact Telephone	301-435-6992
Contact Email	<a href="mailto:clara.cheng@nih.gov">clara.cheng@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025
Synopsis	<p>Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic EPL and recurrent pregnancy loss.</p>

117690	<a href="#">RFA-MH-23-330 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-MH-23-330	13-Feb-2024	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	James Churchill, Ph.D.
Contact Telephone	301-326-8800

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Feb-2024 , 13-Jun-2024 , 11-Oct-2024 , 13-Feb-2025 , 13-Jun-2025 , 15-Oct-2025 , 13-Feb-2026</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching independent research careers. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (RFA-MH-22-331).</p>				
114028	<a href="#">RFA-NS-22-069 -- HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-22-069	13-Jan-2024 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name D.P. Mohapatra, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email <a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a></p> <p>Sponsor Website</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Jan-2024 [Optional][LOI/Pre-App], 12-Feb-2024</p> <p>Synopsis This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in basic and clinical pain domains to understand the biology of specific human pain conditions as well as pain associated with various diseases/disorders, including mechanistic underpinning of heterogeneity and stratification of patients with specific pain conditions and co-morbidities. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. Proposed research should support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider transformative objectives with defined 5-year outcomes that will produce major advances in the understanding of human pain conditions and are likely to improve strategies for effective management of human pain.</p>				
112346	<p><a href="#">Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM)</a></p>	National Institutes of Health/DHHS	NOT-MD-22-012	08-Dec-2023	Not Specified
	<p>Contact Name Crystal L. Barksdale, PhD MPH</p> <p>Contact Telephone 301-827-4228</p> <p>Contact Email <a href="mailto:crystal.barksdale@nih.gov">crystal.barksdale@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 20-Feb-2024 , 22-Feb-2024 , 08-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 06-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 20-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 09-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025</p> <p>Synopsis This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110969	<a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-144	27-Feb-2024	Not Specified
	<p>Contact Name   Linda Brady, Ph.D.</p> <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Feb-2024 , 25-Jun-2024 , 25-Oct-2024 , 24-Feb-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-143). This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
110968	<a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-143	27-Feb-2024	Not Specified
	<p>Contact Name   Linda Brady, Ph.D.</p> <p>Contact Telephone   301-443-3563</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-Feb-2024 , 25-Jun-2024 , 25-Oct-2024 , 24-Feb-2025</p> <p>Synopsis                      The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA (PAR-22-144) This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
122315	<a href="#">Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-043	09-Feb-2024	Not Specified
	<p>Contact Name Charles Cywin, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:charles.cywin@nih.gov">charles.cywin@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Feb-2024 , 18-Apr-2024 , 15-Jul-2024 , 18-Aug-2024 , 15-Jan-2025 , 18-Apr-2025 , 15-Jul-2025 , 18-Aug-2025 , 15-Jan-2026 , 17-Apr-2026 , 15-Jul-2026 , 18-Aug-2026</p> <p>Synopsis The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery or the Development stage. In the Discovery phase the goal is to characterize and optimize promising hit compounds using medicinal chemistry to establish structure activity relationships (SAR) and structure property relationships (SPR) including in vitro and in vivo properties such as metabolism, selectivity, toxicity, etc. As projects enter or advance to the Development stage the goal is to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects can enter the program at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN recipient Institutions retain their assignment of intellectual property (IP) rights and gain assignment of IP rights from the BPN contractors and consultants (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.</p>				
110997	<p><a href="#">Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-22-167	15-Feb-2024	3,250,000 USD
	<p>Contact Name Soju Chang, M.D., M.P.H.</p> <p>Contact Telephone 301-827-9206</p> <p>Contact Email <a href="mailto:soju.chang@nih.gov">soju.chang@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024 , 18-Jun-2024 , 17-Oct-2024</p> <p>Synopsis The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121868	<a href="#">Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-23-303	05-Feb-2024	Not Specified
	<p>Contact Name: Larissa Avilés-Santa, MD, MPH, Director</p> <p>Contact Telephone: 301-827-6924</p> <p>Contact Email: <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027</p> <p>Synopsis: This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.</p>				
107545	<a href="#">Notice of Special Interest (NOSI): Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators</a>	National Institutes of Health/DHHS	NOT-DC-22-001	07-Jan-2024	Not Specified
	<p>Contact Name: Bracie Watson, Jr., Ph.D.</p> <p>Contact Telephone: 301-402-3458</p> <p>Contact Email: <a href="mailto:watsonb@nidcd.nih.gov">watsonb@nidcd.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 20-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025</p> <p>Synopsis: The National Institute on Deafness and Other Communication Disorders (NIDCD) is interested in expanding the cadre of basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI) is to invite Early Stage Investigators (ESIs), as defined by the NIH <a href="https://grants.nih.gov/grants/new_investigators/index.htm#earlystage">https://grants.nih.gov/grants/new_investigators/index.htm#earlystage</a>, to submit research applications that focus on</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>OM—commonly known as ear infections. There is a critical need for focused, novel, creative and innovative research approaches that accelerate the development of effective ways to prevent and treat OM.</p>				
112420	<a href="#">Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan</a>	National Institutes of Health/DHHS	NOT-OD-22-178	07-Jan-2024	Not Specified
	<p>Contact Name   Melissa C. Green Parker, PhD            Contact Telephone   301-480-1161            Contact Email   <a href="mailto:melissa.greenparker@nih.gov">melissa.greenparker@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025            Synopsis   The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are encouraged.</p>				
112421	<a href="#">Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening</a>	National Institutes of Health/DHHS	NOT-OD-22-179	07-Jan-2024	Not Specified
	<p>Contact Name   Melissa C. Green Parker, PhD            Contact Telephone   301-480-1161            Contact Email   <a href="mailto:melissa.greenparker@nih.gov">melissa.greenparker@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation.			
111986	<a href="#">Notice of Special Interest (NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity</a>	National Institutes of Health/DHHS	NOT-OD-22-135	11-Dec-2023	Not Specified
	Contact Name	Marya Levintova, PhD			
	Contact Telephone	301-496-9535			
	Contact Email	<a href="mailto:marya.levintova@nih.gov">marya.levintova@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024			
	Synopsis	The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.			
120789	<a href="#">RFA-NS-24-021 -- HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-24-021	06-Feb-2024	3,250,000 USD
	Contact Name	D.P. Mohapatra, Ph.D.			
	Contact Telephone	301-496-9964			
	Contact Email	<a href="mailto:dp.mohapatra@nih.gov">dp.mohapatra@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	06-Feb-2024 , 06-Jun-2024 , 08-Oct-2024 , 06-Feb-2025			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on ‘Whole Person Health’ and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112904	<a href="#">Notice of Special Interest (NOSI): Research on the Health of Bisexual and Bisexual+ People</a>	National Institutes of Health/DHHS	NOT-OD-22-166	07-Jan-2024	Not Specified

Contact Name	Christopher Barnhart, PhD
Contact Telephone	301-594-8983
Contact Email	<a href="mailto:christopher.barnhart@nih.gov">christopher.barnhart@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 20-Feb-2024 , 25-Feb-2024 , 11-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 21-Jun-2024 , 25-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025
Synopsis	This Notice of Special Interest (NOSI) solicits research, research training, and research career development on the health and well-being of people who identify as bisexual or bisexual+. “Bisexual” or “bi” in this NOSI may describe those with the potential to be attracted, romantically and/or sexually, to people of more than one sex or gender, not necessarily at the same time, not necessarily in the same way, and not necessarily to the same degree. “Bisexual+” or “bi+” in this NOSI is an



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	umbrella term that is intended to encompass non-monosexual identities, including but not limited to bisexual, pansexual, sexually fluid, and queer.																		
112325	<a href="#">Notice of Special Interest (NOSI): Research on Addressing Violence to Improve Health Outcomes</a>	National Institutes of Health/DHHS	NOT-OD-22-167	07-Jan-2024	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Dara R. Blachman, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-8522</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 11-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.</td> </tr> </table>					Contact Name	Dara R. Blachman, Ph.D.	Contact Telephone	301-496-8522	Contact Email	<a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 11-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025	Synopsis	The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.
Contact Name	Dara R. Blachman, Ph.D.																		
Contact Telephone	301-496-8522																		
Contact Email	<a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 16-Feb-2024 , 11-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025																		
Synopsis	The purpose of this Notice is to highlight interest in addressing the role of violence in health outcomes and integrating violence-related screening and interventions into health care settings. This Notice is to encourage intervention research focused on addressing exposure to violence - including but not limited to child maltreatment, intimate partner violence/teen dating violence, elder mistreatment, peer violence/bullying, and community violence – to improve individual-level health processes and outcomes.																		
108660	<a href="#">Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research</a>	National Institutes of Health/DHHS	NOT-CA-22-037	28-Dec-2023	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Dana Wolff-Hughes, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-620-0673</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:dana.wolff@nih.gov">dana.wolff@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>28-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and</td> </tr> </table>					Contact Name	Dana Wolff-Hughes, PhD	Contact Telephone	240-620-0673	Contact Email	<a href="mailto:dana.wolff@nih.gov">dana.wolff@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	28-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and
Contact Name	Dana Wolff-Hughes, PhD																		
Contact Telephone	240-620-0673																		
Contact Email	<a href="mailto:dana.wolff@nih.gov">dana.wolff@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	28-Dec-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024																		
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.			
114765	<a href="#">Notice of Special Interest (NOSI): Firearm Injury and Mortality Prevention Research</a>	National Institutes of Health/DHHS	NOT-OD-23-039	28-Dec-2023	Not Specified
	<p>Contact Name: Dara R. Blachman, Ph.D.</p> <p>Contact Telephone:</p> <p>Contact Email: <a href="mailto:Dara.blachman-demner@nih.gov">Dara.blachman-demner@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL:</p> <p>Deadline Dates (ALL): 28-Dec-2023 , 07-Jan-2024 , 11-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 20-Feb-2024 , 11-Mar-2024 , 11-Mar-2024 , 03-May-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 21-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 08-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026</p> <p>Synopsis: The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.</p>				
114589	<a href="#">Notice of Special Interest (NOSI): Research to Address 'Ending the HIV Epidemic' Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV</a>	National Institutes of Health/DHHS	NOT-DA-23-013	07-Jan-2024	Not Specified
	<p>Contact Name: Vasundhara Varthakavi, PhD</p> <p>Contact Telephone: 301-443-2146</p> <p>Contact Email: <a href="mailto:vasundhara.varthakavi@nih.gov">vasundhara.varthakavi@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 21-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 09-Aug-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 14-Nov-2024 , 07-Jan-2025 , 05-Feb-2025 , 16-Feb-2025 , 21-Mar-2025 , 07-May-2025 ,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	05-Jun-2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 16-Jun-2026 , 07-Sep-2026 , 05-Oct-2026 , 16-Oct-2026 , 07-Oct-2027			
		The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the ‘Ending the HIV Epidemic in the U.S. (EHE)’ initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.			
122540	<a href="#">Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21)</a>	National Institutes of Health/DHHS	NOT-OD-24-026	16-Feb-2024	Not Specified
	Contact Name	Rebecca Krupenevich, Ph.D.			
	Contact Telephone	(301) 496-3131			
	Contact Email	<a href="mailto:rebecca.krupenevich@nih.gov">rebecca.krupenevich@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to support secondary data analysis to address questions and advance scientific inquiry related to SARS-CoV-2 through the existing data resources in the Rapid Acceleration of Diagnostics Data Hub (RADx DataHub), including and in conjunction with other data resources.			
117360	<a href="#">Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities</a>	National Institutes of Health/DHHS	NOT-MD-23-008	05-Feb-2024	Not Specified
	Contact Name	Deborah E. Linares, Ph.D., M.A.			
	Contact Telephone	301-402-2516			
	Contact Email	<a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 05-Oct-2024 , 08-Oct-2024 , 16-Oct-2024 , 07-Nov-2024 , 05-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 16-Jun-2025 , 05-Oct-2025 , 16-Oct-2025 , 05-Feb-2026 , 16-Feb-2026 , 05-Jun-2026			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This Notice of Special Interest (NOSI) highlights the need for research on strategies and interventions to increase vaccine uptake and implementation among populations experiencing health disparities in the United States (U.S.) and its territories. Research is needed to understand and address misinformation, uncertainty, distrust, and hesitancy regarding uptake of vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), varicella, tetanus, diphtheria, and pertussis [Tdap]) among individuals in the U.S. and its territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities, as well as chronic medical conditions. This NOSI is focused on individuals across the life span (i.e., all ages). The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts.</p>			
122258	<a href="#">Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-295	20-Feb-2024	100,000 USD
	Contact Name	Dave Kaufman			
	Contact Telephone	301-402-4997			
	Contact Email	<a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Feb-2024 , 18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026			
	Synopsis	<p>This Notice of Funding Opportunity (NOFO) invites Small Research Grant (R03) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100331	<a href="#">Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS		15-Feb-2024	Not Specified
	<p>Contact Name   Eric M. Hudak, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:eric.hudak@nih.gov">eric.hudak@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL  </p> <p>Deadline Dates (ALL)   15-Feb-2024 , 15-May-2024</p> <p>Synopsis   The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: <a href="https://heal.nih.gov/">https://heal.nih.gov/</a>.</p>				
121565	<a href="#">Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-23-309	05-Feb-2024	Not Specified
	<p>Contact Name   Sundania J. W. Wonnum, PhD, LCSW</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:sundania.wonnum@nih.gov">sundania.wonnum@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support novel and innovative research that examines and/or intervenes on the underlying and multilevel causes, pathways, and factors adversely impacting the health and well-being of persons with disabilities at the intersections of race and ethnicity, and socioeconomic status.			
105618	<a href="#">Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-294	05-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone	301-945-7573			
	Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.			
112871	<a href="#">RFA-NS-22-070 -- HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-22-070	05-Feb-2024 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:HEALanimalmodels@nih.gov">HEALanimalmodels@nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 [Optional][LOI/Pre-App], 06-Mar-2024</p> <p>Synopsis This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability.</p>				
120821	<p><a href="#">RFA-HD-24-007 -- Understanding and Mitigating Health Disparities Experienced by People with Disabilities Caused by Ableism (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-HD-24-007	07-Jan-2024	2,499,995 USD
	<p>Contact Name Toyin Ajisafe, PhD</p> <p>Contact Telephone 301-827-9242</p> <p>Contact Email <a href="mailto:toyin.ajisafe@nih.gov">toyin.ajisafe@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.</p>				
120584	<p><a href="#">Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	PAR-23-256	20-Feb-2024	450,000 USD
	<p>Contact Name Sekai Chideya, M.D., M.P..H</p> <p>Contact Telephone 301-827-1916</p> <p>Contact Email <a href="mailto:Sekai.Chideya@nih.gov">Sekai.Chideya@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Feb-2024 , 11-Mar-2024 , 20-Jun-2024 , 10-Jul-2024</p> <p>Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to support proof-of-concept feasibility trials guided by the NIH Music-based Interventions (MBI) Toolkit for research on brain disorders of aging. These early phase clinical trials will generate evidence supporting the validity of the NIH MBI Toolkit’s guiding principles as well as the necessary pilot data to design a subsequent clinical efficacy or effectiveness study (or pragmatic clinical trial) using music-based interventions in the context of brain disorders of aging, including but not limited to Alzheimer’s disease and Alzheimer’s disease-related dementias, Parkinson’s disease, and stroke. The data collected should address gaps in scientific knowledge in order to facilitate development of a competitive large-scale clinical trial.</p>				
111641	<a href="#">Notice of Special Interest (NOSI): Climate Change and Health</a>	National Institutes of Health/DHHS	NOT-ES-22-006	08-Dec-2023	Not Specified
	<p>Contact Name Claudia L. Thompson</p> <p>Contact Telephone 984-287-3330</p> <p>Contact Email <a href="mailto:thomps01@niehs.nih.gov">thomps01@niehs.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2023 , 11-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 20-Feb-2024 , 11-Mar-2024 , 08-Apr-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 19-Jun-2024 , 09-Jul-2024 , 15-Jul-2024 , 08-Aug-2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 21-Oct-2024 , 12-Nov-2024 , 15-Nov-2024 , 08-Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 19-Feb-2025 , 08-Apr-2025 , 07-May-2025</p> <p>Synopsis The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		on health and well-being over the life course, including the health implications of climate change in the United States and globally.			
112749	<a href="#">Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence</a>	National Institutes of Health/DHHS	NOT-DA-23-007	12-Feb-2024	Not Specified
	Contact Name	Carrie Mulford			
	Contact Telephone	301-827-6473			
	Contact Email	<a href="mailto:Carrie.Mulford@nih.gov">Carrie.Mulford@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Feb-2024 , 20-Mar-2024 , 12-Jun-2024 , 12-Oct-2024 , 12-Feb-2025 , 12-Jun-2025			
	Synopsis	The proposed initiative seeks to test innovative models of service delivery to improve substance use and mental health outcomes for individuals who have actionable needs following exposure to violence.			
122410	<a href="#">Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-24-062	14-Feb-2024	Not Specified
	Contact Name	Sarah Steverman, PhD, MSW			
	Contact Telephone	301-827-5435			
	Contact Email	<a href="mailto:sarah.steverman@nih.gov">sarah.steverman@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Feb-2024 , 14-Aug-2024 , 13-Nov-2024 , 14-Feb-2025 , 14-Aug-2025 , 14-Nov-2025 , 13-Feb-2026 , 14-Aug-2026 , 13-Nov-2026			
	Synopsis	The purpose of this notice of this funding opportunity (NOFO) is to support translational research across epidemiology, addiction services, and prevention to, ultimately, reduce the burden of substance use on public health. This NOFO encourages research that facilitates rapid translation from one discipline to another (e.g., epidemiology to prevention); supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study. The goal is to support translational research improving our ability to 1) identify and characterize malleable individual, familial, behavioral, developmental, and socio-cultural/environmental factors (within the population or precise subgroups)			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>with the potential for multi-directional transfer of knowledge; 2) prevent initiation of substance use or progression to misuse or use disorder; and 3) maximize the efficient delivery of high-quality, personalized addiction treatment and related services to ultimately inform and facilitate real world responses designed to reduce the burden of substance use, misuse and/or addiction on the health of the population. This NOFO invites projects for which preliminary feasibility or pilot data are not available. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.</p>			
107492	<a href="#">Innovation Corps (I-Corps™) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed)</a>	National Institutes of Health/DHHS	PAR-22-073	31-Jan-2024	55,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Reema Railkar, Ph.D.</p> <p>240-276-5720</p> <p><a href="mailto:canariaca@mail.nih.gov">canariaca@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>31-Jan-2024 , 02-Feb-2024 , 30-Apr-2024</p>			
	Synopsis	<p>Through this 'I-Corps™ at NIH' program Funding Opportunity Announcement (FOA), the National Institutes of Health and Center for Disease Control and Prevention (CDC) provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) recipients. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. I-Corps enables and accelerates the transformation of invention to impact patients. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. The participants conduct evidence-based research to identify where the company's technology can have greatest impact on unmet clinical needs. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact relevant Scientific/Research staff listed in Section VII for more information about the program before applying.</p>			
112755	<a href="#">RFA-DA-23-053 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-DA-23-053	19-Feb-2024 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Carrie Mulford, Ph.D.</p> <p>Contact Telephone   301827-6473</p> <p>Contact Email   <a href="mailto:carrie.mulford@nih.gov">carrie.mulford@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024</p> <p>Synopsis   The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to RFA-DA-23-054 , which solicits applications for which pilot data is available.</p>				
112756	<a href="#">RFA-DA-23-054 -- HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-DA-23-054	19-Feb-2024 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name   Carrie Mulford, Ph.D.</p> <p>Contact Telephone   301827-6473</p> <p>Contact Email   <a href="mailto:carrie.mulford@nih.gov">carrie.mulford@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024</p> <p>Synopsis   The goal of this initiative is to support action-oriented research that accelerates the translation of research to practice to address the overdose crisis. There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This Funding Opportunity Announcement (FOA) solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of moving evidence-based and promising treatments into routine use. This FOA invites projects for which preliminary or feasibility data is available. This FOA is a companion to RFA-DA-23-053, which solicits applications for which pilot data is unavailable.</p>					
121852	<a href="#">RFA-DK-23-004 -- Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-DK-23-004	20-Feb-2024 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name   Albert Hwa, Ph.D.</p> <p>Contact Telephone   301-451-1525</p> <p>Contact Email   <a href="mailto:albert.hwa@nih.gov">albert.hwa@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) welcomes applications for the Consortium on Modeling Autoimmune Diabetes (CMAD) that supports the development of in vitro and in vivo models of type 1 diabetes (T1D) to enable studies of human T1D pathophysiology and to serve as platforms for preclinical assessments of new T1D interventions. CMAD is part of the Human Islet Research Network (HIRN).</p>				
122317	<a href="#">Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-063	09-Feb-2024	Not Specified
	<p>Contact Name   Charles Cywin, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:charles.cywin@nih.gov">charles.cywin@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Feb-2024 , 18-Apr-2024 , 15-Jul-2024 , 18-Aug-2024 , 15-Jan-2025 , 18-Apr-2025 , 15-Jul-2025 , 18-Aug-2025 , 15-Jan-2026 , 17-Apr-2026 , 15-Jul-2026 , 18-Aug-2026</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
114250	<a href="#">Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-24-022	07-Jan-2024	400,000 USD

Synopsis The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery or the Development stage. In the Discovery phase the goal is to characterize and optimize promising hit compounds using medicinal chemistry to establish structure activity relationships (SAR) and structure property relationships (SPR) including in vitro and in vivo properties such as metabolism, selectivity, toxicity, etc. As projects enter or advance to the Development stage the goal is to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects can enter the program at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN recipient Institutions retain their assignment of intellectual property (IP) rights and gain assignment of IP rights from the BPN contractors and consultants (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Contact Name Randy King, Ph.D.  
 Contact Telephone 301-451-0707  
 Contact Email [Randy.King@nih.gov](mailto:Randy.King@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2024 , 16-Feb-2024 , 16-Mar-2024 , 07-May-2024 , 16-Jun-2024 , 16-Jul-2024 , 07-Sep-2024 , 16-Oct-2024 , 16-Nov-2024 , 07-Jan-2025 , 16-Feb-2025 , 16-Mar-2025 , 07-May-2025 , 16-Jun-2025 , 16-Jul-2025 , 07-Sep-2025 , 16-Oct-2025 , 16-Nov-2025 , 07-Jan-2026  
 Synopsis This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (<https://grants.nih.gov/policy/early-investigators/index.htm>) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

122207	<a href="#">Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-293	20-Feb-2024	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Dave Kaufman
Contact Telephone	301-402-4997
Contact Email	<a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Feb-2024 , 18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026
Synopsis	<p>This Notice of Funding Opportunity (NOFO) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other interested groups is encouraged, but not required. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: Transdisciplinary research projects and collaborations among researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

backgrounds, and women. Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

122256	<a href="#">Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-23-294	20-Feb-2024	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Dave Kaufman
Contact Telephone	301-402-4997
Contact Email	<a href="mailto:dave.kaufman@nih.gov">dave.kaufman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Feb-2024 , 18-Jun-2024 , 21-Oct-2024 , 20-Feb-2025 , 17-Jun-2025 , 20-Oct-2025 , 19-Feb-2026 , 18-Jun-2026 , 20-Oct-2026
Synopsis	This Notice of Funding Opportunity (NOFO) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genetic or genomic research. Applications may propose studies using either single or mixed methods, that break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses. Applied research designed to address ELSI issues in genetics and genomics will also be considered responsive. Direct engagement with communities and other stakeholders is encouraged, but not required.

111036	<a href="#">Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-105	07-Jan-2024	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Gila Neta, Ph.D.
Contact Telephone	240-276-6785
Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.			
111039	<a href="#">Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-109	07-Jan-2024	275,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
110112	<a href="#">Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-22-145	07-Jan-2024	Not Specified
	<p>Contact Name   Yewande A. Oladeinde, Ph.D.</p> <p>Contact Telephone   301-402-4307</p> <p>Contact Email   <a href="mailto:beda.jean-francois@nih.gov">beda.jean-francois@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025</p> <p>Synopsis   This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.</p>				
122338	<a href="#">FCO--Amendment--Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx)</a>	National Institutes of Health/DHHS	75N99224R00001	15-Dec-2023 [LOI/Pre-App]	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:APECx@arpa-h.gov">APECx@arpa-h.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Dec-2023 [LOI/Pre-App], 16-Feb-2024</p> <p>Synopsis   The Advanced Research Projects Agency for Health (ARPA-H) posts this DRAFT Notice of Funding Opportunity (NOFO) R&amp;D Solicitation in support of its Antigens Predicted for Broad Viral Efficacy through Computational Experimentation (APECx) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. Interested parties are invited to review the attached DRAFT Solicitation 75N99224R0001. As described in ARPA-H-SN-24-01, ARPA-H will host a Proposers' Day on 17 November 2023. The event is intended to facilitate teaming and foster a greater understanding of the APECx Program. The closing date for registration is 9 November 2023. Interested parties are encouraged to register at the link below. For more information about ARPA-H in general, please visit <a href="https://arpa-h.gov/">https://arpa-h.gov/</a>.</p>				
111040	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-106	07-Jan-2024	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Gila Neta, Ph.D.</p> <p>Contact Telephone   240-276-6785</p> <p>Contact Email   <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025 , 16-Feb-2025 , 07-May-2025</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
122607	<p><a href="#">RFA-NS-24-029 -- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)</a></p>	National Institutes of Health/DHHS	RFA-NS-24-029	23-Jan-2024 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Amy Tsou, M.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:amy.tsou@nih.gov">amy.tsou@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-Jan-2024 [Optional][LOI/Pre-App], 22-Feb-2024</p> <p>Synopsis   The purpose of this Notice of Funding Opportunity (NOFO) is to encourage grant applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products. These applications will target EA for intermediate size populations of people living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
118583	<a href="#">NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)</a>	National Library of Medicine/NIH/DHHS	PAR-23-183	26-Feb-2024	160,000 USD
	<p>Contact Name   Yanli Wang, Ph.D.</p> <p>Contact Telephone   301-827-7092</p> <p>Contact Email   <a href="mailto:yanli.wang@nih.gov">yanli.wang@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   26-Feb-2024 , 26-Feb-2025 , 26-Feb-2026</p> <p>Synopsis   This Notice of Funding Opportunity (NOFO) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.</p>				
099844	<a href="#">Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)</a>	National Library of Medicine/NIH/DHHS	PAR-20-304	07-Jan-2024	1,000,000 USD
	<p>Contact Name   Alan VanBiervliet, PhD</p> <p>Contact Telephone   301-594-4882</p> <p>Contact Email   <a href="mailto:vanbiervlietaq@mail.nih.gov">vanbiervlietaq@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis   National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.</p>				
113609	<a href="#">NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-23-034	07-Jan-2024	1,000,000 USD
	<p>Contact Name   Meryl Sufian, PhD</p> <p>Contact Telephone   301-496-4671</p> <p>Contact Email   <a href="mailto:sufianm@mail.nih.gov">sufianm@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.</p>				
115310	<a href="#">Notice of Special Interest (NOSI): Computational and Statistical Methods to Enhance Discovery from Health Data</a>	National Library of Medicine/NIH/DHHS	NOT-LM-23-001	07-Jan-2024	Not Specified
	<p>Contact Name Meryl Sufian, PhD</p> <p>Contact Telephone 301-496-4671</p> <p>Contact Email <a href="mailto:sufianm@mail.nih.gov">sufianm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026</p> <p>Synopsis The National Library of Medicine is issuing this Notice to highlight its interest in receiving grant applications focused on research that aims to reduce or mitigate gaps and errors in health data sets.</p>				
113256	<a href="#">Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions</a>	Office of Behavioral and Social Sciences Research/NIH/DHHS	NOT-OD-22-203	07-Jan-2024	Not Specified
	<p>Contact Name William Elwood, PhD</p> <p>Contact Telephone 301-402-0116</p> <p>Contact Email <a href="mailto:william.elwood@nih.gov">william.elwood@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2024 , 16-Jan-2024 , 01-Feb-2024 , 05-Feb-2024 , 06-Feb-2024 , 13-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 20-Feb-2024 , 07-Mar-2024 , 11-Mar-2024 , 07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024 , 18-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 13-Sep-2024</p> <p>Synopsis To achieve more potent strategies to promote sustained health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of original health-related behavioral interventions that test hypotheses that draw on basic behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms of action of healthier behavior change. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.</p>				
113926	<a href="#">Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23-040	05-Feb-2024	Not Specified
	<p>Contact Name Sige Zou, Ph.D.</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025</p> <p>Synopsis The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP's NIH-wide mission and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation of technologies, tools, and resources that</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.

102835	<a href="#">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-Jan-2024	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Sige Zou, Ph.D.
Contact Telephone	301-435-0749
Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	<p>This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.</p>

107732	<a href="#">Notice of Special Interest (NOSI): Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research</a>	Office of Research Infrastructure Programs/NIH/DHHS	NOT-OD-22-039	07-Jan-2024	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Sige Zou, PhD
Contact Telephone	301-435-0749
Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 07-May-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | With this Notice of Special Interest (NOSI), ORIP intends to support exploratory/developmental and highly innovative projects aimed at developing broadly applicable technologies, tools, and resources for validating animal models and enhancing the rigor, reproducibility, and translatability of animal research. This NOSI is for two-year projects that address key animal resource- and technology-related gaps identified in the “Validation of Animal Models and Tools for Biomedical Research” workshop organized by ORIP, NHLBI, NIA, NIDDK, NIGMS, and NINDS. Animal models of interest for this NOSI include, but are not limited to, invertebrate and vertebrate organisms ranging from *C. elegans* and *Drosophila* to zebrafish, mouse, rat, pig, and nonhuman primates.

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120425	<a href="#">National Artificial Intelligence (AI) Research Institutes</a>	National Science Foundation	23-610	12-Jan-2024 [LOI/Pre-App]	20,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-292-5111</p> <p>Contact Email <a href="mailto:AllInstitutesProgram@nsf.gov">AllInstitutesProgram@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jan-2024 [LOI/Pre-App], 16-Feb-2024 , 17-May-2024</p> <p>Synopsis Artificial Intelligence (AI) has advanced tremendously and today promises personalized healthcare; enhanced national security; improved transportation; and more effective education, to name just a few benefits. Increased computing power, the availability of large datasets and streaming data, and algorithmic advances in machine learning (ML) have made it possible for AI research and development to create new sectors of the economy and revitalize industries. Continued advancement, enabled by sustained federal investment and channeled toward issues of national importance, holds the potential for further economic impact and quality-of-life improvements. The 2023 update to the National Artificial Intelligence Research and Development Strategic Plan, informed by visioning activities in the scientific community as well as interaction with the public, identifies as its first strategic objective the need to make long-term investments in AI research in areas with the potential for long-term payoffs in AI. AI Institutes represent a cornerstone Federal Government commitment to fostering long-term, fundamental research in AI while also delivering significantly on each of the other eight objectives in that strategy. The National Security Commission on Artificial Intelligence (NSCAI) identifies AI Institutes as a key component of a bold, sustained federal push to scale and coordinate federal AI R&amp;D funding and to reinforce the foundation of technical leadership in AI.</p>				
122546	<a href="#">Emerging Frontiers in Research and Innovation (EFRI): Biocomputing through EnGINeering Organoid Intelligence (BEGIN OI)</a>	National Science Foundation	24-508	17-Jan-2024 [LOI/Pre-App]	2,000,000 USD
	<p>Contact Name Sohi Rastegar</p> <p>Contact Telephone 703-292-8305</p> <p>Contact Email <a href="mailto:srastega@nsf.gov">srastega@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jan-2024 [LOI/Pre-App], 22-Feb-2024 , 12-Sep-2024 [LOI/Pre-App], 12-Dec-2024</p>				



## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis   The Emerging Frontiers in Research and Innovation (EFRI) program of the NSF Directorate for Engineering (ENG) serves a critical role in helping ENG focus on important emerging areas in a timely manner. The EFRI Biocomputing through ENGINeering Organoid Intelligence (BEGIN OI) solicitation supports foundational and transformative research to advance the design, engineering, and fabrication of organoid systems that are capable of processing information dynamically while interfacing with non-living systems. This solicitation will be coordinated with the Directorate for Biological Sciences (BIO), the Directorate for Computer and Information Science and Engineering (CISE), the Directorate for Mathematical and Physical Sciences, and the Directorate for Social, Behavioral, and Economic Sciences (SBE). The EFRI program seeks proposals with potentially transformative ideas that represent an opportunity for a significant shift in fundamental engineering knowledge with strong potential for long term impact on national needs or a grand challenge.</p>				
122369	<a href="#">Designing Synthetic Cells Beyond the Bounds of Evolution</a>	National Science Foundation	24-505	01-Feb-2024	6,000,000 USD
	<p>Contact Name   Anthony G. Garza            Contact Telephone   703-292-8440            Contact Email   <a href="mailto:aggarza@nsf.gov">aggarza@nsf.gov</a>            Sponsor Website   <a href="#">Link to sponsor website</a>            Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   01-Feb-2024</p> <p>Synopsis   Because of recent technological advances in synthetic biology and bioengineering, researchers are now able to tailor cells and cell-like systems for a variety of basic and applied research purposes. The goal of this solicitation is to support research that (1) develops cell-like systems to identify the minimal requirements for the processes of life, (2) designs synthetically-modified cells to address fundamental questions in the evolution of life or to explore biological diversity beyond that which currently exists in nature, and (3) leverages basic research in cell design to build novel synthetic cell-like systems and cells for innovative biotechnology applications. Highest funding priority is given to proposals that have outstanding intellectual merit and broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. Proposals submitted to this solicitation should address social, ethical, and safety issues associated with designing and building synthetically modified cells as an integrated component of the project.</p>				
117040	<a href="#">A Science of Science Approach to Analyzing and Innovating the Biomedical Research Enterprise</a>	National Science Foundation	23-569	09-Feb-2024	1,000,000 USD
	<p>Contact Name   Mary Feeney</p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 703-292-7197

Contact Email | [mfeeney@nsf.gov](mailto:mfeeney@nsf.gov)

Sponsor Website | [Link to sponsor website](#)

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 09-Feb-2024

Synopsis | The National Science Foundation (NSF) and the National Institutes of Health (NIH) are interested in proposals that will propel our understanding of the biomedical research enterprise by drawing from the scientific expertise of the science of science policy research community. NSF promotes the progress of science by maintaining the general health of research and education across all fields of science and engineering. The Social, Behavioral and Economic Sciences (SBE) Directorate within NSF supports basic research on people and society. The SBE sciences focus on human behavior and social organizations; how social, economic, political, cultural and environmental forces affect the lives of people from birth to old age; and how people in turn shape those forces. SBE's Science of Science: Discovery, Communication and Impact Program (SoS:DCI) supports research designed to advance the scientific basis of science and innovation policy. The NIH is the U.S. federal agency charged with supporting biomedical research in the U.S. The National Institute of General Medical Sciences (NIGMS) within the NIH supports basic biomedical research that increases understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment and prevention. Both NSF and NIH believe that there are opportunities and needs for building and supporting research projects with a focus on the scientific research enterprise. The two agencies also recognize that when programmatic goals are compatible, coordinated management and funding of a research program can have a positive synergistic effect on the level and scope of research and can leverage the investments of both agencies. Therefore, NIGMS and SBE are partnering to enable collaboration in research between the SoS:DCI program and NIGMS. This partnership will result in a portfolio of high-quality research to provide scientific analysis of important aspects of the biomedical research enterprise and efforts to foster a diverse, innovative, productive and efficient scientific workforce, from which future scientific leaders will emerge.

109075	<a href="#">Algorithms for Modern Power Systems</a>	National Science Foundation	22-569	12-Feb-2024	2,000,000 USD
--------	---	-----------------------------	--------	-------------	---------------

Contact Name | Edsel A. Pena

Contact Telephone | 703-292-8080

Contact Email | [epena@nsf.gov](mailto:epena@nsf.gov)

Sponsor Website | [Link to sponsor website](#)

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Feb-2024</p> <p>Synopsis The Algorithms for Modern Power Systems (AMPS) program will support research projects to develop the next generation of mathematical and statistical algorithms for improvement of the security, reliability, and efficiency of the modern power grid. The program is a partnership between the Division of Mathematical Sciences (DMS) at the National Science Foundation (NSF) and the Office of Electricity Delivery &amp; Energy Reliability (OE) at the U.S. Department of Energy (DOE).</p>				
122414	<a href="#">Incorporating Human Behavior in Epidemiological Models</a>	National Science Foundation	24-507	14-Feb-2024	1,000,000 USD
	<p>Contact Name Zhilan J. Feng</p> <p>Contact Telephone 703-292-7523</p> <p>Contact Email <a href="mailto:zfeng@nsf.gov">zfeng@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Feb-2024</p> <p>Synopsis The Incorporating Human Behavior in Epidemiological Models (IHBEM) Program supports research that incorporates research on social and behavioral processes in mathematical epidemiological models. The program provides support for projects that involve balanced participation from the mathematical sciences and from the social, behavioral, and economic sciences.</p>				
101263	<a href="#">Enabling Discovery through GENomics (EDGE)</a>	National Science Foundation	21-546	15-Feb-2024	1,200,000 USD
	<p>Contact Name Theodore J. Morgan</p> <p>Contact Telephone 703-292-7868</p> <p>Contact Email <a href="mailto:tmorgan@nsf.gov">tmorgan@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Feb-2024</p> <p>Synopsis Through the Enabling Discovery through GENomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative and functional genomics. The EDGE</p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype, an area relevant to Understanding the Rules of Life: Predicting Phenotype, one of the 10 Big Ideas for NSF investment. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes.

112502	<a href="#">NSF Dynamic Language Infrastructure - NEH Documenting Endangered Languages</a>	National Science Foundation	22-615	15-Feb-2024	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name | Mary Paster  
 Contact Telephone | 703-292-2762  
 Contact Email | [mpaster@nsf.gov](mailto:mpaster@nsf.gov)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Feb-2024

Synopsis | This funding partnership between the National Science Foundation (NSF) and the National Endowment for the Humanities (NEH) supports projects to develop and advance knowledge concerning dynamic language infrastructure in the context of endangered human languages — languages that are both understudied and at risk of falling out of use. Made urgent by the imminent loss of roughly half of the approximately 7,000 currently used languages, this effort aims to exploit advances in human-language technology to build computational infrastructure for endangered language research. The program supports projects that contribute to data management and archiving, and to the development of the next generation of researchers. Funding can support fieldwork and other activities relevant to the digital recording, documentation and analysis, and archiving of endangered language data, including the preparation of lexicons, grammars, text samples, and databases. Funding is available in the form of one- to three-year senior research grants and conference proposals. Fellowship support is available through a separate funding opportunity administered by NEH.

112505	<a href="#">Dynamic Language Infrastructure-Doctoral Dissertation Research Improvement Grants</a>	National Science Foundation	22-616	15-Feb-2024	15,000 USD
--------	---	-----------------------------	--------	-------------	------------

Contact Name | Mary Paster

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	703-292-2762 <a href="mailto:mpaster@nsf.gov">mpaster@nsf.gov</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 15-Feb-2024
Synopsis	This program supports doctoral research focusing on building dynamic language infrastructure (DLI). Developing language infrastructure includes the documentation and preservation of languages in ways that articulate or advance linguistic theory, as well as the use of digitization techniques and novel computational methods that support and advance the study of language. Special emphasis is given to languages that are endangered, i.e., understudied and at risk of falling out of use. The program supports the development of the next generation of researchers that contribute to language data management and archiving and to the analysis of these archives to advance language infrastructure. Funding can support fieldwork and other activities relevant to the digital recording, documenting and archiving of endangered languages, including the preparation of lexicons, grammars, text samples and databases. Funding in this solicitation is in the form of doctoral dissertation research improvement grants (DDRIs) for up to 24 months and this solicitation addresses the preparation and evaluation of proposals for DDRI proposals.

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
115139	<a href="#">Special Emphasis Notice (SEN): Research on Climate Change and Healthcare</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	08-Dec-2023	Not Specified
	Contact Name	Brent Sandmeyer, MPH			
	Contact Telephone	301-427-1441			
	Contact Email	<a href="mailto:Brent.sandmeyer@ahrq.hhs.gov">Brent.sandmeyer@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Dec-2023 , 12-Dec-2023 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 26-Feb-2024 , 08-Apr-2024 , 12-Apr-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 26-Jun-2024 , 08-Aug-2024 , 12-Aug-2024 , 05-Oct-2024 , 12-Oct-2024 , 16-Oct-2024 , 26-Oct-2024 , 08-Dec-2024 , 12-Dec-2024 , 25-Jan-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 26-Feb-2025 , 08-Apr-2025 , 12-Apr-2025 , 25-May-2025 , 12-Jun-2025 , 08-Aug-2025 , 12-Aug-2025 , 25-Sep-2025 , 25-Sep-2025 , 12-Oct-2025 , 12-Dec-2025 , 12-Feb-2026 , 12-Jun-2026 , 12-Oct-2026 , 12-Feb-2027			
	Synopsis	This Special Emphasis Notice (SEN) announces AHRQ's interest in receiving health services research grant applications that address the intersection of climate change and healthcare.			
109186	<a href="#">Notice of Special Interest (NOSI): Health Services Research on Health System and Healthcare Professional Responsiveness to COVID-19</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-22-010	25-Jan-2024	Not Specified
	Contact Name	Leeann Comfort, PhD, MPP			
	Contact Telephone				
	Contact Email	<a href="mailto:Leeann.Comfort@ahrq.hhs.gov">Leeann.Comfort@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 25-Jan-2025 , 05-Feb-2025			
	Synopsis	This Special Emphasis Notice (SEN) informs the research community that the Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to develop models of care that improve access, quality, and outcomes of care related to COVID-19 and post-acute sequelae from COVID-19 (PASC).			
114270	<a href="#">Special Emphasis Notice (SEN): Interest in Healthcare</a>	Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-003	25-Jan-2024	Not Specified

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Associated Infections and Combating Antibiotic Resistant Bacteria Research</a>	Quality/DHHS			
	<p>Contact Name   Leyi Lin, MD</p> <p>Contact Telephone   301-427-1333</p> <p>Contact Email   <a href="mailto:leyi.lin@ahrq.hhs.gov">leyi.lin@ahrq.hhs.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2024 , 05-Feb-2024 , 25-May-2024 , 05-Jun-2024 , 25-Sep-2024 , 05-Oct-2024 , 25-Jan-2025 , 05-Feb-2025 , 25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026 , 05-Oct-2026</p> <p>Synopsis   The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research seeking to reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by antimicrobial resistant organisms. HAIs continue to cause significant patient harm and are also associated with considerable financial consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been associated with observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the importance of developing and studying resilient and adaptable countermeasures.</p>				
107009	<a href="#">Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-22-047	05-Feb-2024	2,500,000 USD
	<p>Contact Name   James Cleeman, MD</p> <p>Contact Telephone   301-427-1330</p> <p>Contact Email   <a href="mailto:james.cleeman@ahrq.hhs.gov">james.cleeman@ahrq.hhs.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Feb-2024 , 05-Jun-2024 , 05-Oct-2024 , 05-Feb-2025 , 05-Jun-2025 , 05-Oct-2025 , 05-Feb-2026 , 05-Jun-2026 , 05-Oct-2026</p> <p>Synopsis   Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R01 Research Project Grant award mechanism.</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121715	<a href="#">FCO--AMENDMENT--FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science</a>	Food and Drug Administration/DHHS	FDABAA-24-00123	14-Feb-2024	Not Specified
	<p>Contact Name   Ian Weiss</p> <p>Contact Telephone   301-796-5728</p> <p>Contact Email   <a href="mailto:Ian.Weiss@fda.hhs.gov">Ian.Weiss@fda.hhs.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Feb-2024</p> <p>Synopsis   In accordance with FAR 6.102(d)(2) and 35.016, the US Food and Drug Administration (FDA) solicits for the acquisition of basic and applied research and development proposals to support regulatory science and innovation through this Broad Agency Announcement (BAA). Research and development activities acquired under this BAA are intended to advance scientific knowledge in specific research areas as well as sub areas of interest defined within the BAA that serve the FDA in accomplishing its mission to protect and promote the health of our nation. Proposals submitted under this announcement are not limited solely to the PSC code "AJ11" specified in this announcement. FDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. Join us to learn more about the FY 2024 BAA, and how to apply. Save the date for the 2023 FDA Broad Agency Announcement (BAA) Day! October 25, 2023. BAA Day for FY23 2024 will be hosted on October 25th, 2023, as a virtual only event and will provide an opportunity to learn more about the application process and FDA's priorities for regulatory research. <a href="https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023">https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023</a></p>				
122568	<a href="#">Recognizing &amp; Addressing Maternal Warning Signs for Morbidity &amp; Mortality During Pregnancy &amp; the Postpartum Period</a>	Food and Nutrition Service/Department of Agriculture	USDA-FNS- MMMWS-24	15-Dec-2023 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name   Dawn Addison, Grant Officer</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:Dawn.Addison@usda.gov">Dawn.Addison@usda.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Dec-2023 [Optional][LOI/Pre-App], 14-Feb-2024</p>				



## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>WIC provides important services to eligible individuals and families; however, research is needed to identify additional opportunities and logical, evidence-based pathways to improve maternal health in the context and with deep understanding of the WIC program. While a body of evidence is available detailing interventions to reduce maternal morbidity and mortality, there are several limitations to relating this research to the WIC setting: reviews are relatively dated, interventions have largely not been tested in the WIC setting, there is a lack in diversity of populations addressed in these interventions, and technology and service delivery approaches have changed drastically in recent years resulting (e.g., remote and hybrid service delivery). This RFA will provide up to \$5,000,000 in funding, through a one-time cooperative agreement, to an external entity that will provide financial, technical, and evaluation to initiate and administer a competitive subgrant program for WIC State and local agencies. Eligible external entities include accredited public and private institutions of higher education (colleges/universities), non-profit research entities, and other non-profit organizations.</p>			
122392	<a href="#">Regional AIDS Education and Training Centers</a>	HIV/AIDS Bureau/HRSA/DHHS	HRSA-24-059	05-Feb-2024	Not Specified
	Contact Name	Makeva M. Rhoden			
	Contact Telephone	240-461-6176			
	Contact Email	<a href="mailto:AskAETCProgram@hrsa.gov">AskAETCProgram@hrsa.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	05-Feb-2024			
	Synopsis	<p>This notice announces the opportunity to apply for the Ryan White HIV/AIDS Program (RWHAP) Part F Regional AIDS Education and Training Centers (AETC) Program. The AETC Program consists of a network of HIV experts who, collectively, work to increase and support a workforce capable of and who intend to provide care and treatment to people with or at-risk of HIV. The aim of the program during the next five-year period of performance (July 1, 2024 – June 30, 2029) is to build on the previous work and successes of the AETC program and their local partners and implement a modernized and strengthened program framework based on industry standards.</p>			
122531	<a href="#">University Program: Consortia for Nuclear Nonproliferation</a>	National Nuclear Security Administration Service Center/Department of Energy	DE-FOA-0003180	06-Feb-2024	25,000,000 USD
	Contact Name	Virginia Hernandez			
	Contact Telephone	505-845-6442			
	Contact Email	<a href="mailto:virginia.hernandez@nnsa.doe.gov">virginia.hernandez@nnsa.doe.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Program URL				
	Deadline Dates (ALL)	06-Feb-2024			
	Synopsis	<p>The intent of this Funding Opportunity Announcement (FOA) is to award two (2) five-year cooperative agreements to consortia consisting of accredited IHEs to provide the opportunity to receive and administer Federal financial assistance funds for student and faculty research, fellowships, and scholarship funding awarded by DOE/NNSA, DNN R&amp;D. Each cooperative agreement will be awarded to a consortium of IHEs which will include the participation of DOE Laboratories, Plants, and Other Field Sites as consortium-member(s). Individual IHEs consortium-member shall make specific contributions and shall receive specified portions of the funding.</p>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122301	<a href="#">Future-Proofing Plants to a Changing Climate</a>	Biotechnology and Biological Sciences Research Council (BBSRC)		06-Feb-2024 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:trilateral_plants@bbsrc.ukri.org">trilateral_plants@bbsrc.ukri.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	06-Feb-2024 [LOI/Pre-App], 22-May-2024			
	Synopsis	Applications are invited for research grant funding towards future proofing plants for a changing climate. Proposal must involve UK, USA and German researchers. Applicants may request between: £300,000 to £800,000 (80% full economic cost (FEC)) for the UK component €300,000 to €800,000 for the German component \$300,000 to \$800,000 for the USA component The duration of a project can be up to three years.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
016874	<a href="#">Early Career Achievement Award</a>	Academy of Management Human Resources Division		01-Feb-2024	1,500 USD
	Contact Name				
	Contact Telephone				
	Contact Email				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Early Career Achievement Award recognizes the early career achievement of HR scholars. The award winner will be announced at the Academy meeting during the HR Division Awards Ceremony and receive a plaque and a \$1500 honorarium.			
	Applicant Types				
	Funding Limit	1,500.00 see detail			
	Limited Submission	No			
085316	<a href="#">Bridge Grant</a>	Alpha-1 Foundation		02-Feb-2024	25,000 USD
	Contact Name	Vanessa Valencia			
	Contact Telephone				
	Contact Email	<a href="mailto:vvalencia@alpha1.org">vvalencia@alpha1.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of individuals affected by Alpha-1 worldwide. The objective of Bridge Grants is to provide support for excellent AAT-related research projects that have been submitted to and approved by the National Institutes of Health (NIH), but cannot be supported by the available NIH funds. A maximum of \$25,000 may be requested. Up to 1 year of support is available.			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
067833	<a href="#">Postdoctoral Research Fellowship Grant</a>	Alpha-1 Foundation		02-Feb-2024	150,000 USD
	Contact Name	Vanessa Valencia			
	Contact Telephone	305-567-9888 x242			
	Contact Email	<a href="mailto:vvalencia@alpha1.org">vvalencia@alpha1.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	This grant provides support for postdoctoral research fellows who are starting their research careers and are working in the laboratories of established researchers or conducting research with the mentorship of established researchers. A maximum of \$75,000 per year may be requested.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
067831	<a href="#">Research Grants</a>	Alpha-1 Foundation		02-Feb-2024	200,000 USD
	Contact Name	Vanessa Valencia			
	Contact Telephone	305-567-9888 x242			
	Contact Email	<a href="mailto:vvalencia@alpha1.org">vvalencia@alpha1.org</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	This grant provides funds to encourage the development of new information that contributes to the understanding of the basic biology of AAT expression, and the pathogenesis/management of AAT Deficiency. A maximum of \$100,000 per year may be requested. The Principal Investigator should devote at least 10% effort to the Research Grant.			
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			
067828	<a href="#">Pilot and Feasibility Grants</a>	Alpha-1 Foundation		02-Feb-2024	75,000 USD
	Contact Name	Vanessa Valencia			
	Contact Telephone	703-964-5840			
	Contact Email	<a href="mailto:pcsupport@altum.com">pcsupport@altum.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	This grant provides funds to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to AAT Deficiency. A maximum of \$75,000 may be requested.			
	Applicant Types				
	Funding Limit	75,000.00 maximum			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
074532	<a href="#">Milton Safenowitz Post-Doctoral Fellowship Award</a>	ALS Association		13-Feb-2024	150,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:researchgrants@als.org">researchgrants@als.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024			
	Synopsis	The ALS Association offers support for a post-doctoral fellowship for research in ALS. Awards are \$150,000 in total funding over 2 years.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
059477	<a href="#">Neuroimaging and CSF Biomarker Development Program</a>	Alzheimer's Drug Discovery Foundation		05-Feb-2024 [LOI/Pre-App]	600,000 USD
	Contact Name	Meriel Owen, PhD, Associate Director, Scientific Affairs			
	Contact Telephone	212-901-8000			
	Contact Email	<a href="mailto:mowen@alzdiscovery.org">mowen@alzdiscovery.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 [LOI/Pre-App], 08-Apr-2024 , 13-May-2024 [LOI/Pre-App], 22-Jul-2024 , 30-Sep-2024 [LOI/Pre-App], 09-Dec-2024			
	Synopsis	The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.			
	Applicant Types				
	Funding Limit	600,000.00 maximum			
	Limited Submission	No			
055305	<a href="#">Drug Development RFP</a>	Alzheimer's Drug Discovery Foundation		05-Feb-2024	5,000,000 USD
	Contact Name	Aaron Burstein, PharmD, Head of Search & Evaluation			
	Contact Telephone	212-901-8000			
	Contact Email	<a href="mailto:aburstein@alzdiscovery.org">aburstein@alzdiscovery.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 , 08-Apr-2024 , 13-May-2024 , 22-Jul-2024 , 30-Sep-2024			
	Synopsis	The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.			
	Funding Limit	5,000,000.00 maximum			
	Limited Submission	No			
077008	<a href="#">Research Grants in Hearing and Balance - Investigator Research Grant</a>	American Academy of Audiology		15-Feb-2024	20,000 USD
	Contact Name				
	Contact Telephone	703-790-8466			
	Contact Email	<a href="mailto:kwerner@audiology.org">kwerner@audiology.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024			
	Synopsis	The American Academy of Audiology and the American Academy of Audiology Foundation wish to support basic and applied research in hearing and balance. Such research will benefit persons with hearing loss and/or balance deficits by improving the ability of professionals in audiology to evaluate and manage hearing and balance disorders. The American Academy of Audiology Foundation and the American Academy of Audiology will make grants for research projects with duration of one year. Grants of up to \$20,000 will be made based on the merit of the research project and application. Grants may be made for basic research or clinical/applied research.			
	Applicant Types				
	Funding Limit	20,000.00 maximum			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
096985	<a href="#">Postdoctoral Fellowship Program</a>	American Association for Anatomy		01-Feb-2024	20,000 USD
	Contact Name				
	Contact Telephone	301-634-7910			
	Contact Email	<a href="mailto:info@anatomy.org">info@anatomy.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Postdoctoral Fellowship provides salary support of \$20,000 to an AAA member who is a postdoctoral trainee working in any aspect of biology relevant to the anatomical sciences.			
	Applicant Types				
	Funding Limit	20,000.00 see detail			
	Limited Submission	No			
015290	<a href="#">Research and Clinical Research Professor Grants</a>	American Cancer Society, Inc.		01-Feb-2024 [LOI/Pre-App]	400,000 USD
	Contact Name	Kim Smith, Extramural Research Manager, Extramural Discovery Science			
	Contact Telephone	800-227-2345			
	Contact Email	<a href="mailto:grants@cancer.org">grants@cancer.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Feb-2024 [LOI/Pre-App], 01-Apr-2024</p> <p>Synopsis The American Cancer Society offers a limited number of grants to investigators who have the rank of full professor and made seminal contributions in the area of cancer control that have changed the direction of clinical, psychosocial, behavioral, health policy, or epidemiologic cancer research. The award of up to \$80,000 per year can be budgeted at the recipient's discretion for creative pursuits in cancer research.</p> <p>Applicant Types</p> <p>Funding Limit 80,000.00 per year</p> <p>Limited Submission No</p>				
010661	<a href="#">Resident Research Preceptorship</a>	American College of Rheumatology		01-Feb-2024	15,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Feb-2024</p> <p>Synopsis The purpose of this Resident Research Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician scientists to the field of rheumatology. The award is worth \$15,000 for a three-month research preceptorship, to be completed in reasonable portions within 12 months of the award's start date.</p> <p>Applicant Types</p>				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	15,000.00 maximum			
	Limited Submission	No			
114585	<a href="#">Glenn Foundation Discovery Award</a>	American Federation for Aging Research		15-Feb-2024 [LOI/Pre-App]	525,000 USD
	Contact Name				
	Contact Telephone	212-703-9977			
	Contact Email	<a href="mailto:grants@afar.org">grants@afar.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024 [LOI/Pre-App]			
	Synopsis	This funding program specifically seeks to include principal investigators who may not have previously worked in the area of aging, but whose research and expertise are applicable to understanding the biological mechanisms of normal aging and its relevance to age-associated health decline. Up to two three-year awards will be made in 2024. Each award is for \$525,000.			
	Applicant Types				
	Funding Limit	525,000.00 maximum			
	Limited Submission	No			
089670	<a href="#">Fellow Abstract Award</a>	American Gastroenterological Association		22-Feb-2024	Not Specified
	Contact Name				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-654-2055
Contact Email	<a href="mailto:awards@gastro.org">awards@gastro.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Feb-2024
Synopsis	The American Gastroenterological Association (AGA) provides \$500 Fellow Abstract Awards to support recipients who are MD, PhD or equivalent fellows giving abstract-based oral or poster presentations at Digestive Disease Week (DDW). The top scoring abstract will be designated the Fellow Abstract of the Year and receive a \$1,000 award.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

089669	<a href="#">Student Abstract Award</a>	American Gastroenterological Association		22-Feb-2024	Not Specified
--------	--	--	--	-------------	---------------

Contact Name	
Contact Telephone	301-654-2055
Contact Email	<a href="mailto:awards@gastro.org">awards@gastro.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Feb-2024

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The American Gastroenterological Association (AGA) provides \$500 Student Abstract Awards to support recipients who are graduate students, medical students or medical residents (residents up to postgraduate year three) giving abstract-based oral or poster presentations at Digestive Disease Week (DDW). The top scoring abstract will be designated the Student Abstract of the Year and receive a \$1,000 award.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	Yes			
110787	<a href="#">AGA Abstract Award for Health Disparities Research</a>	American Gastroenterological Association		22-Feb-2024	500 USD
	Contact Name				
	Contact Telephone	301-654-2055			
	Contact Email	<a href="mailto:awards@gastro.org">awards@gastro.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Feb-2024			
	Synopsis	This \$500 travel award supports recipients who are graduate students, medical students, medical residents (residents up to postgraduate year three), clinical fellows or postdoctoral fellows giving abstract-based oral or poster presentations at Digestive Disease Week (DDW) that communicate research into health or health care disparities.			
	Applicant Types				
	Funding Limit	500.00 maximum			
	Limited Submission	No			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106409	<a href="#">AMS Congressional Fellowship</a>	American Mathematical Society		01-Feb-2024	100,479 USD
	Contact Name				
	Contact Telephone	401-455-4000			
	Contact Email				
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The American Mathematical Society (AMS), in conjunction with the American Association for the Advancement of Science (AAAS), sponsors this fellowship. It includes an orientation on congressional and executive branch operations, and a year-long seminar series on issues involving science, technology and public policy. The AMS Congressional Fellow spends a year working on the staff of either a member of Congress or a congressional committee, working in legislative and policy areas requiring scientific and technical input.			
	Applicant Types				
	Funding Limit	100,479.00 minimum			
	Limited Submission	No			
121075	<a href="#">AMSSM Minority Research Grant</a>	American Medical Society for Sports Medicine		09-Feb-2024	10,000 USD
	Contact Name	Sarah Sund			
	Contact Telephone	913.327-1415			
	Contact Email	<a href="mailto:ssund@amssm.org">ssund@amssm.org</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	09-Feb-2024
Synopsis	The purpose of the AMSSM minority research grant is to provide research opportunities specifically for historically underrepresented minorities in biomedical research to advance representation across diverse backgrounds and promote health equity in sports medicine research.
Applicant Types	
Funding Limit	10,000.00 maximum
Limited Submission	No

071243	<a href="#">Development Grants</a>	American Neuromuscular Foundation		10-Jan-2024 [LOI/Pre-App]	50,000 USD
--------	------------------------------------	-----------------------------------	--	---------------------------	------------

Contact Name	
Contact Telephone	507-538-1037
Contact Email	<a href="mailto:foundation@neuromuscularfoundation.org">foundation@neuromuscularfoundation.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jan-2024 [LOI/Pre-App], 21-Feb-2024
Synopsis	The AANEM Foundation is offering development grants intended as seed money to help launch research into muscle and nerve disorders by promising new researchers.
Applicant Types	



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	50,000.00 see detail			
	Limited Submission	No			
115560	<a href="#">Robert M. Berne Distinguished Lectureship</a>	American Physiological Society		08-Feb-2024	3,000 USD
	Contact Name	Huabo Su			
	Contact Telephone	+1 844.526.1700			
	Contact Email	<a href="mailto:hsu@augusta.edu">hsu@augusta.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Feb-2024			
	Synopsis	The Cardiovascular Section offers the Robert M. Berne Distinguished Lectureship to recognize an emerging leader in cardiovascular research whose current research is particularly stimulating, such that the presentation of this work would contribute to interest in, and growth of, the Cardiovascular Section.			
	Applicant Types				
	Funding Limit	3,000.00 see detail			
	Limited Submission	No			
091770	<a href="#">Residents/Fellows in Radiation Oncology Research Seed Grant</a>	American Society for Radiation Oncology		23-Feb-2024	25,000 USD
	Contact Name				
	Contact Telephone	703-502-1550			
	Contact Email	<a href="mailto:science@astro.org">science@astro.org</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Feb-2024			
	Synopsis	The American Society for Therapeutic Radiology and Oncology offers Residents/Fellows in Radiation Oncology Seed Grants to fund novel projects, and support residents or fellows who are interested in radiation-oncology related basic science, or clinical research.			
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
100564	<a href="#">Residents/Fellows in Radiation Oncology Biology Seed Grant</a>	American Society for Radiation Oncology		23-Feb-2024	25,000 USD
	Contact Name				
	Contact Telephone	703-502-1550			
	Contact Email	<a href="mailto:science@astro.org">science@astro.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Feb-2024			
	Synopsis	The American Society for Therapeutic Radiology and Oncology offers Residents/Fellows in Radiation Oncology Biology Seed Grants to fund novel projects, and support residents or fellows performing biological research in radiation oncology and/or cancer focused sciences. The biology-focused seed grant will support the next generation of researchers who are planning a career in basic science or translational research.			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	No			
084785	<a href="#">Research Institute Grants -- Discovery &amp; Innovation (D&amp;I) Grants</a>	American Society for Reproductive Medicine (ASRM)		15-Feb-2024	750,000 USD
	Contact Name				
	Contact Telephone	205-978-5000			
	Contact Email	<a href="mailto:research@asrm.org">research@asrm.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024			
	Synopsis	The ASRM Research Institute Discovery & Innovation Grant (\$50,000 per year or greater) are to develop research projects addressing fundamental questions of major clinical significance to reproductive medicine. Preference for funding will be given to projects that attempt to answer timely, basic, and clinically relevant questions of potential high impact to the practice of reproductive medicine and which are currently not fundable (either because of applicable existing federal law or because of relatively lower prioritization) by federal funding agencies.			
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	No			
032663	<a href="#">Clinical Research Training Institute (CRTI) Program</a>	American Society of Hematology		01-Dec-2023 [LOI/Pre-App]	Not Specified

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission	 202-776-0544 <a href="mailto:training@hematology.org">training@hematology.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 01-Dec-2023 [LOI/Pre-App], 29-Feb-2024 The ASH Clinical Research Training Institute (CRTI) is a unique, year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers.  0.00 see detail No
--	--

032661	<a href="#">ASH Medical Student Physician-Scientist Award</a>	American Society of Hematology		01-Feb-2024	42,000 USD
--------	---	--------------------------------	--	-------------	------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	 202-776-0544 <a href="mailto:awards@hematology.org">awards@hematology.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 01-Feb-2024 The ASH Medical Student Physician-Scientist Award provides an opportunity for first-, second-, and third-year medical students to gain experience in hematology research under the mentorship of an ASH member and to learn more
--	---

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		about the specialty. Awardees must agree to spend more than 80 percent of their time during the immersive, year-long project conducting laboratory, translational, or clinical hematology research. The award provides \$42,000 of funding for a one-year period, which includes \$32,000 to support the trainee, \$4,000 for research supplies, \$4,000 for insurance and educational expenses (including one course), and \$2,000 for meeting attendance (including the ASH annual meeting).			
	Applicant Types				
	Funding Limit	42,000.00 see detail			
	Limited Submission	No			
101609	<a href="#">CESERT Pyramid Grants</a>	Association for Surgical Education		01-Feb-2024	Not Specified
	Contact Name	Lois Ehrlich			
	Contact Telephone	310-215-1226			
	Contact Email	<a href="mailto:lois@surgicaleducation.com">lois@surgicaleducation.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Association for Surgical Education Foundation (ASEF) is offering a series of education research grants to start July 1, 2024.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
098919	<a href="#">Postdoctoral Fellowships</a>	Banting and Best Diabetes Centre		27-Feb-2024	36,500 USD
	Contact Name	Rose LaBarbera			
	Contact Telephone	416-978-4656			
	Contact Email	<a href="mailto:diabetes.bbdc@utoronto.ca">diabetes.bbdc@utoronto.ca</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Feb-2024			
	Synopsis	The fellowships offered by the Banting & Best Diabetes Centre (BBDC) are in-training awards for individuals who hold (or are expecting to complete) a doctoral degree (PhD) or medical degree (MD or equivalent). The objective of these awards is to attract and foster young investigators to initiate and/or continue research training in the field of diabetes. The one-year fellowships are to be used for full-time diabetes research training at the University of Toronto or one of its affiliated institutions. These awards become tenable July 1, 2024 (and no later than September 1, 2024).			
	Applicant Types				
	Funding Limit	50,000.00 maximum			
	Limited Submission	No			
089931	<a href="#">PhD Fellowships</a>	Boehringer Ingelheim Fonds		01-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone	+49 (0)6131 2750 80			
	Contact Email	<a href="mailto:secretariat@bifonds.de">secretariat@bifonds.de</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Feb-2024 , 01-Jun-2024 , 01-Oct-2024 Synopsis The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
007345	<a href="#">Health Research Grants</a>	California Table Grape Commission		30-Nov-2023 [LOI/Pre-App]	40,000 USD
	Contact Name Contact Telephone 559-447-8350 Contact Email <a href="mailto:healthresearch@grapesfromcalifornia.com">healthresearch@grapesfromcalifornia.com</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 30-Nov-2023 [LOI/Pre-App], 01-Feb-2024 Synopsis The California Table Grape Commission (commission) seeks to fund research projects that assess the benefits of table grapes to human health, using a freeze-dried powder made from fresh table grapes. Of continued interest this year is human clinical research on the impact of grapes on brain, eye, GI, immune, and skin health, however applicants are welcome to propose grape research in other areas of interest. Applicant Types				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Funding Limit	40,000.00 maximum
Limited Submission	No

030571	<a href="#">CART Grants Program</a>	Coins for Alzheimer's Research Trust Fund (CART)		01-Dec-2023 [LOI/Pre-App]	300,000 USD
--------	-------------------------------------	--	--	------------------------------	-------------

Contact Name	Dr. Gary Goforth, MD, Vice President of Grants
Contact Telephone	828-243-5870
Contact Email	<a href="mailto:gagoforth@earthlink.net">gagoforth@earthlink.net</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Dec-2023 [LOI/Pre-App], 09-Feb-2024
Synopsis	The CART Grants program encourages exploratory and developmental AD research projects within the United States by providing support for the early and conceptual plans of those projects that may not yet be supported by extensive preliminary data, but have the potential to substantially advance biomedical research. Proposals should be distinct from those projects designed to increase knowledge in a well-established area unless it is intended to extend previous discoveries toward new directions or applications. Applications may encompass a project period of up to two years with a combined budget for direct costs up to \$300,000.
Applicant Types	
Funding Limit	300,000.00 maximum
Limited Submission	No



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
019497	<a href="#">Support for Ongoing Clinical Research in Thalassemia</a>	Cooley's Anemia Foundation, Inc.		18-Dec-2023 [LOI/Pre-App]	100,000 USD
	Contact Name				
	Contact Telephone	212-279-8090			
	Contact Email	<a href="mailto:grants@thalassemia.org">grants@thalassemia.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Dec-2023 [LOI/Pre-App], 05-Feb-2024			
	Synopsis	The Cooley's Anemia Foundation invites national and international applicants to apply for grants to support Ongoing Clinical Research projects in thalassemia.			
	Applicant Types				
	Funding Limit	50,000.00 per year			
	Limited Submission	No			
019493	<a href="#">Support for Trials in Thalassemia Cell and Gene Therapy Grant</a>	Cooley's Anemia Foundation, Inc.		18-Dec-2023 [LOI/Pre-App]	75,000 USD
	Contact Name				
	Contact Telephone	212-279-8090			
	Contact Email	<a href="mailto:grants@thalassemia.org">grants@thalassemia.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Dec-2023 [LOI/Pre-App], 05-Feb-2024</p> <p>Synopsis The Cooley's Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for thalassemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support. The research may not be conducted at a for-profit laboratory.</p> <p>Applicant Types</p> <p>Funding Limit 75,000.00 maximum</p> <p>Limited Submission No</p>				
001955	<a href="#">Research Fellowship</a>	Cooley's Anemia Foundation, Inc.		05-Feb-2024	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-279-8090</p> <p>Contact Email <a href="mailto:info@thalassemia.org">info@thalassemia.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024</p> <p>Synopsis The Cooley's Anemia Foundation invites national and international clinical and basic science investigators (postdoctoral or junior faculty) to apply for its prestigious fellowship program. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. Fellowship awards are limited to a maximum of \$50,000 per year.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
074640	<a href="#">IBD Ventures</a>	Crohn's & Colitis Foundation of America		23-Feb-2024 [LOI/Pre-App]	500,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:entrepreneurship@crohnscolitisfoundation.org">entrepreneurship@crohnscolitisfoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Feb-2024 [LOI/Pre-App]			
	Synopsis	The Crohn's & Colitis Foundation seeks to accelerate the development of products that aim to improve the quality of life of patients with inflammatory bowel diseases. Toward that end, the Foundation has launched IBD Ventures, a program and dedicated funding mechanism to support product-oriented research and development. Companies and academic investigators can apply. Funding up to \$500,000 per project per year will be considered. In addition, funded programs will be offered accelerator resources and advising.			
	Applicant Types				
	Funding Limit	500,000.00 maximum			
	Limited Submission	No			
033065	<a href="#">Clinical Pilot and Feasibility Awards</a>	Cystic Fibrosis Foundation		13-Feb-2024	Not Specified
	Contact Name	Dara Riva, Program Officer			
	Contact Telephone	301-841-2614			
	Contact Email	<a href="mailto:driva@cff.org">driva@cff.org</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Feb-2024 , 04-Apr-2024 [LOI/Pre-App], 13-Aug-2024</p> <p>Synopsis The Clinical Pilot and Feasibility Award is intended to support a project involving human subjects or samples that will develop and test new hypotheses and/or new methods in research areas relevant to cystic fibrosis.</p> <p>Applicant Types</p> <p>Funding Limit 0.00 see detail</p> <p>Limited Submission Yes</p>					
089449	<a href="#">Research Grants</a>	Daisy Foundation		05-Feb-2024 [LOI/Pre-App]	7,500 USD
<p>Contact Name Faith Thomas</p> <p>Contact Telephone 707-996-7936</p> <p>Contact Email <a href="mailto:FaihtThomas@daisyfoundation.org">FaihtThomas@daisyfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 [LOI/Pre-App], 24-Mar-2024</p> <p>Synopsis The DAISY Foundation is eager to support the delivery of patient- and family-centered care of disadvantaged populations by funding nursing research and evidence-based practice (EBP) projects designed to address social determinants of health aimed at improving health outcomes. Research Grants are available for up to \$7,500.</p> <p>Applicant Types</p>					

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	7,500.00 maximum			
	Limited Submission	No			
066130	<a href="#">Damon Runyon Clinical Investigator Award</a>	Damon Runyon Cancer Research Foundation		01-Feb-2024	600,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:awards@damonrunyon.org">awards@damonrunyon.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	<p>The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to \$100,000 of any medical school debt still owed by the awardee. For the purpose of this award, clinical research is defined as: a) Patient-oriented research: Research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: patient-based studies of mechanisms of human disease, diagnostic and therapeutic interventions, clinical trials and development of new technologies for the detection, treatment and prevention of human cancers. b) Epidemiologic and behavioral studies. c) Outcomes research and health services research.</p>			
	Applicant Types				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	600,000.00 see detail			
	Limited Submission	Yes			
120545	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Targeting Aquatic Extremophiles for Sourcing Novel Enzymes, Drugs, Metabolites and Chemicals</a>	European Commission	HORIZON-CL6-2024-CircBio-01-10	22-Feb-2024	4,905,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="#">See notes for contact information.</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Feb-2024			
	Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2024-CircBio-01-10 - Targeting aquatic extremophiles for sourcing novel enzymes, drugs, metabolites and chemicals The topic is part of the call: Circular Economy and Bioeconomy Sectors			
	Applicant Types				
	Funding Limit	4,500,000.00 see detail			
	Limited Submission	No			
120719	<a href="#">Digital, Industry and Space -- Bio-Intelligent Manufacturing Industries (Made in Europe Partnership) (RIA)</a>	European Commission	HORIZON-CL4-2024-TWIN-TRANSITION-01-01	07-Feb-2024 [LOI/Pre-App]	5,450,000 USD

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email <a href="#">See notes for contact information.</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a>				
	Deadline Dates (ALL) 07-Feb-2024 [LOI/Pre-App], 24-Sep-2024 Synopsis Proposals are invited against the following topic: HORIZON-CL4-2024-TWIN-TRANSITION-01-01 - Bio-Intelligent Manufacturing Industries (Made in Europe Partnership) (RIA) The topic is part of the call: Twin Green And Digital Transition 2024 Two Stage Applicant Types Funding Limit 5,000,000.00 see detail Limited Submission No				
120633	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Holistic Approaches for Effective Monitoring of Water Quality in Urban Areas</a>	European Commission	HORIZON-CL6-2024-ZEROPOLLUTION-02-1-two-stage	21-Feb-2024 [LOI/Pre-App]	5,450,000 USD
	Contact Name Contact Telephone Contact Email <a href="#">See notes for contact information.</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a>				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	21-Feb-2024 [LOI/Pre-App], 17-Sep-2024			
	Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2024-ZEROPOLLUTION-02-1-two-stage - Holistic Approaches for Effective Monitoring of Water Quality in Urban Areas The topic is part of the call: Clean Environment and Zero Pollution			
	Applicant Types				
	Funding Limit	5,000,000.00 see detail			
	Limited Submission	No			
121419	<a href="#">Culture, Creativity and Inclusive Society -- Beyond the Horizon: A Human-Friendly Deployment of Artificial Intelligence and Related Technologies</a>	European Commission	HORIZON-CL2-2024-TRANSFORMATIONS-01-06	07-Feb-2024	3,270,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="#">See notes for contact information.</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Feb-2024			
	Synopsis	Proposals are invited against the following topic: HORIZON-CL2-2024-TRANSFORMATIONS-01-06: Beyond the horizon: A humanfriendly deployment of artificial intelligence and related technologies This topic is part of the call: A Sustainable Future for Europe			
	Applicant Types				



## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Funding Limit	3,000,000.00 see detail
Limited Submission	No

120598	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Citizens' Science as an Opportunity to Foster the Transition to Sustainable Food Systems</a>	European Commission	HORIZON-CL6-2024-FARM2FORK-01-6	22-Feb-2024	5,450,000 USD
--------	--	---------------------	---------------------------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="#">See notes for contact information.</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Feb-2024
Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2024-FARM2FORK-01-6 - Citizens' Science as an Opportunity to Foster the Transition to Sustainable Food Systems The topic is part of the call: Fair, Healthy and Environmentally-Friendly Food Systems From Primary Production to Consumption
Applicant Types	
Funding Limit	5,000,000.00 see detail
Limited Submission	No

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
120565	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Additional Activities for the European Partnership for a Climate Neutral, Sustainable and Productive Blue Economy</a>	European Commission	HORIZON-CL6-2024-GOVERNANCE-01-1	28-Feb-2024	65,400,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="#">See notes for contact information.</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-Feb-2024			
	Synopsis	Proposals are invited against the following topic: HORIZON-CL6-2024-GOVERNANCE-01-1 - Additional Activities for the European Partnership for a Climate Neutral, Sustainable and Productive Blue Economy The topic is part of the call: Innovative Governance, Environmental Observations and Digital Solutions In Support of the Green Deal			
	Applicant Types				
	Funding Limit	60,000,000.00 see detail			
	Limited Submission	No			
120563	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Societal Perceptions and Benefits of Rural Life and Jobs: Will COVID 19 Generate a Long-Lasting Shift?</a>	European Commission	HORIZON-CL6-2024-COMMUNITIES-01-2	22-Feb-2024	6,540,000 USD

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email <a href="#">See notes for contact information.</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 22-Feb-2024 Synopsis Proposals are invited against the following topic: HORIZON-CL6-2024-COMMUNITIES-01-2 - Societal Perceptions and Benefits of Rural Life and Jobs: Will COVID 19 Generate a Long-Lasting Shift? The topic is part of the call: Resilient, Inclusive, Healthy and Green Rural, Coastal and Urban Communities Applicant Types Funding Limit 6,000,000.00 see detail Limited Submission No				
120570	<a href="#">Food, Bioeconomy, Natural Resources, Agriculture and Environment -- Develop Innovative Applications to Support the European Green Deal, Building on Meteorological Satellite Data</a>	European Commission	HORIZON-CL6-2024-GOVERNANCE-01-6	28-Feb-2024	4,360,000 USD
	Contact Name Contact Telephone Contact Email <a href="#">See notes for contact information.</a> Sponsor Website <a href="#">Link to sponsor website</a>				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 28-Feb-2024 Synopsis Proposals are invited against the following topic: HORIZON-CL6-2024-GOVERNANCE-01-6 - Develop Innovative Applications to Support the European Green Deal, Building on Meteorological Satellite Data The topic is part of the call: Innovative Governance, Environmental Observations and Digital Solutions In Support of the Green Deal Applicant Types Funding Limit 4,000,000.00 see detail Limited Submission No				
122474	<a href="#">European High Performance Computing Joint Undertaking (EuroHPC JU) -- Energy Efficient Technologies in HPC</a>	European Commission	HORIZON-EUROHPC-JU-2023-ENERGY-04-01	07-Feb-2024	21,800,000 USD
	Contact Name Contact Telephone Contact Email <a href="#">See notes for contact information.</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 07-Feb-2024 Synopsis The EuroHPC JU is accepting applications for the call: Energy Efficient Technologies in HPC. The objective of this call is to develop innovative energy efficient HPC software technologies tailored to exascale and post-exascale supercomputers. In line with the European Union's priority to promote the new Green Deal, the EuroHPC JU is committed to addressing energy efficiency and environmental sustainability throughout the whole spectrum of HPC				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	technologies, such as low-power hardware technology, dynamic power-saving and innovative techniques including advanced cooling and heat recycling. While energy efficiency poses multidimensional challenges across the entire HPC value chain, the EuroHPC JU also aims at improving the amount and quality of R&D output per energy unit consumed . Among the expected outcomes, the call aims to reach: Substantial improvement of energy efficiency while increasing overall throughput and utilisation of supercomputers, An empowered and energy-conscious user community, The establishment of standardised metrics to better measure the efficiency of supercomputers and enable detailed comparisons between supercomputers and data centres, The creation of a comprehensive data repository to house the complete collective operational dataset from all participating HPC centres and other relevant data, A holistic and modular European software stack of interoperable components with well-defined and well-documented interfaces, covering energy aware and dynamic workload management, monitoring and operational data analytics deployed in pre-exascale and exascale production environments.			
	Funding Limit	20,000,000.00 see detail			
	Limited Submission	No			
028276	<a href="#">Postdoctoral Fellowships</a>	European Molecular Biology Organisation (EMBO)		09-Feb-2024	Not Specified
	Contact Name	Kelly Sheehan-Rooney, Programme Head			
	Contact Telephone	+ 49 6221 8891 112			
	Contact Email	<a href="mailto:fellowships@embo.org">fellowships@embo.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Feb-2024			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	EMBO Postdoctoral Fellowships support excellent postdoctoral researchers throughout Europe and the world for a period of up to two years. International mobility is a key requirement. Research proposals must be within EMBO's scientific scope.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
013103	<a href="#">Career Development Award</a>	Foundation Fighting Blindness		01-Feb-2024	375,000 USD
	Contact Name				
	Contact Telephone	410-423-0600			
	Contact Email	<a href="mailto:grants@FightingBlindness.org">grants@FightingBlindness.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Career Development Program's goal is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease by: facilitating advances in laboratory and clinical research; elucidating the mechanism for the cause and pathogenesis of retinal degenerative diseases; and developing innovative strategies to prevent, treat and cure these diseases. In general, each five-year award will be for a total of \$375,000, received as five annual payments of \$75,000.			
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105021	<a href="#">Program Project Award (PPA)</a>	Foundation Fighting Blindness		27-Feb-2024	2,500,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grants@FightingBlindness.org">grants@FightingBlindness.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Feb-2024			
	Synopsis	<p>The Program Project Award (PPA) engages cross-disciplinary investigators to drive collaborative retinal degenerative disease research efforts. The PPA enables studies that are too large or technically complex for a single investigator to undertake in a reasonable amount of time and to address current knowledge and/or therapeutic gaps. The effort is unified around a single, well-articulated research hypothesis and clearly defined milestones relevant to the Foundation's mission. The PPA award address knowledge gaps or therapeutic goals identified by The Foundation or an equally significant gap or goal approved by the Foundation. Funding for this effort will be considered up to \$500,000 per year up to five (5) years.</p>			
	Applicant Types				
	Funding Limit	2,500,000.00 maximum			
	Limited Submission	No			
000277	<a href="#">Mentored Research Training Grants (MRTG)</a>	Foundation for Anesthesia Education & Research		15-Feb-2024	250,000 USD
	Contact Name				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 630-912-2554 Contact Email <a href="mailto:FAER@faer.org">FAER@faer.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Feb-2024 Synopsis Mentored Research Training Grants (MRTG) help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators. Applicant Types Funding Limit 125,000.00 per year Limited Submission No				
000512	<a href="#">Research Fellowship Grant (RFG)</a>	Foundation for Anesthesia Education & Research		15-Feb-2024	75,000 USD
	Contact Name Contact Telephone 630-912-2554 Contact Email <a href="mailto:FAER@faer.org">FAER@faer.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Feb-2024				



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Research Fellowship Grants are intended to provide anesthesiology residents and fellows with the opportunity to obtain significant training in research techniques and scientific methods. The RFG is a one-year (12-month), \$75,000 primary investigator (no co-investigators) award for anesthesiology trainees after the CA-1 year.			
	Applicant Types				
	Funding Limit	75,000.00 maximum			
	Limited Submission	No			
036254	<a href="#">Keith Michael Andrus Cardiac Award</a>	Friedreich's Ataxia Research Alliance		01-Feb-2024	300,000 USD
	Contact Name				
	Contact Telephone	484-879-6160			
	Contact Email	<a href="mailto:grants@curefa.org">grants@curefa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA. The applicant may request a budget of up to \$150,000 per year for one or two years.			
	Applicant Types				
	Funding Limit	150,000.00 per year			
	Limited Submission	No			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
036255	<a href="#">Kyle Bryant Translational Research Award</a>	Friedreich's Ataxia Research Alliance		01-Feb-2024	500,000 USD
	Contact Name				
	Contact Telephone	484-879-6160			
	Contact Email	<a href="mailto:grants@curefa.org">grants@curefa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Kyle Bryant Translational Research Award is given to proposals focused on pre-clinical and clinical investigations that will advance treatments for Friedreich's Ataxia. The applicant may request a budget of up to \$250,000 per year for one or two years.			
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	No			
006873	<a href="#">Bronya J. Keats Research Collaboration Award</a>	Friedreich's Ataxia Research Alliance		01-Feb-2024	400,000 USD
	Contact Name				
	Contact Telephone	484-879-6160			
	Contact Email	<a href="mailto:grants@curefa.org">grants@curefa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Feb-2024 Synopsis The Bronya J. Keats Research Collaboration Award honors its namesake for her academic career in understanding the GAA triplet repeat mutation in FA, and her continued role in managing FARA's grant program. Proposals should focus on FA research that relies on collaboration among investigators from at least two different Institutions. Applicant Types Funding Limit 200,000.00 per year Limited Submission No				
073959	<a href="#">Research Grants</a>	Gerber Foundation		15-Feb-2024	Not Specified
	Contact Name Contact Telephone 231-924-3175 Contact Email <a href="mailto:tgf@gerberfoundation.org">tgf@gerberfoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Feb-2024 Synopsis The Gerber Foundation provides support for studies to improve the nutrition and/or health of infants and toddlers. The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age. Applicant Types Funding Limit 0.00 see detail				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
066522	<a href="#">Elvin McDonald Research Endowment Fund Grants</a>	Gesneriad Society, Inc.		01-Feb-2024	2,000 USD
	Contact Name	Dr. Alain Chautem			
	Contact Telephone				
	Contact Email	<a href="mailto:Alain.Chautems@ville-ge.ch">Alain.Chautems@ville-ge.ch</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Gesneriad Society, Inc. provides grants from the Elvin McDonald Research Endowment Fund (EMREF) to students and researchers who seek a better understanding of the anatomy, physiology, relationships, distribution, growth and development, or the pests and diseases of gesneriads.			
	Applicant Types				
	Funding Limit	2,000.00 maximum			
	Limited Submission	No			
000381	<a href="#">Emerging Research Grants</a>	Hearing Health Foundation		23-Feb-2024 [LOI/Pre-App]	Not Specified
	Contact Name	Christopher Geissler, Ph.D., Director of Program and Research Support			
	Contact Telephone	212-257-6140			
	Contact Email	<a href="mailto:grants@hhf.org">grants@hhf.org</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Feb-2024 [LOI/Pre-App], 29-Feb-2024			
	Synopsis	Through the Emerging Research Grants (ERG) program, Hearing Health Foundation (HHF) provides seed money to researchers working on the entire spectrum of hearing research and balance research, including many underfunded areas of otology. ERG awards are for up to \$50,000 per year, one year in length in the first instance, and renewable for a second year.			
	Applicant Types				
	Funding Limit	50,000.00 per year			
	Limited Submission	No			
069446	<a href="#">Addressing Evidence-Based Health Benefits of Human-Animal Interaction</a>	Human Animal Bond Research Institute		22-Feb-2024	45,000 USD
	Contact Name	Matt Cryer			
	Contact Telephone	202-728-7616			
	Contact Email	<a href="mailto:MCryer@HABRI.org">MCryer@HABRI.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Feb-2024			
	Synopsis	The Human-Animal Bond Research Institute (HABRI) is calling for research proposals to investigate the health outcomes of pet ownership and/or animal-assisted activity or therapy, both for the people and the animals involved.			
	Applicant Types				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	45,000.00 on average			
	Limited Submission	No			
074080	<a href="#">ISA Scholarships</a>	Instrumentation, Systems, and Automation Society		28-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone	+1 919-549-8411			
	Contact Email	<a href="mailto:info@isa.org">info@isa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-Feb-2024			
	Synopsis	The ISA Scholarships are awarded to college or university students who demonstrate outstanding potential for long-range contribution to the fields of automation and control.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
122501	<a href="#">Travel Award for Health or Agricultural Department Employees in North America</a>	International Association for Food Protection		13-Feb-2024	2,500 USD
	Contact Name				
	Contact Telephone	515-276-3344			
	Contact Email	<a href="mailto:travel@foodprotection.org">travel@foodprotection.org</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024			
	Synopsis	The award consists of a plaque and travel funds to attend the Annual Meeting of the International Association for Food Protection. The sponsor provides travel funds for city, county, state, or provincial health or agricultural department employees (epidemiologists, food and molecular microbiologists, and environmental health specialists) working in North America to attend the Annual Meeting of the International Association for Food Protection and to encourage participation in association activities. For the 2024 program year, it is our pleasure to support the travel of up to five qualified health or agricultural department employees in North America to attend IAFP 2024, to be held July 14–17 2024, in Long Beach, California. This award is sponsored by IAFP and the IAFP Foundation.			
	Applicant Types				
	Funding Limit	2,500.00 see detail			
	Limited Submission	No			
122497	<a href="#">Ewen C.D. Todd Control of Foodborne Illness Award</a>	International Association for Food Protection		13-Feb-2024	1,500 USD
	Contact Name				
	Contact Telephone	515-276-3344			
	Contact Email	<a href="mailto:awards@foodprotection.org">awards@foodprotection.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Feb-2024			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	An award is presented to an individual for dedicated and exceptional contributions to the reduction of risks to foodborne illness. The award consists of a plaque and a \$1,500 honorarium			
	Applicant Types				
	Funding Limit	1,500.00 maximum			
	Limited Submission	No			
016198	<a href="#">Grants Program</a>	Johnson Controls Foundation		01-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-Jun-2024			
	Synopsis	The Johnson Controls Foundation makes charitable contributions to nonprofit organizations, primarily in communities where Johnson Controls has a presence. The Foundation is organized and directed to be operated for charitable purposes which include the distribution and application of financial support to soundly managed and operated organizations or causes which are fundamentally philanthropic. The Foundation contributes to organizations in the United States that operate not for profit and are recognized by the Internal Revenue Service as tax-exempt institutions.			
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

010942	<a href="#">Lasker-DeBakey Clinical Medical Research Award</a>	Lasker Foundation		06-Feb-2024	Not Specified
--------	--	-------------------	--	-------------	---------------

Contact Name	Attention: David Keegan
Contact Telephone	212-286-0222
Contact Email	<a href="mailto:dkeegan@laskerfoundation.org">dkeegan@laskerfoundation.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Feb-2024
Synopsis	The Lasker-DeBakey Clinical Medical Research Award is awarded for a major advance that improves the lives of many thousands of people. Each Award consists of an honorarium, a citation and an inscribed statuette of the Winged Victory of Samothrace, symbolizing victory over death and disease.
Applicant Types	
Funding Limit	0.00 see detail
Limited Submission	No

071136	<a href="#">Albert Lasker Basic Medical Research Award</a>	Lasker Foundation		05-Feb-2024	Not Specified
--------	--	-------------------	--	-------------	---------------

Contact Name	David Keegan
Contact Telephone	212-286-0222
Contact Email	<a href="mailto:dkeegan@laskerfoundation.org">dkeegan@laskerfoundation.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 05-Feb-2024 Synopsis The Albert Lasker Basic Medical Research Award honors individuals who have made a fundamental discovery that opens up a new area of biomedical science. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
055958	<a href="#">New Investigator Research Grant Program</a>	Leukemia Research Foundation		16-Feb-2024	150,000 USD
	Contact Name Contact Telephone 847-424-0600 Contact Email <a href="mailto:grants@leukemiarf.org">grants@leukemiarf.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 16-Feb-2024 , 26-Apr-2024 Synopsis The New Investigator Research Grant Program supports early-career investigators of exceptional creativity who propose highly innovative research projects with the potential to impact broad, essential areas of leukemia research. For the program to support the best and brightest minds, applications are sought from investigators who reflect the full diversity of the research workforce and represent diverse backgrounds, institutions, and geographic locations. Applicant Types Funding Limit 150,000.00 maximum Limited Submission No				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
013312	<a href="#">Surgery - Abdominal Transplant Surgery Fellowship (Minnesota)</a>	Mayo Clinic College of Medicine and Science		07-Feb-2024	Not Specified
	Contact Name	Stephanie L. Putzier, Education Coordinator			
	Contact Telephone	507-266-8731			
	Contact Email	<a href="mailto:rsttransplantcenter@mayo.edu">rsttransplantcenter@mayo.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Feb-2024			
	Synopsis	The Abdominal Transplant Surgery Fellowship at Mayo Clinic's campus in Rochester, Minnesota, provides fellows with the best possible foundation for a career in transplantation surgery. The American Society of Transplant Surgeons (ASTS) has accredited Mayo Clinic for training in liver and kidney transplantation.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
001651	<a href="#">Postbaccalaureate Research Education Program (PREP)</a>	Mayo Graduate School		01-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone	507-266-2912			
	Contact Email	<a href="mailto:officeforeducationdiversity@mayo.edu">officeforeducationdiversity@mayo.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Feb-2024 Synopsis The Post-baccalaureate Research Education Program (PREP) encourages individuals from underrepresented groups or from disadvantaged backgrounds who hold a recent baccalaureate degree in a biomedically relevant area of study to pursue a research doctorate. The program focus is to strengthen the research skills and academic competitiveness of program participants in an effort to help meet the critical need for diverse investigators in basic and translational research. Applicant Types Funding Limit 0.00 see detail Limited Submission No				
085076	<a href="#">Albert Szent-Gyorgyi Prize for Progress in Cancer Research</a>	National Foundation for Cancer Research		29-Feb-2024	30,000 USD
	Contact Name Hali Harmann, Ph.D. Contact Telephone 301-654-1250 Contact Email <a href="mailto:ASGPrize@nfc.org">ASGPrize@nfc.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 29-Feb-2024 Synopsis The Szent-Györgyi Prize serves to stimulate continued investment in the pioneering research that will produce scientific breakthroughs. It intends to deepen the understanding of the underlying basis of cancer and the translation of this knowledge to improve the lives for cancer patients. By calling attention annually to achievements in this area,				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>it is the goal of the Szent-Györgyi Prize to heighten awareness of the research and discovery that leads to new cancer treatments and cancer cures.</p> <p>30,000.00 maximum</p> <p>No</p>			
071600	<a href="#">Research Grants</a>	National Pancreas Foundation		15-Feb-2024	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>Carrie Anderson, National Program Manager</p> <p>866-726-2737</p> <p><a href="mailto:Carrie@pancreasfoundation.org">Carrie@pancreasfoundation.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>15-Feb-2024</p> <p>The National Pancreas Foundation (NPF) provides support for the funding of research related to pancreatic diseases.</p>			
085042	<a href="#">Summer Student Research Grants</a>	National Psoriasis Foundation		15-Feb-2024	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>	<p></p> <p>503-244-7404</p>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:research@psoriasis.org">research@psoriasis.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Feb-2024			
	Synopsis	Through Summer Student Research Grants, NPF supports undergraduate and medical students conducting research focused on psoriatic disease or related comorbidities, under the mentorship of well-established researchers in the psoriatic disease community.			
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			

018808	<a href="#">Discovery Grants</a>	National Psoriasis Foundation		01-Feb-2024	75,000 USD
--------	----------------------------------	-------------------------------	--	-------------	------------

	Contact Name				
	Contact Telephone	503-244-7404			
	Contact Email	<a href="mailto:research@psoriasis.org">research@psoriasis.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The National Psoriasis Foundation (NPF) is seeking grant applications that encourage the advancement of innovative research into psoriasis, psoriatic arthritis, and related comorbidities. Discovery Grants fund researchers while they explore preliminary ideas and conduct proof-of-concept experiments. The goal is to stimulate the development of			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	new research programs in the field of psoriatic disease capable of competing for long-term funding from the National Institutes of Health or similar agencies in the future.
Applicant Types	
Funding Limit	75,000.00 maximum
Limited Submission	No

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
121739	<a href="#">More than Skin Deep: Mental Health Grant</a>	National Psoriasis Foundation		01-Feb-2024	100,000 USD

Contact Name	
Contact Telephone	503-244-7404
Contact Email	<a href="mailto:research@psoriasis.org">research@psoriasis.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024
Synopsis	The National Psoriasis Foundation (NPF) is seeking grant applications from researchers interested in conducting projects focused on mental health in psoriatic disease.
Applicant Types	
Funding Limit	100,000.00 maximum

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
018807	<a href="#">Translational Research Grant</a>	National Psoriasis Foundation		01-Feb-2024	200,000 USD
	Contact Name				
	Contact Telephone	503-244-7404			
	Contact Email	<a href="mailto:research@psoriasis.org">research@psoriasis.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	Translational Research Grants fund research initiatives that focus on the rapid translation of basic scientific discoveries into clinical applications with a clear benefit for patients with psoriatic disease.			
	Applicant Types				
	Funding Limit	100,000.00 per year			
	Limited Submission	No			
085055	<a href="#">Psoriatic Disease Research Fellowships</a>	National Psoriasis Foundation		15-Feb-2024	50,000 USD
	Contact Name				
	Contact Telephone	503-244-7404			
	Contact Email	<a href="mailto:research@psoriasis.org">research@psoriasis.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 15-Feb-2024 Synopsis Psoriatic Disease Research Fellowships provide support to eligible institutions to develop and enhance the opportunities for physicians training for research careers in academic dermatology and rheumatology. Applicant Types Funding Limit 50,000.00 maximum Limited Submission No				
085049	<a href="#">Early Career Research Grants</a>	National Psoriasis Foundation		01-Feb-2024	50,000 USD
	Contact Name Contact Telephone 503-244-7404 Contact Email <a href="mailto:research@psoriasis.org">research@psoriasis.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Feb-2024 Synopsis The goal of this award is to support scientists at this challenging early career stage and to welcome them into the collaborative community of scientists, clinicians, and patients involved with NPF research. Applicant Types Funding Limit 50,000.00 maximum Limited Submission No				
058602	<a href="#">Research Associateship Programs -- U.S. Army Medical Research and Materiel Command</a>	National Research Council		01-Feb-2024	80,000 USD

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Dr. Tom Jurkiw, NRC Program Administrator
Contact Telephone	202-334-2782
Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024
Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the U.S. Army Medical Research and Materiel Command.
Applicant Types	
Funding Limit	80,000.00 see detail
Limited Submission	No

058604	<a href="#">Research Associateship Programs -- U.S. Army Research Laboratory (ARL)</a>	National Research Council	01-Feb-2024	80,000 USD
--------	--	---------------------------	-------------	------------

Contact Name	Dr. Eric Basques, NRC Program Administrator
Contact Telephone	202-334-2707
Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army Research Laboratory (ARL)			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058544	<a href="#">Research Associateship Programs -- National Institute of Standards and Technology (NIST)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			
	Contact Telephone	202-334-2782			
	Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the National Institute of Standards and Technology (NIST).			
	Applicant Types				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
001033	<a href="#">Research Associateship Programs -- Naval Research Laboratory</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Naval Research Laboratory.			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058601	<a href="#">Research Associateship Programs -- U.S. Army CCDC Chemical Biological Center (CCDC CBC)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone   202-334-2707 Contact Email   <a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024 Synopsis   The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army CCDC Chemical Biological Center (CCDC CBC). Applicant Types   Funding Limit   80,000.00 see detail Limited Submission   No				
001045	<a href="#">Research Associateship Programs -- Armed Forces Radiobiology Research Institute</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name   Dr. Tom Jurkiw, NRC Program Administrator Contact Telephone   202-334-2782 Contact Email   <a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Armed Forces Radiobiology Research Institute.			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
070292	<a href="#">Research Associateship Programs -- Environmental Protection Agency Faculty Fellowship Program (EPA/FFP)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the Environmental Protection Agency Faculty Fellowship Program (EPA/FFP).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
118195	<a href="#">Research Associateship Programs -- National Security Agency</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			
	Contact Telephone	202-334-2782			
	Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the National Security Agency.			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
118194	<a href="#">Research Associateship Programs -- Naval Air Warfare Center Weapons Division</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			
	Contact Telephone	202-334-2782			
	Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Naval Air Warfare Center Weapons Division.			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058607	<a href="#">Research Associateship Programs -- U.S. Environmental Protection Agency (EPA)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Environmental Protection Agency (EPA).			
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058603	<a href="#">Research Associateship Programs -- U.S. Army CCDC Soldier Center (CCDC SC)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army CCDC Soldier Center (CCDC SC).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
058605	<a href="#">Research Associateship Programs -- U.S. Army Research Office (ARO)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army Research Office (ARO).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058592	<a href="#">Research Associateship Programs -- Army Aviation and Missile Research, Development, and Engineering Center (AMRDEC)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Army Aviation and Missile Research, Development, and Engineering Center (AMRDEC).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058572	<a href="#">Research Associateship Programs -- Naval Postgraduate School</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			
	Contact Telephone	202-334-2782			
	Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Naval Postgraduate School (NPS).</p> <p>80,000.00 see detail</p> <p>No</p>			
058545	<a href="#">Research Associateship Programs -- National Oceanic and Atmospheric Administration (NOAA)</a>	National Research Council		01-Feb-2024	80,000 USD

Contact Name	Dr. Tom Jurkiw, NRC Program Administrator
Contact Telephone	202-334-2782
Contact Email	<a href="mailto:tjurkiw@nas.edu">tjurkiw@nas.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024
Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the National Oceanic and Atmospheric Administration (NOAA).
Applicant Types	
Funding Limit	80,000.00 see detail
Limited Submission	No

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
058542	<a href="#">Research Associateship Programs -- Air Force Research Laboratory</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Air Force Research Laboratory.			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
058596	<a href="#">Research Associateship Programs -- U.S. Army Research, Development &amp; Engineering Command, NVESD (RDEC/NVESD)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army Research, Development & Engineering Command, NVESD (RDEC/NVESD).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
001613	<a href="#">Research Associateship Programs -- Federal Highway Administration (FHWA)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the Federal Highway Administration (FHWA).</p> <p>80,000.00 see detail</p> <p>No</p>			
057794	<a href="#">Research Associateship Programs -- National Energy Technology Laboratory</a>	National Research Council		01-Feb-2024	80,000 USD

Contact Name	Dr. Eric Basques, NRC Program Administrator
Contact Telephone	202-334-2707
Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024
Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the National Energy Technology Laboratory.
Applicant Types	
Funding Limit	80,000.00 maximum
Limited Submission	No

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
058606	<a href="#">Research Associateship Programs -- U.S. Army CCDC Armaments Center (CCDC Armaments)</a>	National Research Council		01-Feb-2024	80,000 USD
	Contact Name	Dr. Eric Basques, NRC Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	<a href="mailto:ebasques@nas.edu">ebasques@nas.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024 , 01-Aug-2024 , 01-Nov-2024			
	Synopsis	The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is for the NRC Research Associateship Program at the U.S. Army Combat Capabilities Development Command Armaments Center (CCDC Armaments).			
	Applicant Types				
	Funding Limit	80,000.00 see detail			
	Limited Submission	No			
114353	<a href="#">NTSAD Research Initiative Program</a>	National Tay-Sachs & Allied Diseases Association, Inc.		01-Dec-2023 [LOI/Pre-App]	50,000 USD
	Contact Name	Valerie Greger			
	Contact Telephone	617-277-4463			
	Contact Email	<a href="mailto:vgreger@ntsad.org">vgreger@ntsad.org</a>			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Dec-2023 [LOI/Pre-App], 16-Feb-2024
Synopsis	National Tay-Sachs & Allied Diseases Association's Research Initiative Program is soliciting proposals for innovative research projects studying the following diseases: Tay- Sachs, Canavan, GM1, and Sandhoff diseases.
Applicant Types	
Funding Limit	50,000.00 maximum
Limited Submission	No

026473	<a href="#">Lee Kuan Yew Postdoctoral Fellowship</a>	National University of Singapore	01-Feb-2024	Not Specified
--------	--	----------------------------------	-------------	---------------

Contact Name	Ms Radhiga K Mohan
Contact Telephone	+65 65164823
Contact Email	<a href="mailto:rkm@nus.edu.sg">rkm@nus.edu.sg</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024
Synopsis	The prestigious Lee Kuan Yew Postdoctoral Fellowship was established in 1991 under the Lee Kuan Yew Endowment Fund. It aims to promote the development of young and outstanding academics in science, medicine and engineering. The scheme is open to nationals of all countries.
Applicant Types	

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	0.00 see detail			
	Limited Submission	No			
088606	<a href="#">Young Investigator Grants</a>	North American Spine Society		05-Feb-2024 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	630-230-3694			
	Contact Email	<a href="mailto:research@spine.org">research@spine.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Feb-2024 [LOI/Pre-App], 06-May-2024			
	Synopsis	The North American Spine Society (NASS) awards funding to promising Young Investigators to encourage and promote quality spine-related research. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$ 50,000 per year.			
	Applicant Types				
	Funding Limit	50,000.00 per year			
	Limited Submission	No			
088605	<a href="#">Research Grants</a>	North American Spine Society		05-Feb-2024 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	630-230-3694			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:research@spine.org">research@spine.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 [LOI/Pre-App], 06-May-2024</p> <p>Synopsis The North American Spine Society (NASS) research grants provide funding for promising research projects by qualified investigators in the field of spine. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$ 50,000 per year.</p> <p>Applicant Types</p> <p>Funding Limit 50,000.00 per year</p> <p>Limited Submission No</p>				
088607	<a href="#">Nontraditional Nonsurgical Treatment Grants</a>	North American Spine Society		05-Feb-2024 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 630-230-3694</p> <p>Contact Email <a href="mailto:research@spine.org">research@spine.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Feb-2024 [LOI/Pre-App], 06-May-2024</p> <p>Synopsis The North American Spine Society (NASS) offers the Nontraditional, Nonsurgical Treatment Grant to support research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy. If TNF-inhibitors</p>				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	other than etanercept are used in research and/or treatment funded, comparison studies using perispinal etanercept in at least as many research subjects or patients should be done. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$ 50,000 per year.			
	Funding Limit	50,000.00 per year			
	Limited Submission	No			
024601	<a href="#">Resident Research Project Grant</a>	Orthopaedic Research & Education Foundation		07-Dec-2023 [LOI/Pre-App]	5,000 USD
	Contact Name				
	Contact Telephone	847-430-5109			
	Contact Email	<a href="mailto:grants@oref.org">grants@oref.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Dec-2023 [LOI/Pre-App], 08-Feb-2024			
	Synopsis	The Resident Research Project Grant provides \$5,000 over one year and provides funding to residents who are interested in research. Funding covers research expenses, but not salary or travel. Work should clearly be achievable by the resident as a free-standing project even when it is a part of a larger work.			
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
046755	<a href="#">Postdoctoral Fellowships for Clinical Neurologists</a>	Parkinson's Foundation		22-Feb-2024	140,000 USD
	Contact Name				
	Contact Telephone	212-923-4700			
	Contact Email	<a href="mailto:grants@parkinson.org">grants@parkinson.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Feb-2024			
	Synopsis	The Postdoctoral Fellowships are two-year fellowships for young scientists, fresh from their PhD training or neurology residency, to study at major research institutions. The Parkinson's Foundation seeks research proposals from promising early-career scientists that will directly impact the understanding of Parkinson's disease or its treatment.			
	Applicant Types				
	Funding Limit	140,000.00 maximum			
	Limited Submission	No			
001994	<a href="#">Postdoctoral Fellowships for Basic Scientists</a>	Parkinson's Foundation		22-Feb-2024	124,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grants@parkinson.org">grants@parkinson.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 22-Feb-2024 Synopsis The Postdoctoral Fellowships for Basic Scientists are two-year fellowships for young scientists, fresh from their PhD training or neurology residency, to study at major research institutions. The program grants \$124,000 over two years to Basic Scientists, including \$57,000 for the postdoctoral fellowship salary stipend and an annual \$5,000 research allowance. Applicant Types Funding Limit 124,000.00 see detail Limited Submission No				
087892	<a href="#">Impact Awards</a>	Parkinson's Foundation		22-Feb-2024	150,000 USD
	Contact Name Contact Telephone Contact Email <a href="mailto:grants@parkinson.org">grants@parkinson.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 22-Feb-2024 Synopsis The Parkinson's Foundation Impact Awards are designed for researchers both established and new to the field of Parkinson's disease (PD). All research proposals must demonstrate a significant research focus and impact on PD. Awards are up to a maximum of \$150,000 for 12-18 months. Applicant Types				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	150,000.00 maximum			
	Limited Submission	No			
002181	<a href="#">Summer Student Fellowships</a>	Parkinson's Foundation		02-Feb-2024	4,000 USD
	Contact Name				
	Contact Telephone	212-923-4700			
	Contact Email	<a href="mailto:grants@parkinson.org">grants@parkinson.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Summer Student Fellowships Program supports students, specifically advanced undergraduates and medical students, in their pursuit of Parkinson's-related summer research projects. The goal of the Parkinson's Foundation Summer Student Fellowships is to cultivate students' early interest in helping to solve, treat and end Parkinson's and providing the tools they need to transition into leaders in the field.			
	Applicant Types				
	Funding Limit	4,000.00 see detail			
	Limited Submission	No			
074693	<a href="#">Visiting Scholar Award</a>	Parkinson's Foundation		02-Feb-2024	4,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grants@parkinson.org">grants@parkinson.org</a>			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Parkinson's Foundation Visiting Scholar Award provides a stipend to support the travel and housing of scholar while visiting a host laboratory to learn new techniques that will benefit their Parkinson's research.			
	Applicant Types				
	Funding Limit	4,000.00 see detail			
	Limited Submission	No			
061543	<a href="#">Faculty Starter Grant in Value Assessment-Health Outcomes Research</a>	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2024	100,000 USD
	Contact Name				
	Contact Telephone	202-572-7756			
	Contact Email	<a href="mailto:foundation@phrma.org">foundation@phrma.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The PhRMA Foundation Faculty Starter Grant in Value Assessment-Health Outcomes Research (VA-HOR) offers financial support to individuals beginning independent research careers in VA-HOR. Applicants must be in a tenure-track position within the first five years of their independent status. The PhRMA Foundation Faculty Starter Grant in Value Assessment-Health Outcomes Research provides funding of \$100,000 for one year.			



## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	100,000.00 maximum			
	Limited Submission	No			
061524	<a href="#">Predoctoral Fellowship in Value Assessment-Health Outcomes Research</a>	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2024	60,000 USD
	Contact Name				
	Contact Telephone	202-572-7756			
	Contact Email	<a href="mailto:foundation@phrma.org">foundation@phrma.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The PhRMA Foundation's Predoctoral Fellowship in Value Assessment-Health Outcomes Research (VA-HOR) is designed to support promising students (U.S. and non-U.S. citizens) during advanced stages of training and thesis research in value assessment and health outcomes research. This award provides \$30,000 in stipend support per year for 12, 18, or 24 months.			
	Applicant Types				
	Funding Limit	30,000.00 per year			
	Limited Submission	No			

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
061525	<a href="#">Postdoctoral Fellowship in Value Assessment-Health Outcomes Research</a>	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2024	120,000 USD
	Contact Name				
	Contact Telephone	202-572-7756			
	Contact Email	<a href="mailto:foundation@phrma.org">foundation@phrma.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The PhRMA Foundation's Postdoctoral Fellowship in Value Assessment-Health Outcomes Research (VA-HOR) supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in value assessment and/or health outcomes research.			
	Applicant Types				
	Funding Limit	60,000.00 per year			
	Limited Submission	No			
022929	<a href="#">Research Medical Student Grant</a>	Radiological Society of North America		02-Feb-2024	3,000 USD
	Contact Name	Keshia Osley, Assistant Director, Grant Administration			
	Contact Telephone	630-571-7816			
	Contact Email	<a href="mailto:grants@rsna.org">grants@rsna.org</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Medical Student Research Grant gives medical students the opportunity to gain research experience in medical imaging while they're still in school.			
	Applicant Types				
	Funding Limit	3,000.00 see detail			
	Limited Submission	No			
113719	<a href="#">Medical Student Research Grant</a>	Radiological Society of North America		02-Feb-2024	6,000 USD
	Contact Name				
	Contact Telephone	630-590-7789			
	Contact Email	<a href="mailto:grants@rsna.org">grants@rsna.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	Medical Student Research Grants provide medical students the opportunity to gain research experience in medical imaging while they're still in school. Recipients will define objectives, develop research skills and test hypotheses, all before even choosing a residency program. Ultimately, this experience gives students a chance to consider academic radiology as a future career option.			
	Applicant Types				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Funding Limit	6,000.00 see detail			
	Limited Submission	No			
016946	<a href="#">Resident/Fellow Research Grant</a>	Radiological Society of North America		02-Feb-2024	Not Specified
	Contact Name	Keshia Osley, Assistant Director, Grant Administration			
	Contact Telephone	630-571-7816			
	Contact Email	<a href="mailto:grants@rsna.org">grants@rsna.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	Resident/Fellow Research Grants provide young radiologists the chance to gain insight and experience in scientific investigation while they're still in training. The funding supports them as they learn research techniques and methods early, and sets recipients up for careers in academic radiologic science.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
071713	<a href="#">Medical and Graduate Student Preceptorship</a>	Rheumatology Research Foundation		01-Feb-2024	4,000 USD
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Medical and Graduate Student Preceptorship program introduces medical and graduate students to rheumatology-related health care by supporting a 4-Week or 8-Week, full-time clinical or research experience in the broad area of rheumatic disease.			
	Applicant Types				
	Funding Limit	4,000.00 see detail			
	Limited Submission	No			
104673	<a href="#">Health Professional Online Education Grant</a>	Rheumatology Research Foundation		01-Feb-2024	Not Specified
	Contact Name				
	Contact Telephone	404-365-1373			
	Contact Email	<a href="mailto:Foundation@rheumatology.org">Foundation@rheumatology.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Rheumatology Research Foundation offers a Health Professional Online Education Grant for non-physician rheumatology health professionals to complete the Advanced Rheumatology Course or the Fundamentals of Rheumatology Course. The award amount is equal to the registration cost of the course awardee decides to take and will be paid directly to the awardee.			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>0.00 see detail</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Applicant Types		Funding Limit	0.00 see detail	Limited Submission	No														
Applicant Types																									
Funding Limit	0.00 see detail																								
Limited Submission	No																								
073243	<a href="#">Ernst Schering Prize</a>	Schering (Ernst) Foundation/ Schering Stiftung		04-Feb-2024	54,500 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Contact Name</td> <td>Dr. Katja Naie, Director</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>+49 (0)30-20 62 29 62</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td><a href="mailto:naie@scheringstiftung.de">naie@scheringstiftung.de</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>04-Feb-2024</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The Ernst Schering Prize is awarded annually in the amount of 50,000 EUR to honor scientists worldwide whose pioneering basic research has yielded new, inspiring models or led to fundamental shifts in biomedical knowledge.</td> </tr> <tr> <td style="border-right: 1px solid black;">Applicant Types</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Funding Limit</td> <td>50,000.00 maximum</td> </tr> <tr> <td style="border-right: 1px solid black;">Limited Submission</td> <td>No</td> </tr> </table>						Contact Name	Dr. Katja Naie, Director	Contact Telephone	+49 (0)30-20 62 29 62	Contact Email	<a href="mailto:naie@scheringstiftung.de">naie@scheringstiftung.de</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	04-Feb-2024	Synopsis	The Ernst Schering Prize is awarded annually in the amount of 50,000 EUR to honor scientists worldwide whose pioneering basic research has yielded new, inspiring models or led to fundamental shifts in biomedical knowledge.	Applicant Types		Funding Limit	50,000.00 maximum	Limited Submission	No
Contact Name	Dr. Katja Naie, Director																								
Contact Telephone	+49 (0)30-20 62 29 62																								
Contact Email	<a href="mailto:naie@scheringstiftung.de">naie@scheringstiftung.de</a>																								
Sponsor Website	<a href="#">Link to sponsor website</a>																								
Program URL	<a href="#">Link to program URL</a>																								
Deadline Dates (ALL)	04-Feb-2024																								
Synopsis	The Ernst Schering Prize is awarded annually in the amount of 50,000 EUR to honor scientists worldwide whose pioneering basic research has yielded new, inspiring models or led to fundamental shifts in biomedical knowledge.																								
Applicant Types																									
Funding Limit	50,000.00 maximum																								
Limited Submission	No																								
056778	<a href="#">NSF REU Internships at Scripps Research</a>	Scripps Research Institute		15-Feb-2024	6,250 USD																				
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>858-784-8469</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td></td> </tr> </table>						Contact Name		Contact Telephone	858-784-8469	Contact Email															
Contact Name																									
Contact Telephone	858-784-8469																								
Contact Email																									

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Feb-2024
Synopsis	This NSF Research Experiences for Undergraduates (REU) Site award to Scripps Research located in La Jolla, CA, supports the training of 10 students in a 10-week program that probes the structure and function of macromolecules. This program offers its diverse participants an academic structure that integrates cutting-edge research with professional skills development and faculty mentoring.
Applicant Types	
Funding Limit	6,250.00 see detail
Limited Submission	No

071837	<a href="#">Research Grants</a>	SENS Research Foundation		01-Feb-2024	Not Specified
--------	---------------------------------	--------------------------	--	-------------	---------------

Contact Name	Kelly Boemmel
Contact Telephone	650-336-1780
Contact Email	<a href="mailto:foundation@sens.org">foundation@sens.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Feb-2024 , 01-May-2024
Synopsis	SENS Research Foundation (SRF) regularly funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.				
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
087014	<a href="#">High Impact Research Award</a>	Sjogrens Syndrome Foundation, Inc.		01-Feb-2024	10,000 USD
	Contact Name				
	Contact Telephone	800-475-6473			
	Contact Email	<a href="mailto:research@sjogrens.org">research@sjogrens.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Feb-2024			
	Synopsis	The Sjögren's Foundation strives to foster research that will have the greatest potential impact on Sjögren's patients. The High Impact Grant is a \$100,000 grant to support larger research concepts or continued larger-scale research after initial proof-of-concept research has been obtained.			
	Applicant Types				
	Funding Limit	10,000.00 maximum			
	Limited Submission	No			
085972	<a href="#">Public Awareness Grant</a>	Society for the Advancement of Behavior Analysis		07-Feb-2024	5,000 USD



## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone 269-492-9310 Contact Email <a href="mailto:saba@abainternational.org">saba@abainternational.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 07-Feb-2024 Synopsis The Society for the Advancement of Behavioral Analysis (SABA) will award grants of up to US\$5,000 to support projects designed to deliver messaging focused on behavior science and behavior analytic solutions to important problems. Applicant Types Funding Limit 5,000.00 maximum Limited Submission No				
001413	<a href="#">Research Grants</a>	St. Baldrick's Foundation		08-Dec-2023 [LOI/Pre-App]	Not Specified
	Contact Name Laura Chung, Director of Grants Administration Contact Telephone 626-792-8247 x236 Contact Email <a href="mailto:Laura@StBaldricks.org">Laura@StBaldricks.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 08-Dec-2023 [LOI/Pre-App], 23-Feb-2024				

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>These grants are for specific two-year research projects which are hypothesis driven and may be either laboratory, clinical, or epidemiological in nature. Please submit a realistic budget for the project. Grants will be \$100,000/year or less.</p> <p>0.00 see detail</p> <p>Yes</p>			
001382	<a href="#">St. Baldrick's Scholars (Career Development Award)</a>	St. Baldrick's Foundation		08-Dec-2023 [LOI/Pre-App]	330,000 USD

Contact Name	
Contact Telephone	626-792-8247
Contact Email	<a href="mailto:Grants@StBaldricks.org">Grants@StBaldricks.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Dec-2023 [LOI/Pre-App], 23-Feb-2024
Synopsis	The three year Scholar (Career Development) Award, with an option for two additional years based on progress, is meant to help develop the independent research of highly qualified individuals still early in their careers. Recipients are called St. Baldrick's Scholars. The award provides up to \$110,000 per year, for a three year minimum.
Applicant Types	
Funding Limit	110,000.00 per year
Limited Submission	Yes

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
044867	<a href="#">REU Site: Nanotechnology for Health, Energy and the Environment</a>	State University of New York at Stony Brook		16-Feb-2024	6,000 USD
	Contact Name	Attn: EU Nanotechnology 2024 Application			
	Contact Telephone	631-632-1485			
	Contact Email	<a href="mailto:CIE@stonybrook.edu">CIE@stonybrook.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Feb-2024			
	Synopsis	The multidisciplinary Research Experiences for Undergraduates (REU) program at Stony Brook University has a focus on the application of nanotechnology and nanomaterials to societal needs in health, energy, and the environment. The program is a summer research experience for academically talented undergraduates, qualified, motivated, and interested in the nanotechnology field. Participants will receive a \$6,000 summer stipend for full-time research.			
	Applicant Types				
	Funding Limit	6,000.00 maximum			
	Limited Submission	No			
010754	<a href="#">Summer Scholars Program</a>	Stowers Institute for Medical Research		02-Feb-2024	5,000 USD
	Contact Name				
	Contact Telephone	816-926-4400			
	Contact Email	<a href="mailto:summerscholars@stowers.edu">summerscholars@stowers.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Stowers Summer Scholars Program is an intensive research internship at the Stowers Institute for Medical Research for those interested in a research career.			
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			
075167	<a href="#">Department of Pediatrics Summer Training Program</a>	Strong Children's Research Center		09-Feb-2024	3,000 USD
	Contact Name	Joseph LaPenna			
	Contact Telephone	585-273-2977			
	Contact Email	<a href="mailto:scrc@urmc.rochester.edu">scrc@urmc.rochester.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Feb-2024			
	Synopsis	The Strong Children's Research Center's Summer Training Program is a competitive 10-week summer training program for students who have completed their junior or senior years of undergraduate college or first year of medical school. The goal of the program is to expose students to an academic pediatric environment and to encourage them to choose careers in research, pediatrics, and academic medicine. Participating students are paid a stipend of \$3000 for the ten-week program.			
	Applicant Types				
	Funding Limit	3,000.00 see detail			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
021905	<a href="#">Southwest National Primate Research Center (SNPRC) Summer Internship</a>	Texas Biomedical Research Institute		02-Feb-2024 [Optional]	Not Specified
	Contact Name	Crystal Bolden-Rush, PhD, Director of Research Education			
	Contact Telephone	210-258-9400			
	Contact Email	<a href="mailto:crush@txbiomed.org">crush@txbiomed.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024 [Optional], 23-Feb-2024			
	Synopsis	The Southwest National Primate Research Center (SNPRC) provides educational and training opportunities for a limited number of undergraduate and graduate (Ph.D. and veterinary) students during an 8-week summer session annually.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
077661	<a href="#">Young Investigator Award</a>	Tourette Association of America		15-Dec-2023 [LOI/Pre-App]	160,000 USD
	Contact Name				
	Contact Telephone	718-224-2999			
	Contact Email	<a href="mailto:resmed@tourette.org">resmed@tourette.org</a>			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Dec-2023 [LOI/Pre-App], 28-Feb-2024			
	Synopsis	The Tourette Association of America (TAA) aims to encourage early career researchers to invest their efforts and expertise in increasing our biological understanding of Tourette Syndrome (TS), pursuing clinical research aimed at improving patient care, and developing and testing new therapies. The Young Investigator Award provides up to \$80,000 per year for a total of 2 years (\$160,000 total).			
	Applicant Types				
	Funding Limit	80,000.00 per year			
	Limited Submission	No			
026902	<a href="#">Pilot Research Program</a>	Tulane National Primate Research Center		01-Feb-2024 [LOI/Pre-App]	60,000 USD
	Contact Name	Pyone Pyone Aye DVM, PhD			
	Contact Telephone	985-871-6486			
	Contact Email	<a href="mailto:paye@tulane.edu">paye@tulane.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	01-Feb-2024 [LOI/Pre-App], 01-May-2024			
	Synopsis	The purpose of the Pilot Research Program is to provide funds to investigators who show promise of developing a strong career in nonhuman primate biomedical research or who wish to add a nonhuman primate component to their			

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p>existing research programs. The program is also open to investigators with established research programs using nonhuman primates who wish to develop substantially new research directions.</p> <p>60,000.00 maximum</p> <p>No</p>			
049319	<a href="#">Hearst Health Prize</a>	University of California, Los Angeles		16-Feb-2024	100,000 USD

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> <p>Applicant Types</p> <p>Funding Limit</p> <p>Limited Submission</p>	<p><a href="mailto:info@hearsthealth.hearst.com">info@hearsthealth.hearst.com</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>16-Feb-2024</p> <p>The purpose of the Hearst Health Prize is to proliferate best practices to help promote promising new ideas in the field that will help to improve health outcomes. The Hearst Health Prize discovers and showcases successfully implemented programs that have made a measurable difference in human health. The winner of the Hearst Health Prize receives \$100,000.</p> <p>100,000.00 see detail</p> <p>No</p>			
--	---	--	--	--	--

## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
007191	<a href="#">Fellowship for Visiting Professors</a>	University of Montreal's Centre de recherche en éthique		02-Feb-2024	Not Specified
	Contact Name	Valéry Giroux, CRÉ Associate Director			
	Contact Telephone	514-343-6111 x 2958			
	Contact Email	<a href="mailto:valery.giroux@umontreal.ca">valery.giroux@umontreal.ca</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Feb-2024			
	Synopsis	The Centre de recherche en éthique (CRÉ) invites applications for its visiting professor scheme for the period of September 1st 2024 to August 31st 2025. This Fellowship is opened to university professors on sabbatical. The length of the stay can vary depending on the dossier and the kind of research envisaged.			
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
075166	<a href="#">Summer Scholars Program</a>	University of Rochester Medical Center		28-Feb-2024	6,470 USD
	Contact Name	Ben Lovell			
	Contact Telephone	585-275-2933			
	Contact Email	<a href="mailto:Benjamin_Lovell@urmc.rochester.edu">Benjamin Lovell@urmc.rochester.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			



## Non Federal Funding Opportunities

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 28-Feb-2024 Synopsis The Summer Scholars program is designed to encourage students from historically underrepresented minority groups in the STEM fields interested in a PhD degree in the Biological or Biomedical Sciences and for students with a potential interest in attending graduate school at the University of Rochester. Applicant Types Funding Limit 647.00 per week Limited Submission No				
078193	<a href="#">Summer Research Internship Program (SRIP)</a>	University of Virginia Health System		01-Feb-2024	Not Specified
	Contact Name Contact Telephone 434-924-1757 Contact Email <a href="mailto:srip@virginia.edu">srip@virginia.edu</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Feb-2024 Synopsis The University of Virginia School of Medicine offers summer research internship opportunities to qualified college undergraduates considering a career in biomedical research. Generous financial support, housing, and travel are provided to participants. Applicant Types Funding Limit 0.00 see detail Limited Submission No				

## Non Federal Funding Opportunities

*The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at [DevCorpFound@mountsinai.org](mailto:DevCorpFound@mountsinai.org) for assistance or questions.*

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------